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ABSTRACT 
 
 
In patients with atrial fibrillation (AF) there appears a close link between arterial stiffness, endothelial 
function and cardiac remodelling thereby contributing to the development and progression of AF as 
well as to its complications. However this complex interaction(s) is not well understood.  
 
In the cross-sectional study of patients with paroxysmal AF, higher arterial stiffness (PP, Pr) is 
strongly associated with endothelial-dependent macro-vascular dysfunction (Δ%AIx Salbutamol). 
Similarly a strong relationship observed between arterial stiffness (PP, PWVcf, Pr) and abnormal LA 
remodelling (LAV and LAD) in PAF patients. Higher levels of vWf and soluble E-Selectin at baseline 
are independently associated with increased risk of adverse clinical events (including AMI and 
ischaemic stroke) in ‘real world’ AF patients, and may aid clinical risk stratification towards 
identifying patients at higher risk. 
 
In the longitudinal study of dual chamber pacemaker patients there was a close relationship observed 
between arterial stiffness (PP, PWVcf, Pr), macro-vascular (Δ%AIx Sal) / micro-vascular (∆%LDF 
Ach) endothelial function and cardiac remodelling (EF, E/A ratio, EM, AM). These findings support 
the close interaction between ventricular contraction, arterial system and endothelial function towards 
the development of AF in pacemaker patients, beyond the adverse effects of pacing per se. 
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AN INTRODUCTION TO MY MD THESIS 
 
Arterial stiffness, macro-vascular, micro-vascular endothelial function and cardiac remodelling 
in atrial fibrillation 
 
Various studies have revealed the presence of endothelial damage and (dys) function in patients with 
atrial fibrillation (AF). Similarly, higher arterial stiffness appears to predict the development of AF. 
Pacing from the right ventricular apex may pose deleterious effects by causing both electrical and 
mechanical dys-synchrony. Also, both the degree and percentage of pacing appear to precipitate AF 
and heart failure in long-term. Nevertheless, the whole pathophysiological model neglects the close 
interaction between arterial stiffening properties and ventricular contraction as well as its effects on 
cardiac structure and function towards the development of AF; on top of the ill effects of pacing per 
se. This thesis assesses the close interaction between arterial stiffness (assessed using pulse pressure, 
carotid-femoral pulse wave velocity, reservoir pressure), macro-vascular (measurement of 
augmentation index using applanation tonometry in response to salbutamol and glyceryl trinitrate) 
/micro-vascular endothelial function (assessed using laser Doppler flowmetry and iontophoresis in 
response to acetyl choline and sodium nitroprusside) and cardiac remodelling (assessed using 
conventional trans-thoracic echocardiogram) in patients with atrial fibrillation. 
 
Chapter 1 is a literature review on atrial fibrillation including its epidemiology, risk factors and its 
classification. I have also discussed briefly its pathophysiology, clinical and economic implications. I 
have elaborated on treatment strategies in particular focussing on updated stroke prevention 
guidelines and evidence as well as the assessment of bleeding risk in AF patients. In Chapter 2, I have 
reviewed the prothrombotic state in AF – ‘Virchow’s triad’ of thrombogenesis and the vasoactive and 
haemostatic functions of normal endothelium as well as its’ effects during damage and dysfunction. 
Chapter 3, gives an overview of the available literature on the non-invasive and invasive assessment 
of endothelial (dys) function and damage in AF. In Chapter 4, I have reviewed ‘arterial stiffness’ and 
its assessment using pulse pressure, pulse wave velocity and pulse wave analysis, and also discussed 
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the available literature on arterial stiffness and its association in the development of AF. Chapter 5, 
gives an overview of the effects of right ventricular pacing and the risks of AF. Here I have also 
discussed the correlation of atrial high rate episodes and AF, as well as its’ clinical implications.  
 
Chapter 6 includes the aims, hypotheses and methodologies including study design, general statistics 
and ethical considerations. In Chapters 7-8, (unpublished original research article), I have assessed the 
interaction between arterial stiffness, endothelial function and cardiac remodelling in patients with 
paroxysmal AF (cross-sectional study). In Chapter 9 (published original research article), I have 
analysed the prognostic value of the plasma markers, von Willebrand factor and soluble E-selectin, in 
patients with AF on clinical outcomes including ischaemic stroke, acute myocardial infarction and all 
cause death. In Chapters 10-11 (published original research article) I have assessed the association 
between arterial stiffness, endothelial function and cardiac remodelling in patients with dual chamber 
pacemakers and atrial high rate events at baseline. Chapters 12-13 (unpublished original research 
article) assess the changes in arterial stiffness, endothelial function and cardiac remodelling in patients 
with pacemakers with atrial high rate events at 1-year follow-up. In Chapter 14, I have discussed the 
conclusions including clinical implications of the study results, strengths and limitations, as well as 
suggestions for future studies. 
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CHAPTER ONE 
 
1. Atrial fibrillation 
1.1. Epidemiology 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice. AF is 
characterised by uncoordinated atrial activation with consequent loss of atrial mechanical function. 
On the electrocardiogram (ECG), AF is defined by the absence of consistent P waves, replaced by 
chaotic rapid fibrillatory waves that vary in shape, amplitude and cycle lengths and are often 
associated with irregular ventricular response in the presence of intact atrio-ventricular (AV) nodal 
conduction.  
 
The prevalence of AF appears to increase substantially with advancing age (Feinberg, Blackshear, 
Laupacis, Kronmal, & Hart, 1995; Go et al., 2000). The estimated prevalence of AF from 
Framingham cohort varies widely from 0.7% in people aged between 45-64 years to almost 9% in 
persons aged ≥ 80 years (Stewart, Hart, Hole, & McMurray, 2001) (Kannel, Wolf, Benjamin, & Levy, 
1998). Nonetheless, Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study revealed 
the overall AF prevalence was roughly around 1% and was relatively more common in men. Higher 
prevalence of AF has been noted with advancing age with 0.1% in patients aged < 55years vs. 3.8% in 
those who are ≥ 60 years vs. 9.0% among patients aged ≥ 80 years. It was estimated that 
approximately 2.3 million adults’ currently in United States have AF, and projected a 2.5-fold 
increase to 5.6 million by the year 2050. (Go et al., 2000) 
  
In the Framingham Heart study, overall incidence of AF observed was 3/1000 person-years in men 
and 2/1000 person-years in women aged between 55-64 years, over a period of 38-year follow-up. 
(Kannel et al., 1998) Similarly in Scottish Renfrew Paisley study, the observed AF incidence was 
2.1/1000 person-years in men and 1.7/1000 person-years in women over a period of 20 years. 
(Stewart et al., 2001) In the Canadian Manitoba follow-up study (with 44 years follow-up) the overall 
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incidence of AF noted was 2/1000 person-years. (Krahn, Manfreda, Tate, Mathewson, & Cuddy, 
1995) However, in the Rotterdam study the incidence of AF was 1.1/1000 person-years at ages 55-60 
years and substantially increased to 20.7/1000 person-years in ages between 80-85 years. (Heeringa, 
van der Kuip, et al., 2006) The sub-analysis of the Framingham Heart study data suggested at 40 years 
or older, the lifetime risks of developing AF were 26% in men and 23% in women. Even without any 
prior or concurrent heart failure or MI, the lifetime risks for AF were approximately 16%. (Lloyd-
Jones et al., 2004) With increasing proportions of the population across the world being elderly, AF is 
likely to become a greater public health burden with an expected steep increase in both the prevalence 
as well as in its incidence in the future. 
 
1.2. Risk factors for AF 
In the population-based Framingham Heart Study, the risk factors associated with the development of 
AF includes congestive heart failure (OR, 4.5 for males and 5.9 for females), old age (OR, 2.1 for 
males and 2.2 for females), presence of hypertension (OR, 1.5 for males and 1.4 for females), 
presence of diabetes mellitus (OR, 1.4 for males and 1.6 for females) and valvular heart disease (OR, 
1.8 for males and 3.4 for females). There was a significant association noted between the risk of AF 
and myocardial infarction (OR, 1.4) in males. (Benjamin et al., 1994) Addressing these cardiovascular 
risk factors may help in reducing the overall incidence of AF.  
 
It is evident that abnormal left atrial (LA) remodelling is closely related to the development and 
progression of AF. In a prospective study from Olmstead County, there was a 48% higher risk of AF 
demonstrated with a 30% increase in LA volume. (Tsang, Barnes, Gersh, Bailey, & Seward, 2004) 
Hypertension is the most common associated condition with AF (in population based studies) and 
poor BP control may predispose to adverse LA remodelling (dilatation and fibrosis) due to a decrease 
in ventricular compliance, increasing ventricular stiffness and increased LV diastolic filling pressures. 
These processes may perpetuate adverse left atrial (LA) remodelling and thereby pose a higher risk 
for the development of AF. Indeed in the Framingham Heart Study, the level of systolic blood 
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pressure and duration of hypertension have shown to predict adverse LA remodelling (Vaziri, Larson, 
Lauer, Benjamin, & Levy, 1995) Finally, genetic predispositions interacting with environmental 
factors described above may also be relevant. Specific genetically-linked forms of the arrhythmia 
have been described. (Brugada et al., 1997; Chen, Ballew, Herron, Rodeheffer, & Olson, 2007; Fatini 
et al., 2006; Hodgson-Zingman et al., 2008; Otway et al., 2007; Tsai et al., 2004). The common 
cardiac and non-cardiac causes for developing AF are listed below in Table 1.1 
 
Table 1.1: Risk factors for the development of AF 
Cardiac Hypertension 
 Ischaemic heart disease 
 Congestive heart failure 
 Rheumatic heart disease 
 Sick sinus syndrome 
 Pre-excitation syndromes (Wolf Parkinson White syndrome) 
 Atrial septal defect 
 Atrial myxoma 
 Pericarditis and pericardial effusion 
 Cardiomyopathies 
 Post-operative AF (POAF) 
Non-Cardiac Acute infections 
 Electrolyte imbalance 
 Pulmonary embolism 
 Lung carcinoma 
 Pleural effusion 
 Obstructive sleep apnoea 
 Thyrotoxicosis 
 Excess alcohol/caffeine consumption 
 Illicit drugs including cocaine, amphetamines and cannabis 
 
1.3. Classification of AF 
AF is classified into 4 types based on the temporal presentation / pattern of arrhythmia, as highlighted 
in National Institute for Health and Care Excellence (NICE) guidelines [CG180] for atrial fibrillation. 
(Published in June 2014) 
(i) First detected episode of AF 
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(ii) Paroxysmal AF (self-terminating episodes lasting for less than 7 days, but commonly 
less than 24 hours) 
(iii) Persistent AF (non self-terminating events lasts longer than 7 days requiring either 
electrical or pharmacological cardioversion to abort the episodes) 
(iv) Permanent AF (resistant episodes unsuccessful to terminate despite cardioversion or 
generally accepted by both the physician and the patient). 
Both paroxysmal and persistent AF often recurs and remains progressive in the long term. Results 
from the Canadian registry of atrial fibrillation (CARAF) revealed the rate of progression of disease 
from paroxysmal AF to permanent state up to 9% and from persistent to permanent state up to 40% at 
one year follow-up. (Kerr et al., 2005) ‘Lone atrial fibrillation’ is quite a unique clinical entity, 
specific to AF without any traditional risk factors or precipitants or presence of co-existent heart 
disease and remains a diagnosis by exclusion (TABLE 1.1).  
 
1.4. Pathophysiology of AF – a brief overview 
The pathophysiology associated in the development of AF is highly complex and multifactorial.  
Current pathophysiological models support the concept of ‘electrical remodelling’ and ‘structural 
changes’ in the atrial tissue. Such remodelling provides the substrate promoting the initiation and self-
perpetuation of this arrhythmia confirming the concept ‘AF begets AF’. (Wijffels, Kirchhof, Dorland, 
& Allessie, 1995) Electrical remodelling is associated with shortening of the atrial refractory period, 
loss of rate adaptation and prolongation of atrial conductivity. (Hertervig, Yuan, Carlson, Kongstad-
Rasmussen, & Olsson, 2002; C. P. Lau & Tse, 1997) Also there is accumulation of calcium within the 
atrial myocytes, leading to the reduction of the inward L-type Ca2+ current thereby shortening the 
atrial effective refractory period. This appears to promote and subsequently maintain multiple wavelet 
re-entry circuits. (Boldt et al., 2004; Nattel, 2002) Similarly, ‘structural remodelling’ includes left 
atrial dilatation, atrial and interstitial fibrosis; which occurs in parallel with the functional changes in 
the atria and appears to facilitate sustained AF. (Boldt et al., 2004; Kostin et al., 2002; Schotten et al., 
2002) Against this substrate, ‘focal triggers’ involving automaticity and multiple re-entrant wavelets 
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may precipitate AF. Multiple ectopic foci identified as the source of these triggers include pulmonary 
veins (PV), superior vena cava, ligament of Marshall, left posterior wall, crista terminalis and 
coronary sinus. Notably very distinct electrophysiological characteristics in pulmonary veins (short 
effective refractory period, pronounced decremental conduction) were observed in patients with AF 
(Allessie, Ausma, & Schotten, 2002; Manios et al., 2000).  However the exact stimulus for this focal 
triggering is still uncertain; local inflammation has been proposed as a plausible mechanism towards 
the initiation of arrhythmia. 
 
1.5. Clinical and economical implications of AF 
Indeed AF is associated with a significant increase in CV mortality via its thrombo-embolic 
complications and predisposition to heart failure. Also it has an indirect effect on morbidity by 
impairment of cognitive function as well as affecting quality of life (QOL). (Benjamin et al., 1998; 
Kannel, Abbott, Savage, & McNamara, 1982; Ott et al., 1997; Savelieva, Paquette, Dorian, Luderitz, 
& Camm, 2001; Stewart, Hart, Hole, & McMurray, 2002) However the increased mortality risk 
observed with this arrhythmia is directly linked to its greater predisposition to stroke(s) and thrombo-
embolism. AF is associated with four to five-fold increased risk of stroke (Kannel et al., 1998), and it 
is estimated that roughly 15% of all strokes were related to AF. Notably the stroke risk associated 
with AF substantially increases with ageing. An exponential increase in the annual stroke risk related 
to AF observed in the Framingham Study rising from 1.5% in patients aged between 50–59 years 
compared to 23.5% aged between 80-89 years. (Wolf, Abbott, & Kannel, 1991) Often patients with 
AF related stroke tends to have worse outcomes with greater neurological disability, protracted 
hospital stay, higher stroke recurrences and subsequent increased mortality. (Marini et al., 2005)In the 
Canadian Manitoba follow-up study (Krahn et al., 1995), there was a two-fold increased risk in stroke, 
three-fold increased risk of heart failure and one-fold higher risk in total mortality noted in AF 
patients. Very similar results observed in the west of Scotland, Renfrew Paisley study of AF patients 
with two to three-fold higher risk of fatal/non-fatal strokes, three-fold greater risk of heart failure and 
AF remains an independent predictor of all-cause mortality. (Stewart et al., 2002).  
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Without any doubt, AF either directly or indirectly affects patient’s quality of life. In a study, AF 
patients (both silent and symptomatic) were noted to have significantly impaired total functional 
capacity, lower global life satisfaction and poor perception of general health compared to healthy 
subjects in sinus rhythm. (Savelieva et al., 2001) Similar results were observed in a small Canadian 
study of AF patients (Paquette et al., 2000) and also in symptomatic AF patients post AV-nodal 
ablation. (S. H. Lee et al., 1998; Natale et al., 1996) As an ever-growing public health issue, AF 
imposes a significant financial burden to health care services. Clearly there is a trend towards more 
AF related hospitalisations (both as primary and or secondary diagnosis) over the decades which is 
still rising. (Wattigney, Mensah, & Croft, 2003) The total cost incurred including hospitalisations, 
medical therapy and long-term nursing care due to AF accounts for more than 1% of the health care 
costs in UK. Unsurprisingly, with the rise in incidence and prevalence of AF the cost of its 
management in 2000 (2.4%) was double that of 1995; 1.2% of National Health Service budget. 
(Stewart, 2004)  
 
1.6. Treatment of AF – a brief overview 
The pivotal treatment in the management of AF patients is the choice of appropriate anti-thrombotic 
therapy towards thrombo-prophylaxis. Remainder of the treatment options are tailored to patients’ 
symptoms and their hemodynamic stability. In patients with symptomatic AF (both paroxysmal and or 
persistent AF), rhythm control may be the preferred option. However, typically in asymptomatic AF 
patients often treatment simply requires adequate heart rate control.  
1.6.1. Rhythm control strategies 
 
1.6.1.1. Pharmacological and electrical cardioversion 
For patients who present with AF with an onset of less than 48 hours, both electrical and 
pharmacological cardioversion appear to be safe in the absence of valvular heart disease. Heparin 
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(unfractionated or low molecular weight) should be used as thrombo-prophylaxis peri-cardioversion. 
There are numerous pharmacological agents that can be used to restore and maintain sinus rhythm 
(SR) These pharmacological agents have different modes of actions and the most commonly used 
classification to describe various drugs is the ‘Vaughan-Williams’ classification. The choice of drugs 
in AF is dependent on many factors, such as duration of the AF, co-morbidities and the clinical 
condition of each patient as well as patient preference. The commonly used drugs to achieve 
pharmacological cardioversion and to maintain SR are Class 1c (flecainide, propafenone) and class 
3(sotalol, Amiodarone, Ibutilide) drugs. If the onset is more than 48 hours or unclear, formal 
anticoagulation with a target INR (International Normalization Ratio) of 2.5 (range 2-3) is 
recommended for a minimum of 3 weeks before electrical cardioversion. Warfarin should then be 
continued for a minimum of 4 weeks post cardioversion to prevent any thrombus formation due to 
atrial stunning during this period.  In patients with risk factors for stroke or where there is a high risk 
of AF recurrence, consideration should be made towards continuing warfarin long term.  For centres 
or hospitals that are able to arrange a TOE, an immediate cardioversion can be performed once atrial 
thrombus has been ruled out [so-called TOE-guided cardioversion approach]. 
 
1.6.1.2. Non-pharmacological treatments (Ablation therapy) 
Antiarrhythmic drugs have limited efficacy and pro-arrhythmic risks. This has prompted the 
exploration of alternative non-pharmacological therapies to treat AF. Most of the non-
pharmacological therapy approaches are directed to eliminate the triggers and to modify the 
electrophysiological substrate for the prevention and treatment for AF. The recognition of the 
pulmonary vein as the common source of rapidly depolarising arrhythmogenic foci that induces 
paroxysmal AF and the success in surgical approach (e.g., Modified Maze procedure) have provided a 
platform for several ablation therapies (Kosakai et al., 1995). For patients with paroxysmal AF, 
elimination of these foci can achieve a success rate as high as 90%.  Nonetheless, the success rate does 
depend on operator experience and the different techniques that are employed for the procedure.  
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1.6.2. Rate control strategies 
In asymptomatic and hemodynamically stable patients or patients presented >48 hours since onset, a 
strategy of rate control and anticoagulation would offer sufficient time to determine the cause of AF. 
In the acute clinical setting, a well-controlled heart rate can be achieved by intravenous or oral use of 
beta-blockers and/or atrio-ventricular (AV) nodal blocking drugs - for example verapamil, diltiazem, 
digoxin – which would improve the haemodynamic status and alleviate symptoms.  
 
1.6.3. Preventing stroke and thromboembolism in AF 
The risk of stroke with AF is not homogeneous, and a recent analysis from the Stroke Risk in Atrial 
Fibrillation Working Group identified history of hypertension, old age (>75 years), previous history 
of stroke or transient ischemic attack (TIA) and presence of diabetes as independent risk factors for 
stroke in AF patients.(Stroke Risk in Atrial Fibrillation Working, 2007) This is broadly consistent 
with the systematic review from the UK National Institute for Health and Clinical Excellence (NICE) 
guidelines [CG180] for atrial fibrillation (Published in June 2014) on the stroke risk factors. 
 
Despite various validated risk stratification schemes available, the CHADS2 scoring system (Figure 
1.2) is the simplest and most commonly used schema in clinical practice to stratify the risk of stroke 
in patients with AF (Gage et al., 2001).  The cumulative risk score predicts annual adjusted stroke risk 
(Figure 1.3) which has been categorised into low, moderate and high risk.  Thus, for a quick, simple 
and easy assessment, if a patient has a CHADS2 score of ≥2, the patient is high risk and should be 
anticoagulated.  For a more refined risk stratification schema, since the CHADS2 schema does not 
include many stroke risk factors, the NICE guidelines stroke risk algorithm should be used (discussed  
later in section of “antithrombotic therapy” in page 10 and illustrated in figure 1.1). 
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Table 1.2.  CHADS2 stroke risk stratification model (Gage et al., 2001) 
CHADS2 risk criteria 
 
Individual Score 
Congestive heart failure 1 
Hypertension (systolic of ≥ 160 mm of Hg) or treated hypertension 1 
Age ≥ 75 years 1 
Diabetes mellitus 1 
Previous stroke or transient ischemic attacks 2 
 
Table 1.3. Cumulative CHADS2 score and annual adjusted stroke risk (Gage et al., 2001) 
Cumulative score Adjusted stroke risk (% per year) 
0 1.9 (1.2 – 3) 
1 2.8 (2.0 – 3.8) 
2 4 (3.1 – 5.1) 
3 5.9 (4.6 – 7.3) 
4 8.5 (6.3 -11.1) 
5 12.5 (8.2 – 17.5) 
6 18.2 (1.05 – 27.4) 
 
Alternatively, a refinement of the NICE guidelines, CHADS2 schema and the 2006 ACC/AHA/ESC 
guidelines schema has recently been proposed – which is referred to as CHA2DS2-VASc, whereby the 
acronym denotes Cardiac failure or dysfunction, Hypertension, Age ≥75[Doubled], Diabetes, 
Stroke[Doubled], Vascular disease, Age 65-74 and Sex category [Female]), whereby 2 points are 
assigned for a history of stroke or age ≥75; and 1 point each for age 65-74 years, a history of 
hypertension, diabetes, cardiac failure and vascular disease.   The CHA2DS2-VASc score improves 
upon the CHADS2 score in identifying high-risk patients,  classifies a smaller proportion of patients 
into the ‘intermediate/moderate’ risk category, and appropriately categorises a truly ‘low risk’ group 
(CHA2DS2-VASc score =0), with no thromboembolic events during follow-up. Patients with 
paroxysmal AF have a similar stroke risk compared to patients who are in sustained AF, and should 
be managed similarly. (Lip, 2008) Patients with atrial flutter should be managed similarly to those 
patients with AF, depending on the coexistence of stroke risk factors. 
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Antithrombotic therapy 
Antithrombotic therapy is an essential part of AF management irrespective of rate or rhythm control 
treatment strategy. Indeed, a rhythm control strategy does not necessary reduce the risk of 
thromboembolism, and current guidelines suggest that if the risk of recurrence of AF is high, lifelong 
anticoagulation should be considered after cardioversion. Appropriate choice of thrombo-prophylaxis 
in AF is not easy and treatment has to balance stroke risk, contraindications and co-morbidities.  
 
A practical algorithm-based risk stratification scheme for thrombo-prophylaxis in AF is summarised 
in Figure 1.1, as recommended by the UK NICE guidelines for AF management [CG180] (Published 
in June 2014). The vitamin K antagonist, warfarin is the most commonly used anticoagulant used in 
AF. However, clinical trials suggest that the newer oral anticoagulants like direct thrombin inhibitor 
(dabigatran), factor Xa inhibitors (apixaban) may be comparable to warfarin in reducing the risk of 
thrombo-embolism in AF patients. (Connolly et al., 2011; Connolly et al., 2009; Granger et al., 2011)  
 
1.6.4. Assessment of bleeding risk in patients with AF 
One of the important risks of antithrombotic agents is bleeding. The assessment of bleeding risk 
becomes part of the clinical assessment of patients with AF before starting anticoagulation therapy.  
Risk factors associated with anticoagulation-related bleeding complications are broadly recognised, 
and can include elderly age, uncontrolled hypertension, history of myocardial infarction or ischaemic 
heart disease, cerebrovascular disease, anaemia or history of bleeding and the concomitant use of 
other medications such as antiplatelet agents. It is crucial to assess bleeding risk in all AF patients, 
who are a candidate for any form of antithrombotic therapy and should be undertaken on an individual 
patient basis. Until recently, formal bleeding risk assessment was not recommended in clinical 
guidelines partly attributed to the paucity of validated simple bleeding risk tools. Nevertheless, a new 
bleeding risk score HAS-BLED which has been validated in Euro Heart Survey ((Pisters et al., 2010), 
provides the best discrimination of bleeding risk in patients with AF compared to other bleeding risk 
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scores like ATRIA and HAEMORR2HAGES (Apostolakis, Lane, Guo, Buller, & Lip, 2013; Roldan 
et al., 2013).  
 
The acronym HAS-BLED represents each of the bleeding risk factors and assigns 1 point for the 
presence of each of the following; hypertension (uncontrolled systolic blood pressure >160mm of 
Hg), abnormal renal and or liver functions, previous stroke, history of bleeding or its predisposition, 
labile international normalised ratios, elderly (≥ 75 yrs age) and concomitant drugs and or alcohol 
excess. The HAS-BLED score ranges from 0-9, with score ≥3 indicating those with high risk of 
bleeding for which caution and regular review is recommended. The HAS-BLED score has been 
validated in several different cohorts, including large real-world and clinical trial populations as 
recently reviewed in a comprehensive European consensus document (Lip et al., 2011). In addition, 
the advantage of HAS-BLED over other bleeding scores is that it is more user friendly and is made up 
of clinical information that is routinely available (other than international normalised ratio) before 
therapy is initiated, thereby making it more clinically applicable. 
 
Figure 1.1. Stroke prevention in patients with non-valvular AF (NICE recommendations 2014) 
 
 
Assessment of stroke risk stratification 
using CHA2DS2-VASc 
Assessment of bleeding risk using       
HAS-BLED 
Patient who choose not to have treatment Discuss the risk and benefits of anticoagulation 
Identify low risk patients                                      
CHA2DS2-VASc=0 (men), 1 (women) 
No antithrombotic therapy 
CHA2DS2-VASc=1 (men)               
Consider oral anticoagulant 
CHA2DS2-VASc≥2                               
Offer oral anticoagulant 
Discuss the options for anticoagulation with the patient and base the choice on their 
clinical features and preferences 
Vitamin K antagonists (VKA) Non VKA oral anticoagulants 
Annual review of all the patients 
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CHAPTER TWO 
 
2. A review of the pathophysiology of the pro-thrombotic state in atrial fibrillation 
 
2.1.  Mechanism of thrombogenesis in AF: Virchow’s triad of thrombosis 
 
Thromboembolic risk associated with AF is heterogeneous and the pathogenesis of thrombus 
formation in AF is multifactorial. This increased risk of thromboembolism in AF may be related to the 
presence of a prothrombotic or hypercoagulable state, by virtue of ‘Virchow’s triad’ for 
thrombogenesis, as described more than 150 years ago (Virchow, 1856). However the contribution of 
these components of Virchow’s triad (abnormal blood stasis, abnormal blood constituents and related 
to structural abnormalities) in individual patients towards the prothrombotic state in AF appears 
largely heterogeneous.  
 
2.1.1. Abnormal blood stasis 
Non-valvular AF (NVAF) associated mechanical atrial stunning and progressive LA dilatation 
predisposes to abnormal blood stasis. (Sanfilippo et al., 1990) The presence of structural heart disease 
like mitral stenosis promotes further LA dilatation, stasis and thereby increasing risk of thrombosis. 
(Keren et al., 1987) In the Stroke Prevention in Atrial fibrillation Investigators study, dilated LA 
appears to independently predict the risk of stroke, in NVAF patients – confirming its contribution 
towards thrombogenesis. ("Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic 
features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators," 1992) In 
NVAF, abnormal stasis in both LA and left atrial appendage (LAA) visualised as reduced LAA flow 
velocities on Doppler and ‘spontaneous echo contrast’ (SEC), which are independent predictors of 
future strokes and thromboembolism. ("Transesophageal echocardiographic correlates of 
thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in 
Atrial Fibrillation Investigators Committee on Echocardiography," 1998) The pathophysiology 
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involved in the formation of SEC is thought to be related to direct increased interaction between 
fibrinogen and erythrocytes. (Black et al., 1993; Rastegar et al., 2003) 
 
Abnormal blood constituents 
Changes in both haemostasis and coagulation are well established in patients with AF. Increased 
fibrin turnover has been reported in patients with acute and chronic AF, irrespective of the aetiology, 
whether isolated NVAF or associated with structural heart disease.(Lip, Lowe, Rumley, & Dunn, 
1995; Marin et al., 2004; Roldan et al., 1998) Higher concentrations of prothrombin fragments 1 and 2 
and thrombin-anti-thrombin complexes, were noted in patients with AF compared to those in SR. 
(Turgut et al., 2006) Similarly, increased levels of fibrin D-dimer, appear to independently predict the 
presence of LAA thrombi in trans-oesophageal echocardiography (Habara et al., 2007) and has been 
suggested as a useful screening tool to identify those patients with AF with lower risk of 
thromboembolism for safe cardioversion without anticoagulation. Higher concentrations of tissue-
plasminogen activator (t-PA) antigen and t-PA inhibitor (PAI)-1, markers of enhanced fibrinolysis 
were demonstrated in patients with AF. (Kamath, Chin, Blann, & Lip, 2002). The role of platelets in 
this pro-thrombotic state is uncertain. Multiple studies have shown higher levels of β-thromboglobulin 
(platelet-specific-protein, a marker of platelet activation) in patients with both valvular and NVAF 
compared to those in SR. (Kamath et al., 2002; Lip et al., 1996; Shinohara et al., 1998; Yamauchi, 
Furui, Taniguchi, & Sotobata, 1986) Increased levels of platelet microparticles and soluble P-Selectin 
were demonstrated in patients with AF compared to healthy controls, but not significantly different 
between disease groups, (Choudhury, Chung, Blann, & Lip, 2007) implying platelet activation as a 
result of associated cardiovascular disease. In the population-based prospective Rotterdam study, 
higher levels of soluble P-Selectin appear to strongly predict the adverse clinical outcomes in patients 
with AF. (Heeringa, Conway, et al., 2006) 
 
2.1.2. Abnormal structural changes  
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Abnormal structural LA and LAA remodelling occurs as a consequence of AF, as evidenced by 
severe endocardial changes in LAA compared to right atrial appendages, in patients with AF and 
mitral stenosis. (Goldsmith, Blann, Patel, & Lip, 2000) Similarly, ‘rough endocardium’ – wrinkled, 
oedematous and fibrinous changes with areas of endothelial denudation and thrombotic aggregation 
were observed in patients with AF and cerebral embolism. (Masawa, Yoshida, Yamada, Joshita, & 
Ooneda, 1993) Changes including myocyte hypertrophy, necrosis and mononuclear infiltrate were 
evident in patients with AF. (Boldt et al., 2004; Frustaci et al., 1997; Khan, 2003) Disruption of the 
extra-cellular matrix was identified with altered amounts of collagen degradation products, impaired 
matrix degradation, abnormal concentrations of matrix metalloproteinases (MMPs) and their 
inhibitors (tissue inhibitors of MMPs) in patients with AF. (Marin et al., 2003; Tziakas et al., 2007) 
However, increasing attention has been directed towards the ‘blood vessel abnormalities’ a part of 
structural changes, as a key component mediating thrombogenesis in AF, which can be recognised as 
the presence of endothelial damage and / or dysfunction.   
 
2.2.  Normal endothelium 
The ‘endothelium’ is made up of a solitary layer of endothelial cells lining the whole vasculature. 
Once thought to be an inert vascular lining, the endothelium is now known to have various vasomotor 
and haemostatic functions; as well as acting as a semi-permeable barrier and facilitating the transport 
of circulating molecules to sub-endothelial tissue. Indeed, the endothelium exhibits both autocrine and 
paracrine actions on platelets, leucocytes and vascular smooth muscle cells thereby regulating 
vascular tone, immune response and coagulation to maintain intravascular homeostasis. The 
endothelium is in effect an ‘organ’ (weighs approximately 1kg), and its function or (dys) function can 
be measured by the circulating secreted/shed products or assessing its effects on the vasculature. 
(Augustin, Kozian, & Johnson, 1994) However, endothelial cells phenotypes do significantly vary 
within the vascular tree; as well as in their expressions of surface receptors and the antigens. Often, 
they generate varied responses for an identical stimulus at different regions within the vasculature. 
Notably, responses between the cultured endothelial cells in vitro and endothelial cells in vivo might 
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not be identical; therefore this should be taken into account whilst interpreting studies on endothelial 
function. Figure 2 summarises the endothelial cell products involved in maintenance of haemostasis 
and vascular tone. 
 
The endothelium has been shown to be damaged or dysfunctional in many disease states; e.g., in 
patients with hypertension, vascular atherosclerotic disease and in septicaemia.  Indeed, endothelial 
cell injury, activation or dys-regulation has been implicated in the pathogenesis or consequences of 
many vascular disorders (Blann, Naqvi, Waite, & McCollum, 1993; Haines et al., 1983; Jager et al., 
1999; Woywodt et al., 2003). In some disease states, endothelial dysfunction or injury has been 
associated with thrombotic tendency, as the endothelium may promote a prothrombotic environment 
by overproduction of pro-coagulant factors, such as von Willebrand factor, and reduced 
expression/secretion of antithrombotic factors such as nitric oxide. However, in order to appreciate 
how the endothelium may be associated with thromboembolism in cardiovascular disease and as risk 
factor for vascular disease, we should first understand endothelial physiology as well as it’s 
antithrombotic and prothrombotic functions. 
 
2.3. Vasoactive functions of endothelium 
The endothelium maintains the vascular tone by producing numerous vaso-active substances which 
act on the smooth muscle cells. Some of these molecules have additional roles beyond its effects on 
endothelium per se; for example, regulating haemostasis as well as influence on local inflammatory 
cells. 
2.3.1. Nitric oxide 
The importance of the endothelium in the modulation of vascular tone was demonstrated in vitro by 
‘intact endothelium’ mediated relaxation of isolated rabbit aorta in response to perfusion with 
acetylcholine. (Furchgott & Zawadzki, 1980) This “endothelial-derived relaxing factor” (EDRF) was 
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later identified as nitric oxide (NO). (Ignarro, Byrns, Buga, & Wood, 1987; Palmer, Ferrige, & 
Moncada, 1987) 
 
NO is produced by endothelial cells from L-arginine (Radomski, Palmer, & Moncada, 1987) via 
eNOS and maintains the vascular tone.  Alterations in the calcium levels within the cells tend to 
activate eNOS as a response to mediators like bradykinin, acetylcholine, insulin, substance P and or 
due alterations in the pulsatile flow within the vasculature. On top, NO has established antithrombotic 
effects, by inhibiting platelet aggregation and adhesion (mediated by cGMP) (Mellion et al., 1981) 
and well supported by in vivo study results. (Freedman et al., 1996) NO has also been shown to 
modulate the fibrinolytic system and decreases plasma levels of fibrinogen, at least in animal models. 
(Lidbury, Korbut, & Vane, 1990) Synthesis of  NO by the endothelial cells often stabilises IkB (the 
pre-molecule of nuclear factor kappa B) resisting proteolysis, thereby inhibiting the expression of 
endothelial adhesion molecules, (Lefer & Lefer, 1996) suppresses leucocyte migration and reduces 
VSMC proliferation and migration (Garg & Hassid, 1989). Thus, endothelial cell (dys) function 
results in reduced NO production and/or availability, thereby promoting a pro-thrombotic and pro-
atherosclerotic state due to consequent vasoconstriction, higher expression of adhesion molecule and 
dysregulation of platelets, leucocytes and vascular smooth muscle cells. 
 
2.3.2. Prostacyclin  
Arachidonic acid is the main precursor for the production of prostacyclin (PGI2) with the help of co-
enzyme prostacyclin synthase within the endothelial cells (Fischer & Weber, 1985) Numerous 
inflammatory stimuli like IL-1, PDGF, EGF appear to have an influence on the synthesis of PGI2. 
Prostacyclin largely mediates its vasodilating action(s) by increasing the cytosolic cAMP, thereby 
activating protein kinase A, which subsequently leads to vascular smooth muscle relaxation. However 
PGI2 also down-regulates the levels of ET-1 (a potent vasoconstrictor) and decreases the levels of 
intracellular Ca2+ which aids in relaxing the vascular smooth muscle. It also exhibits anti-thrombotic 
effect by inhibiting platelet aggregation and thrombosis by down-regulating thromboxane A2 and 
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PDGF. Of note, the endothelium-dependent actions of both NO and PGI2 were thought to be very 
synergistic in maintaining vascular tone and homeostasis. 
 
2.3.3. Endothelin 
Endothelin (ET) is derived from preproendothelin peptides and poses potent vasoconstricting 
properties. There are 4 different isoforms of endothelin (ET-1, ET-2, ET-3 & ET-4) (Masaki, Vane, & 
Vanhoutte, 1994); however, ET-1 originates only from endothelial cells. Indeed the physiological 
mechanisms associated with the endothelin system in the maintenance of vascular tone are highly 
complex. ET-1 exerts its vaso-active actions through a close interaction between ETA and ETB 
receptors in vascular smooth muscle cells and endothelial cell. (Seo, Oemar, Siebenmann, von 
Segesser, & Luscher, 1994) ET-1 can also trigger proliferation of smooth muscle cells and augments 
various gene expressions, e.g., collagenase and PDGF. On the other hand, activation of ETB receptors 
in endothelial cells indirectly releases NO and subsequently results in the relaxation of VSMC. 
(Verhaar et al., 1998) It is predominantly endothelial cell products (ET, NO and prostacyclin) that 
regulate vascular tone, although only NO appears to have additional thrombo-regulatory properties. 
 
2.3.4. Endothelium-derived hyperpolarising factor (EDHF) 
In addition to NO and prostacyclin, the residual endothelial dependent vasodilatation appears to be 
mediated by the EDHF. (Taylor & Weston, 1988) As the name suggests, EDHF is associated with the 
initial VSMC hyperpolarisation via activation of calcium-dependent potassium (K+) channels causing 
K+ efflux. However, this is followed by VSMC relaxation mediated by EDHF activating K+ channels 
accompanied by the closure of voltage-dependent calcium channels. (McGuire, Ding, & Triggle, 
2001) In contrast to NO, it appears that the effects of EDHF were more pronounced in resistance 
(small) arteries compared to conduit (large) arteries. This complex biochemical cascade of actions are 
mediated by the activation of various families of K+ channels via the metabolites of arachidonic acid 
(cyclo-oxygenase, lipo-oxygenase and cytochrome P450 pathways), hydrogen peroxide, hydrogen 
sulphide and other various peptides released from endothelial cells. 
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2.4. Haemostatic functions of endothelium 
As the interface between the vessel wall(s), circulating factors and platelets, the endothelium in its 
normal state has a number of antithrombotic properties and a vasoactive role. As already discussed, 
the endothelium regulates vascular tone by the production and release of numerous vasoactive 
substances in response to various stimuli. Endothelial cells also express adhesion molecules and can 
produce both procoagulants and anticoagulants. Thus, the endothelium should physiologically confer 
an anticoagulant surface to allow smooth blood flow and prevent platelet adhesion and thrombosis. 
However, in response to a number of physical and chemical stimuli this equilibrium can be altered to 
the direction of a prothrombotic state. These changes may offers protection in conditions like 
haemorrhage, sepsis, inflammation or trauma; but equally may perpetuate disease states, where these 
responses are inappropriate and may become ‘pathological’. For example, endothelial damage/ 
dysfunction has been implicated in the pathophysiology of hypertension (Blann et al., 1993), diabetes 
mellitus (Jager et al., 1999), ischaemic heart disease (Haines et al., 1983), hyperlipidaemia (Blann, 
Maxwell, Burrows, & Miller, 1995), inflammatory vasculitis (Woywodt et al., 2003) and in smokers. 
(Blann & McCollum, 1993) 
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Figure 2.1. Endothelial cell products involved in maintenance of homeostasis and vascular tone 
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CHAPTER THREE 
This chapter is based on a published paper titled “Assessment of endothelial (dys) function in atrial 
fibrillation. A review of Literature”.  S Krishnamoorthy, HS Lim, GYH Lip. Ann of Medicine. Aug 
2009; 26: 1-150.  However I have updated the literature to ensure that this chapter includes key papers 
published since the review was published.  
3. Assessment of endothelial function in atrial fibrillation 
3.1.  Introduction 
The endothelium maintains haemostatic balance and vascular tone via the production of NO. The 
latter suppresses smooth muscle proliferation (Castellot, Addonizio, Rosenberg, & Karnovsky, 1981), 
inhibits platelet adhesion (an antithrombotic effect) (Radomski et al., 1987) and leucocyte adhesion on 
the vascular wall. (Kubes, Suzuki, & Granger, 1991) Damaged or dysfunctional endothelium may 
result in the release of pro-thrombotic and pro-inflammatory molecules (e.g., von Willebrand factor, 
Selectin’s and adhesion molecules) and increased vascular tone and/or reduced vascular reactivity. 
However this continuum of endothelial dysfunction and subsequent damage appears to be closely 
related to the development as well as the progression of AF and thromboembolism.  
 
The assessment of endothelial function has conventionally included the measurement of circulating 
biochemical markers related to the endothelium (e.g., von Willebrand factor, vascular cell adhesion 
molecule and E-Selectin levels) and the vasomotor response to endothelium-dependent (e.g., 
increased blood flow or vascular dimension in response to acetylcholine or salbutamol) relative to 
endothelium-independent mechanisms (e.g,. glyceryl trinitrate).  
 
More recently, the quantification of circulating endothelial cells has been proposed as an additional 
measure of endothelial damage. These diverse methods have been used to assess endothelial function 
in patients with AF and summarised in Table 3.1.  
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Table 3.1: Techniques used in the assessment of endothelial function in atrial fibrillation 
Techniques Assessment by measuring 
Circulating markers von Willebrand factor 
 Asymmetrical di-methyl arginine 
 E-Selectin 
 Circulating endothelial cells/Endothelial progenitor cells 
 Circulating microparticles 
 Soluble thrombomodulin 
Non-invasive Flow mediated dilatation (vaso-response) 
 Positron emission tomography (coronary flow reserve) 
Invasive Strain gauge venous occlusion plethysmography (vaso-response) 
 
3.2.  Circulating markers of endothelial dysfunction in AF 
 
3.2.1. Von Willebrand Factor: 
vWf is a glycoprotein secreted by vascular endothelial cells into the circulation in response to 
endothelial damage. (Bowie et al., 1986) vWf promotes platelet adhesion to the damaged endothelium 
and may be the first step in the formation of thrombus in the arterial circulation. Of note, vWf is also 
produced by megakaryocytes but contained within the platelets. Under normal physiological 
conditions, circulating plasma vWf is derived predominantly from endothelial cells, but platelets may 
contribute to the circulating pool in pathological states. (Blann & Taberner, 1995) The secretion of 
vWf is mediated through multiple cytokines (e.g., IL-1, TNF – alpha and endotoxin), and thus vWf 
has been described as an acute phase protein. (Pottinger, Read, Paleolog, Higgins, & Pearson, 1989) 
However, other work has suggested that high vWf antigen levels in the absence of other indicators of 
an acute phase response may be suggestive of damage/injury to the endothelium. (Blann, 1991) 
Circulating vWf levels are also related to blood group, being higher in non-O blood groups compared 
to the O-group. (Koster, Blann, Briet, Vandenbroucke, & Rosendaal, 1995)   Despite these 
pathophysiological determinants, measurement of plasma vWf by ELISA is frequently used as a 
plasma biomarker of endothelial damage/dysfunction.   
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High plasma vWf levels have been reported in various studies of patients with AF. In an early 
Swedish study, Gustafsson et al clearly demonstrated higher levels of vWf in patients with AF with or 
without strokes, when compared to controls in sinus rhythm. (Gustafsson, Blomback, Britton, 
Hamsten, & Svensson, 1990) In a cross-sectional study, Lip et al demonstrated raised vWf levels in 
patients with chronic AF, independent of underlying structural heart disease. (Lip et al., 1995) In a 
heart failure study, increased levels of plasma vWf were noted in patients with LV systolic 
dysfunction who had AF compared to those who remained in sinus rhythm. (Freestone, Gustafsson, et 
al., 2008) Results from the Rotterdam study revealed a true association between vWf and the risk of 
AF.  For every 10IU/dl rise in the levels of vWf the risk of AF increased by 1.2 fold and this effect is 
more evident with female gender, but not among males. (Conway, Heeringa, et al., 2003) It also 
appears female gender is independently associated with increased risk of stroke and 
thromboembolism with AF, even after adjusting for other confounders. This noticeable greater 
endothelial dysfunction in females was postulated as one of the possible mechanism(s) attributing to 
their higher stroke risk. (Lane & Lip, 2009)  Plasma vWf does not appear to be affected by treatment 
with either aspirin or warfarin. (Li-Saw-Hee, Blann, & Lip, 2000)  
 
Structural abnormalities within the left atrial endocardium have been related to circulating vWf levels. 
For example, Goldsmith et al found higher systemic levels of vWf were correlated to the degree of 
left atrial appendage endocardial damage in patients with mitral valve disease, especially those who 
were in AF. (I. Goldsmith et al., 2000) In addition, studies using immuno-histochemistry of the left 
atrial appendage samples in patients with non-valvular AF found over-expression of vWf which 
correlated well with the degree of platelet adhesion and the presence of structural heart disease. 
(Fukuchi et al., 2001; Nakamura et al., 2003) Raised vWf levels have been reported in patients with 
mitral stenosis and AF; however levels were not significantly different in samples from the left/right 
atria, when compared to peripheral venous sampling. (Li-Saw-Hee, Blann, Goldsmith, & Lip, 1999; 
Yamamoto et al., 1995)  Abnormal vWf levels also correlate with risk factors for thrombus on trans-
oesophageal echocardiography. Indeed, Heppell et al reported the raised levels of vWf correlated with 
spontaneous echo contrast and the presence of left atrial thrombus in patients with non-rheumatic AF. 
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(Heppell, Berkin, McLenachan, & Davies, 1997) Irrespective of the arrhythmia (either paroxysmal or 
persistent) significantly higher levels of vWf were noted in AF patients compared to controls in sinus 
rhythm. (Scridon, Girerd, Rugeri, Nonin-Babary, & Chevalier, 2013) 
 
Elevated levels of plasma vWf have prognostic implications.  The SPAF (Stroke Prevention in Atrial 
Fibrillation) III study suggested a close association between vWf levels and CV events in AF patients.  
There was a 1.2% absolute increase in risk of stroke for every 20 IU/dl increase in vWf levels. 
(Conway, Pearce, Chin, Hart, & Lip, 2003) Previous history of cerebrovascular disease, old age, 
presence of diabetes and congestive cardiac failure independently predicts higher levels of vWf. 
(Conway, Pearce, Chin, Hart, & Lip, 2002) In a small study, Pinto et al demonstrated that higher 
levels of vWf at baseline appear to predict new-onset ischaemic stroke during 3-year follow-up in 
chronic NVAF patients. (Pinto et al., 2009) This is consistent with other data suggesting that raised 
levels of vWf predicted future cardiovascular events (stoke, myocardial infarction and death) and was 
associated with poor prognosis in patients with coronary artery disease. (Jansson, Nilsson, & Johnson, 
1991) Importantly, the addition of plasma vWf levels to clinical stroke risk factors appears to improve 
the risk stratification of patients with AF. (Lip, Lane, Van Walraven, & Hart, 2006)   
 
3.2.2. Asymmetric di-methyl arginine (ADMA) 
ADMA is an endogenous substance produced from proteolysis of methylated arginine related 
proteins. ADMA exerts a competitive inhibitory effect on nitric oxide synthase (NOS) and reduces the 
bioavailability of NO. (McDermott, 1976) Di-methyl-arginine and di-methyl-hydrolase (DDAH) 
metabolises ADMA to L-citruline and di-methylamine. Pharmacological inhibition of DDAH causes 
vasoconstriction of arterial segments in vitro, which was restored by the administration of L-arginine. 
Thus, DDAH levels are inversely related to the levels of ADMA. (Cooke, 2000) Elevated levels of 
ADMA have been reported in patients with coronary artery disease, (Cooke, 2004) hypertension, 
(Matsuoka et al., 1997) diabetes, (Abbasi et al., 2001) hypercholesterolemia, (Boger et al., 1998) 
atherosclerosis (Miyazaki et al., 1999) and renal failure (Vallance, Leone, Calver, Collier, & 
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Moncada, 1992). ADMA levels can be measured using high performance liquid chromatography or 
by an ELISA technique. 
 
Higher levels of ADMA have been shown in patients with acute AF (compared to chronic AF and 
healthy controls) prior to cardioversion, suggesting that AF may acutely and adversely affect 
endothelial function. (Cengel et al., 2008) In another study, higher ADMA levels prior to electrical 
cardioversion may predict the recurrence of AF. (Xia et al., 2008) Goette et al reported higher levels 
of ADMA in patients with AF compared to those in SR. (Goette et al., 2012) In AF patients 
undergoing catheter ablation, higher levels of ADMA measured pre-ablation remains an independent 
predictor of AF recurrence during 10-months follow-up period. (Yang et al., 2011) Similarly in a 
small study, baseline ADMA levels appears to predict clinical adverse events in AF patients 
(independent of CHA2DS2-VASc score) over a median follow-up of 30-months. (Chao et al., 2013) 
Recently, Lim et al demonstrated a reduction in the levels of ADMA in patients who remained in SR 
at 6-months following catheter AF ablation compared to their baseline values; however no significant 
difference was observed in the ADMA levels in those who had AF recurrence during follow-up. (Lim 
et al., 2014) 
 
3.2.3. Adhesion molecules 
Adhesion molecules are expressed on the endothelial cell surfaces that promote leukocyte adhesion. 
E-Selectin is specific for endothelial cells and not expressed under normal physiological states, but its 
expression may be increased under pathological conditions. (Gearing & Newman, 1993) Raised 
plasma levels of E-Selectin are believed to reflect endothelial activation. (Blann & Lip, 1998) Other 
adhesion molecules, such as ICAM-1 and VCAM-1 are also expressed on macrophages and 
lymphocytes. These molecules play a vital role in chemotaxis and recruitment of leukocytes and 
macrophages during the process of inflammation by the activation of various cytokines (IL-1, TNF-
alpha). (Cybulsky & Gimbrone, 1991) E-Selectin levels can be measured using ELISA, and higher E-
Selectin levels have been reported in hypertension, (Blann, Tse, Maxwell, & Waite, 1994) 
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atherosclerosis, (Blann & Waite, 1996) coronary artery disease (Blankenberg et al., 2001) and cancer. 
(Alexiou et al., 2001) 
 
Higher levels of E-Selectin have been reported in AF patients compared to healthy controls in sinus 
rhythm. (Freestone, Chong, Nuttall, Blann, & Lip, 2007) Interestingly, low baseline E-Selectin levels 
predict the successful maintenance of sinus rhythm at 6 months in AF patients. (Tveit et al., 2007) A 
significant correlation observed between the levels of E-Selectin and endothelial dependent FMD 
(assessed in brachial artery) in AF patients. (Freestone, Chong, Nuttall, & Lip, 2008) In a study of 
patients with systolic heart failure, plasma E-Selectin levels were not significantly different in AF 
patients compared to those in sinus rhythm, despite increases in vWf and NT-pro BNP.  (Freestone, 
Gustafsson, et al., 2008) In a small study of dual chamber pacemaker patients (incorporated with 
arrhythmia detection algorithms), no significant differences observed in the levels of sE-selectin or 
vWf in relation to AF burden (0% vs. 0.1 to 10% vs. 10.1 to 50% or >50%) during 1-month follow-
up. (Watson, Arya, Sulke, & Lip, 2010)  
 
3.2.4. Circulating Endothelial Cells  
Circulating endothelial cells (CECs) are believed to reflect endothelial damage and consequent 
shedding of endothelial cells from the intimal layer of the arterial wall. These cells circulate at very 
low levels as they are normally scavenged by the reticulo-endothelial system. (Blann et al., 2005) 
CECs may be measured by an immuno-magnetic bead separation technique or by flow-cytometry.  
 
Higher CEC levels have been reported in patients with myocardial infarction, (Mutin et al., 1999) 
stroke, (Nadar, Lip, Lee, & Blann, 2005) pulmonary hypertension, (Bull et al., 2003) sickle cell crisis 
(Solovey et al., 1997) and inflammatory vasculitis. (Woywodt et al., 2003) Chong et al demonstrated 
a strong correlation between CEC counts and brachial artery reactivity on flow-mediated dilatation, 
which supports CEC quantification as a measure of endothelial damage/dysfunction. (Chong et al., 
2004) In a small study of patients with acute coronary syndrome, higher CEC levels at 48 hours 
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independently predicted mortality and MACE at one-month and at one-year follow-up. (K. W. Lee, 
Lip, Tayebjee, Foster, & Blann, 2005) Nonetheless, abnormal CECs in AF may simply reflect 
significant target organ damage. Using the magnetic immuno-bead technique, Freestone et al reported 
higher CEC numbers in patients with AF with stroke or cardiac events, when compared to numbers in 
‘chronic stable’ AF and healthy controls. (Freestone et al., 2005)  It is however possible that 
quantification of CEC by the immune-bead technique may not be sufficiently sensitive to detect lesser 
degrees of endothelial damage/dysfunction, which is seen in chronic stable subjects. The mechanism 
of the increased CEC numbers and the prognostic significance of CEC counts in AF also remain 
unclear. Another circulating cell phenotype related to the endothelium are endothelial progenitor cells 
and Goette et al, have demonstrated higher levels of haematopoietic progenitor cells (CD34+) in 
patients with persistent AF, compared to paroxysmal AF and healthy controls. (Goette et al., 2003) A 
further decline in levels of CD34+ cells was seen at 48 hours post direct current cardioversion, 
compared to baseline levels. However, successful restoration of sinus rhythm with electrical 
cardioversion in AF patients was associated with an increase in the levels of circulating progenitor 
cells, compared to their baseline values. (Watson, Shantsila, Blann, & Lip, 2010) 
 
3.2.5. Circulating microparticles (MPs) 
Microparticles (MPs) are small membrane bound vesicles, which are derived from platelets, 
endothelial cells, leucocytes and erythrocytes. (Morel et al., 2006) These microparticles spill into the 
circulation from the shedding of cells during activation, injury or apoptosis and may have 
procoagulant properties. (Diamant, Tushuizen, Sturk, & Nieuwland, 2004; Jesel et al., 2013) 
Increased levels of procoagulant microparticles have been found in diverse conditions such as 
atherosclerosis, (Mallat et al., 1999) myocardial infarction, (Boulanger et al., 2001) diabetes (Morel et 
al., 2004) and stroke. (Y. J. Lee et al., 1993)  However, studies involving microparticles in AF are 
limited. Ederhy et al reported higher endothelial-derived microparticles in patients with either 
permanent or persistent AF compared to controls without any cardiovascular risk factors, but the 
clinical significance of MPs in AF is not clear. (Ederhy et al., 2007) 
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3.2.6. Soluble thrombomodulin:  
Soluble thrombomodulin (sTM) is a transmembrane glycoprotein expressed on the surface of vascular 
endothelial cells. (Sadler, 1997) The thrombin-thrombomodulin complex activates protein C and 
degrades factors V and VIII to mediate a potent anticoagulant property. (Esmon, 1995) sTM is 
normally cleared through kidneys and can be detected in urine even in normal subjects (albeit in small 
quantities). (Ishii & Majerus, 1985) Measurement of the plasma sTM using ELISA has been proposed 
as a marker of endothelial injury in patients with atherosclerosis. In cross-sectional studies, raised 
levels of sTM have been reported in hypertension, (Erdem et al., 1999) diabetes mellitus, (Inukai, 
Fujiwara, Tayama, Aso, & Takemura, 1996) ischemic heart disease , (Blann, Amiral, & McCollum, 
1997) dyslipidaemia, (Constans, Blann, Renard, Guerin, & Conri, 2000), stoke (Dharmasaroja, 
Dharmasaroja, & Sobhon, 2012) and renal failure. (Gris et al., 1994)  However, prospective studies 
suggest that higher levels of sTM may be associated with a low-risk of coronary artery disease and a 
lower prevalence of asymptomatic carotid atherosclerosis. (Salomaa et al., 1999) The precise reasons 
are unclear but this may be related to the down-regulation of sTM expression in endothelial 
dysfunction. 
 
Data on sTM in patients with AF are similarly conflicting. In a study of patients with mitral stenosis 
prior to valvuloplasty, lower levels of sTM were found in patients with AF (in both cardiac and 
peripheral blood samples) compared to patients in sinus rhythm. (Yamamoto et al., 1995) This could 
be related to the discontinuation of warfarin prior to the surgery or may directly reflect endothelial 
cell dysfunction through down-regulation of sTM expression. In contrast, Mondillo et al found 
increased levels of sTM in patients with lone chronic non-rheumatic AF in peripheral venous samples 
when compared to controls in sinus rhythm. (Mondillo et al., 2000) In a small study, Freestone et al 
demonstrated higher levels of sTM in AF patients with acute cardiovascular or cerebrovascular event 
compared to ‘chronic stable’ AF patients without any events. (Freestone et al., 2005) 
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3.3. Non-invasive functional assessment of endothelial function in AF 
3.3.1. Flow mediated dilatation 
Flow mediated dilatation (FMD) is a well-established non-invasive method of assessing endothelial 
function. With the use of high-resolution ultrasound (7-10 MHz), the response of brachial artery to 
NO release during both physiological and pharmacological stress can be quantified. The brachial 
artery, in response to transient occlusion of blood flow (typically with a pressure cuff) and subsequent 
increase in blood flow (on release of occlusion) should vasodilate as increased flow creates an 
increase in shear stress and release of endogenous NO by the endothelium.  Indeed, FMD is used as a 
measure of endothelium-dependent vascular function and is simultaneously compared to endothelium-
independent vasodilatation, typically assessed by the vascular response to exogenous administration 
of pharmacological agents, such as glyceryl trinitrate (GTN). Hence, the relative change in brachial 
artery diameter to transient occlusion (endothelium-dependent) relative to exogenous nitrates 
(endothelium-independent) can be used as an index of endothelial function. 
 
In general, an increase of >10% to stress is accepted as a normal response from baseline.  Notably, 
radial and femoral arteries have been used to assess the vasodilatory response. The vasoresponse from 
conduit arteries correlates well with invasive techniques in the assessment of endothelial function. 
(Anderson et al., 1995; Matsuo et al., 2004; Teragawa et al., 2005) However, the technique of FMD is 
technically challenging and heavily operator-dependent. Guidelines for the use of FMD in the 
assessment of endothelial function have been published in 2002 by the International Brachial Artery 
Reactivity Task Force. (Corretti et al., 2002) Abnormal FMD responses, indicative of endothelial 
dysfunction, have been described in hypertension, (Deng et al., 1999) diabetes mellitus, (Watts, 
O'Brien, Silvester, & Millar, 1996) coronary artery disease, (Takase et al., 1998) dyslipidaemia, 
(Stroes, Koomans, de Bruin, & Rabelink, 1995) ageing, (Celermajer et al., 1994) male sex (van der 
Heijden-Spek et al., 2000) and smoking. (Raitakari, Adams, McCredie, Griffiths, & Celermajer, 1999) 
Subsequent treatment of various cardiovascular risk factors appears to improve FMD. (Muiesan et al., 
1999; O'Driscoll, Green, & Taylor, 1997)  
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The use of FMD to assess endothelial function in AF poses inherent problems due to the beat-to-beat 
variations in both blood flow and pulse pressure.  Nonetheless, FMD has been used to study 
endothelial function in AF in chronic stable AF patients, who have good heart rate control.   Impaired 
FMD (endothelium dependent) corresponds to the changes in plasma levels of both vWf and sE-sel in 
AF patients compared to healthy subjects in SR. (Freestone, Chong, et al., 2008)  Restoring sinus 
rhythm following cardioversion in patients with lone AF or those with hypertension is associated with 
improvement in FMD. (Guazzi, Belletti, Lenatti, Bianco, & Guazzi, 2007; Skalidis et al., 2007) In a 
small study of AF patients, improvement in endothelial function (assessed using reactive hyperaemia 
peripheral arterial tonometry) was noted after restoring sinus rhythm post-catheter ablation. (Yoshino 
et al., 2013) In the Multi-Ethnic Study of Atherosclerosis, participants with lower percentage of 
brachial FMD values (below sex specific median value) were associated with increased risk of AF 
over a median follow-up of 8-years. (O'Neal et al., 2014)  Recently, Polovina et al demonstrated 
impaired FMD measured in the brachial artery in lone persistent AF patients compared to healthy 
controls in sinus rhythm. Notably, in their study a significant negative correlation was observed 
between FMD and the duration of AF. (Polovina, Lip, & Potpara, 2015) Although these investigators 
have used a greater number of cardiac cycles for the assessment of FMD in AF, the intrinsic beat-to-
beat variability could limit the reproducibility of this technique in AF patients. The relationship 
between thromboembolic and cardiovascular complications of AF, to endothelial dysfunction as 
quantified by FMD still remains to be established. 
 
3.4.  Invasive functional assessments of endothelial function in AF 
 
A direct assessment of endothelial vasomotor function in coronary arteries is considered to be the 
‘gold standard’ in assessing coronary vascular endothelial function. Indeed, the coronary flow reserve 
(CFR) is a measure of endothelial function, calculated from the coronary blood flow during 
hyperaemia divided by the blood flow during baseline. (Collins, 1993)  Measurement of CFR 
correlates well with other modalities of endothelial function, such as flow-mediated dilatation. (Gullu 
et al., 2006; Pellegrino et al., 2005) CFR can be measured non-invasively using echocardiography, 
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positron emission tomography (PET) and magnetic resonance imaging; and invasively by using intra-
coronary Doppler studies.  Maximum hyperaemia is achieved physiologically by transient occlusion 
of coronary arteries, (M. Marcus et al., 1981) exercise (Felder et al., 1994) and by pharmacological 
methods through either intracoronary instillation of adenosine/papaverine (Christensen et al., 1991) or 
intravenous administration of adenosine/dipyridamole. (Rossen et al., 1991) A normal response refers 
to a 2-3 fold increase in the myocardial blood flow during hyperaemia at a given perfusion pressure. 
(M. L. Marcus et al., 1990) An abnormal CFR is a measure of endothelial dysfunction and has been 
described in conditions like hypertension, (Olsen et al., 2004) diabetes, (Nahser, Brown, Oskarsson, 
Winniford, & Rossen, 1995) atherosclerosis, (Sellke, Armstrong, & Harrison, 1990) coronary artery 
disease, (Zeiher, Drexler, Wollschlager, & Just, 1991) hypercholesterolemia,(Yokoyama et al., 1996) 
renal failure, (Tok et al., 2005) smoking (Ashikaga et al., 2007) and inflammatory diseases. (Hirata et 
al., 2007; Sulli et al., 2004) Coronary artery endothelial dysfunction is strongly associated with poor 
cardiovascular outcomes. (Schachinger, Britten, & Zeiher, 2000; Suwaidi et al., 2000) 
  
Skalidis et al has shown impaired myocardial perfusion in patients with lone AF invasively by 
measuring time averaged peak coronary blood flow velocity (APV), using an intracoronary Doppler 
wire study.  Adenosine was used to produce maximal hyperaemia and this was compared with 
baseline APV to calculate the CFR. The CFR in left atrial circumflex branch (LACB) was 
significantly reduced in lone AF patients compared to healthy subjects indicating the presence of 
possible localized microvascular endothelial dysfunction. (Skalidis et al., 2008) Using positron 
emission tomography (PET) scan, Range et al demonstrated impaired myocardial blood flow (MBF) 
at rest and hyperaemia (using adenosine) in AF patients compared to healthy controls.  After 
achieving sinus rhythm by cardioversion (at 4.1 months) there was partial improvement noted in the 
MBF at rest suggestive of improved endothelial function following sinus rhythm restoration. (Range 
et al., 2007) Takahashi et al demonstrated impaired endothelial dependent vasodilatation in AF 
patients with subsequent improvement after restoring sinus rhythm with cardioversion. The technique 
used to assess endothelial function was venous occlusion plethysmography and the measurement of 
forearm blood flow (FBF) after intra-arterial administration of acetylcholine and nitroglycerine. 
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(Takahashi et al., 2001) After restoring sinus rhythm, there was a 45% increase in endothelial 
dependent vasodilatation in lone AF patients compared to a 90% increase in AF patients with heart 
disease, relative to baseline levels. Using similar technique, the same group demonstrated 
improvement in the endothelium dependent vasodilatation with exercise in patients with AF after 
restoring sinus rhythm with cardioversion, suggesting an improvement in endothelial function with 
restoration of sinus rhythm. (Takahashi et al., 2002) However, these techniques are invasive, time 
consuming and may not be suitable for large epidemiological studies.  
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Table 3.2: A summary of all the available studies of endothelial function and their key findings in patients with AF. 
 
Author  
 
Year 
 
 
Type of AF 
 
 
Marker(s) 
Studied 
 
Control 
group 
 
Disease 
group 
 
Key findings 
Polovina et al 2015 Lone persistent 
AF 
FMD 28 38 Impaired endothelial dependent vasodilatation in patients 
with lone persistent AF compared to healthy controls. A 
negative correlation noted between FMD and AF duration 
 
Lim et al 2014 Persistent AF ADMA  57 A significant reduction in the levels of ADMA noted in 
patients who remained in SR following catheter AF ablation 
compared to their baseline values (0.15 vs. 0.17 µM/L) 
 
Yang et al 2011 Persistent AF ADMA  138 Higher levels of ADMA measured prior to catheter ablation 
at baseline, predicts AF recurrence at 10 months FU [HR 4.6, 
95% CI 1.81-11.62, p=0.001] 
 
Skalidis et al 
 
2008 
 
Lone AF 
 
Coronary 
flow reserve  
 
 
16 
 
15 
 
Both hyperemic blood flow (30.4 cm/s vs. 45.8, p<0.001) and 
CFR (2.2 vs. 2.8, p<0.001) in left atrial circumflex branch 
were significantly lower in LAF patients compared to healthy 
controls indicating microvascular endothelial dysfunction 
 
Freestone et al 
 
2008  
 
AF+HF 
 
vWf,  
E-selectin 
 
117 
 
AF+HF 52 
SR+HF 138 
 
 
Elevated levels of vWf seen in patients with AF+HF vs. 
SR+HF (p=0.0183) vs. healthy controls (p<0.003). Linear 
relationship with the levels of vWf and the presence of AF 
and correlated with NT-Pro BNP levels.  
 
Freestone et al 
 
2008 
 
Chronic  
 
FMD 
 
26 
 
40 
 
Impaired endothelial dependent vasodilatation in patients 
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permanent 
AF 
with AF compared to healthy controls (8.9% vs. 0%, 
p<0.0001) but no difference seen with endothelium 
independent (GTN induced) vasodilatation in both groups 
 
Cengel et al 
 
2008 
 
Acute & 
chronic AF 
 
ADMA 
 
18 
 
Acute AF 19 
Chronic AF 25 
 
Higher plasma concentrations of ADMA seen in acute AF vs. 
chronic AF vs. healthy controls (0.76 vs. 0.50 vs. 0.36, p 
<0.001). Also significant differences seen between each 
individual group in the levels of ADMA 
 
Xia et al 
 
 
 
2008 
 
Persistent AF 
 
 
ADMA 
 
NS 
 
70 
 
Higher levels of ADMA at baseline predicts the recurrence of 
AF post ECV at 1 month (OR 4.2, 95% CI 1.44-12.22, 
p<0.001). Level of ADMA independently predicts AF 
recurrence (OR 4.19, 95% CI 1.12-15.77, p=0.034) 
 
Freestone et al 
 
2007 
 
PAF, persistent  
& chronic AF 
 
 
vWf,  
E-Selectin, 
sTM 
 
40 
 
PAF 35 
Persistent 50 
Chronic 60 
 
vWf (p<0.001), E-selectin (P<0.003) levels were 
significantly higher in AF patients compared to healthy 
controls. No significant differences seen between individual 
AF groups. Also treatment with warfarin made no difference 
in the levels of vWf or E-selectin 
 
Range et al 
 
2007 
 
Persistent  
AF 
 
MBF,  
CVR with 
PET scan 
 
13 
 
25 
 
Reduced resting MBF (0.95 vs. 1.14 ml/min/ml, p=0.009), 
hyperemic MBF (2.07 vs. 3.33 ml/min/ml, p<0.001) in AF 
compared to healthy controls.  Partial improvement in resting 
MBF after restoring SR with ECV in AF patients 
 
Skalidis et al 
 
 
2007 
 
Persistent 
AF  
 
FMD 
 
25 
 
46 
 
Impaired endothelial dependent vasodilatation seen in AF 
patients compared to healthy controls (8.1 vs. 12.2, p<0.001). 
There was an improvement in endothelial dependent 
vasodilatation after restoring SR with ECV from baseline at 
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1-month (13.6 vs. 8, p<0.001) 
 
Guazzi et al 
 
 
  
2007 
 
Lone AF 
AF+HTN 
AF+DM 
 
FMD 
 
NS 
 
Lone 17 
AF+HTN 16 
AF+DM 17 
 
Improvement in endothelial dependent vasodilatation in both 
supine and head tilting position in patients with Lone AF 
(p<0.01) and AF+HTN (p<0.01) from baseline after restoring 
SR with ECV at 2 weeks and 3 months 
 
Tviet et al 
 
 
2007 
 
Persistent AF 
 
E selectin, 
hsCRP 
 
NS 
 
171 
 
Low levels of E-selectin at the baseline predicts ECV success 
in patients who remained in SR compared to those who had 
relapse of AF at 6 months (32 vs. 37 ng/ml, p=0.042) 
 
Edhery et al 
 
 
 
2007 
 
Permanent or 
Persistent AF 
 
Procoagulant 
microparticle
s 
 
90 
 
45 
 
The levels of annexin V-positive microparticles were higher 
in patients with AF compared to controls with cardiovascular 
risk factors vs. healthy subjects. But no difference seen in the 
levels of platelet derived micro particles in those groups 
 
Freestone et al 
 
 
 
2006 
 
Persistent 
AF 
 
vWf,  
E-selectin, 
sTM, CEC’s 
 
20 
 
30 
 
Increased levels of vWf seen with patients in AF compared to 
healthy controls (p<0.001) and the levels of vWf showed a 
reduction after restoring SR post ECV from baseline 
(p<0.001). However the levels of sTM and CEC’s showed an 
increase following cardioversion 
 
Freestone et al 
 
 
2005 Chronic AF vWf, VEGF 40 59 Higher levels of vWf seen in patients in AF compared to 
healthy controls (p=0.005). Significant correlation between 
vWf and VEGF (p=0.011) suggesting a possible link between 
endothelial function and angiogenesis 
 
Freestone et al 
 
 
2005  
 
Chronic AF 
 
CEC’s, vWf, 
sTM 
 
20 
 
Chronic AF 
28 + acute 
 
Raised levels of CEC’s (p<0.001) and sTM (p=0.004) in AF 
patients with acute cardiovascular or cerebrovascular events  
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 cardio/ 
cerebral events  
63 
compared to chronic stable AF. Also the levels of vWf in 
chronic stable AF compared to healthy controls (p<0.001) 
 
Lip et al 
(SPAF III) 
 
 
2005 
 
Chronic AF 
 
 
vWf 
 
NS 
 
1321  
 
Significantly higher levels of vWf seen in patients with AF 
and CHF compared to patients with no left ventricular 
dysfunction (p<0.001) suggesting that CHF may increase 
thrombotic risk in patients with AF with higher endothelial 
damage 
 
Marin et al 
 
 
 
2004 
 
Acute & 
Chronic AF 
 
vWf, sTM 
 
24 
 
Acute AF 24 
Chronic 24 
 
Increased levels of vWf, sTM in both acute and chronic AF  
patients compared to healthy controls. Levels of both vWf 
and sTM remained elevated at 30 days post ECV suggesting 
a persistent endothelial dysfunction in AF 
 
Goette et al 
 
2004 
 
Lone AF 
 
vWf 
 
13 
 
13 
 
Higher levels of vWf seen after heavy exercise in patients 
with AF compared to baseline (p<0.05) suggesting that heavy 
physical exercise may be a risk factor for thromboembolism 
 
Conway et al 
(SPAF III) 
 
2003 
 
Chronic AF 
 
vWf 
 
NS 
 
994 
 
Higher levels of plasma vWf independently predicts the risk 
of stroke and vascular events with absolute RR 1.2 (95% CI 
1.0-1.4) for every 20 IU/dl increase in vWf 
 
Conway et al 
(Rotterdam 
Study) 
 
2003 
 
Chronic AF 
 
vWf 
 
324 
 
162 
 
Linear association between vWf levels and the presence of  
AF in elderly women (OR 1.17, 95% CI 1.02-1.34) per every 
10IU/dl increase in vWf suggesting that prothrombotic state 
may be subjected to sex difference in AF 
 
Roldan et al 
 
2003 
 
Persistent 
 
E-Selectin 
 
74 
 
191 
 
No correlation between E-Selectin levels and inflammatory 
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NVAF markers. But reduction in the levels of E-selectin with 
anticoagulation (p<0.01) from baseline 
 
Goette et al 
 
 
 
2003 
 
Persistent, PAF 
 
HPC’s 
(CD34+) 
 
17 
 
PAF 12 
Persistent 17 
 
Levels of HPC’s (CD34+) were higher in patients with 
persistent AF compared to healthy controls (P<0.01). Post 
ECVafter restoring SR the levels of CD34+ showed a decline 
at 48 hours 
 
Nakamura et al 
 
 
2003 
 
NVAF with  
Cardio- 
embolism 
 
vWf 
 
4 
 
7 
 
Immunohistochemical staining of left atrial appendages 
specimens showed higher expression of vWf (p=0.02) and 
TF (p=0.001) compared to controls without AF 
 
Nikitovic et al 
 
 
2002 
 
Chronic AF 
 
vWf, NO 
 
21 
 
42 
 
On baseline lower levels of NO (p<0.001) and higher levels 
of vWf (P<0.01) in patients with AF compared to healthy 
controls. After achieving SR post ECV the levels of NO 
showed an increase (p=0.004) at 4 weeks and a decline in 
vWf levels (p=0.02)  
 
Conway et al 
(SPAF III) 
 
 
2002 
 
Chronic AF 
 
vWf 
 
NS 
 
 
1321 
 
Higher levels of vWf seen in patients with AF and 
significantly correlated with advancing age (p<0.001), prior 
cerebral ischemia (p<0.001), recent heart failure (p<0.001), 
diabetes (p<0.001) – risk factors for stroke in AF 
 
Takahashi et al 
 
2002 
 
Persistent AF 
 
Forearm  
Plethysmo- 
graphy 
 
 
NS 
 
10 
 
Improvement in the FBF from baseline with exercise in 
patients with AF after restoring SR post ECV (p<0.05). But 
no significant changes seen in the FBF at rest post - 
cardioversion. 
 
Takahashi et al 
 
2001 
 
Persistent AF 
 
Fore arm 
 
12 
 
Lone AF 14 
 
On baseline impaired FBF with acetylcholine with patients in 
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 Plethysmo- 
graphy 
 
AF+HD 13 AF compared to controls. Improvement in FBF with both 
acetyl choline and nitro-glycerine from baseline after 
restoring SR post ECV (46% with lone AF and 90% with 
AF+HD) 
 
Feng et al 
(Framingham 
Offspring 
Study)  
 
2001 
 
Persistent AF 
 
 
vWf 
 
167 
 
47 
 
Raised levels of vWf seen in patients with AF compared to 
healthy controls (p<0.03) with similar results with other 
haemostatic factors like tPA & fibrinogen 
 
Li Saw Hee et 
al 
 
2001 
 
PAF 
Persistent 
Permanent 
 
vWf 
 
20 
 
PAF 23 
Persistent 23 
Permanent 23 
 
Raised levels of vWf in permanent >Paroxysmal > persistent 
= healthy controls. No differences seen in the levels of vWf 
post cardioversion in patients with persistent AF 
 
Fukuchi et al 
 
2001 
 
Chronic AF 
 
 
vWf 
 
NS 
 
16 
 
Over expression of endocardial immunoreactive vWf in left 
atrial appendages from patients with mitral stenosis 
compared to non-cardiac patients. Significant correlation 
seen with immunohistochemical grade of vWf and degree of 
platelet adhesion 
 
Li Saw Hee et 
al 
 
2000 
 
Chronic AF 
 
vWf, sTM 
 
60 
 
61 
 
Higher levels of vWf seen in patients with AF compared to 
healthy controls (p<0.0001). No changes in the levels of vWf 
seen with either warfarin or warfarin and aspirin combination 
 
Goldsmith et al  
 
 
2000 
 
 
AF+MS 
 
vWf 
 
NS 
 
35 
 
Higher levels of vWf seen in patients with AF (p=0.042) and  
mitral valve disease (p=0.0004) compared with healthy 
controls  
 
Li Saw Hee et 
 
1999 
 
Chronic AF 
 
vWf 
 
25 
 
AF+MS 25 
 
Raised levels of vWf seen in patients in AF compared to 
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al 
 
healthy controls (P<0.005) but no differences seen in the 
levels of vWf in the blood samples collected from either 
cardiac or peripheral sites taken during balloon mitral 
valvotomy 
 
 
Heppell et al 
 
 
 
 
1997 
 
 
Non rheumatic 
AF 
 
 
vWf 
 
 
NS 
 
 
190 
 
Raised levels of vWf seen in patients with AF (P<0.05). 
Higher levels of vWf independently associated with LA 
thrombosis and spontaneous echo contrast (P=0.04) 
 
Lip et al 
 
1995 
 
Chronic AF 
 
vWf 
 
158 
 
87 
Levels of vWf were higher in patients with AF (whilst on no 
treatment) compared to healthy controls (p<0.0001) and 
independent of underlying structural heart disease 
 
Yamamoto et al 
 
 
 
1995 
 
Chronic 
AF+MS 
 
vWf 
 
15 
 
11 
 
Raised levels of vWf in peripheral blood samples in patients 
with mitral stenosis compared to age matched healthy 
controls (p<0.05). But no differences seen between levels of 
vWf in peripheral or left/right atrial blood samples. 
 
Gustaffson et al 
 
1990 
 
AF+stroke 
AF-stroke 
 
vWf 
 
40 
 
20 AF+ 
stroke; vs 20 
Stroke with no 
AF; 
vs 20 
SR+Stroke  
 
 
Higher levels of vWf seen in patients with AF (both groups) 
compared to patients in SR and healthy controls, also 
associated with increased haemostatic markers 
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Table 3.3: Techniques used in the assessment of endothelial function in atrial fibrillation; their 
advantages and disadvantages 
 
Techniques Advantages Disadvantages 
von Willebrand factor Simple venepuncture, 
reproducible with ELISA 
Extensive data in AF 
 
An acute phase protein. Variability 
with blood group reported 
Asymmetrical dimethyl 
arginine 
 
Simple venepuncture,  
reproducible & 
assessed by ELISA 
 
Limited data in AF 
E-Selectin Simple venepuncture, 
reproducible & 
assessed by ELISA 
 
Complex interaction with 
inflammation & therefore less 
specific for ED 
Soluble thrombomodulin Simple venepuncture,  
reproducible & 
assessed by ELISA 
 
Conflicting data in AF. Complex 
interaction with thrombosis & less 
specific for ED 
CEC’s & EPC’s 
 
Simple venepuncture, 
assessed by flow cytometry 
Less reproducible with extreme 
biological variations & with 
limited data in AF 
 
Flow mediated dilatation 
 
Non-invasive, ultrasound 
technique 
 
Operator dependent, difficult 
assessment due to beat to beat 
variability and irregularity of the 
rhythm  
 
Strain gauge venous 
occlusion plethysmography 
 
Very reliable & 
gold standard technique 
Invasive, time-consuming, 
less reproducible and poorly 
tolerated 
 
Intracoronary assessment of 
coronary flow reserve 
 
Very reliable, reproducible 
& gold standard technique 
Invasive, time-consuming and 
poorly tolerated 
Assessment of coronary flow 
reserve with PET scan 
 
Non-invasive and 
reproducible 
 
Costly, limited availability, time- 
consuming and radiation exposure 
 
 
 
 
 
  40 
Conclusion  
Endothelial damage and dysfunction has been described in patients with AF using a range of different 
techniques (Table 3.3). Of the various methods described, measurement of plasma vWf levels has 
been extensively studied and shown to be independently associated with cardiovascular events in 
patients with AF; also may potentially refine thromboembolic risk stratification when combined with 
clinical risk stratification schemes. Such plasma biomarker studies are suitable for large-scale 
population studies, in contrast to more specialized imaging or invasive methods of assessing 
endothelial (dys) function in AF.   
 
Given the associations of endothelial (dys) function with cardiovascular events, further study of the 
clinical significance in patients with AF merits attention.   The pathophysiological mechanism 
underlying endothelial (dys) function and the relationship with the occurrence of AF or risk of 
thromboembolism is uncertain, as further studies are needed to address the impact of associated 
comorbidities - such as hypertension, diabetes mellitus and heart failure - which themselves are 
associated with endothelial dysfunction. Medical therapies such as angiotensin converting enzyme 
inhibitors and statins, which can affect endothelial function, are further confounders.  For our 
understanding of endothelial (dys) function in AF to advance, further studies in lone AF subjects, with 
no significant confounders or drug therapies, may be needed. 
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CHAPTER FOUR 
 
4. A review on arterial stiffness  
4.1. Introduction 
Even historically both evaluation and assessment of an arterial pulse prevailed as an integral part of a 
clinical examination; and the change in pulse characteristics may be an early manifestation of any 
disease process. Since the early description of the arterial pulse waveform by Marley (1863), changes 
in the waveforms were observed with both ageing as well as with disease forms. Nevertheless, arterial 
stiffness as well as its potential clinical implications was poorly understood until Roy (1880) 
commented on the changes in arterial stiffness and its possible health significance. Recently, there has 
been resurgence in the evaluation of arterial stiffness and pulse waveform and its relationship to 
cardiovascular disease.  
 
Arterial stiffness is a general term that describes the rigidity/physiological properties of the arterial 
wall. A number of indices have been used as measures of arterial stiffness including elasticity, 
compliance, distensibility and pulse wave velocity. (M. O'Rourke, 1995) The Table 4.1 illustrates the 
frequently used indices representing arterial stiffness and their definitions. These measurements 
describe different aspects of arterial physiology and cannot be used interchangeably. (Mackenzie, 
Wilkinson, & Cockcroft, 2002) Three different indices will be used in this thesis as measures of 
arterial stiffness are pulse pressure, pulse wave analysis and pulse wave velocity. Therefore, the term 
arterial stiffness will be used in this thesis to encompass any/all of these three indices.  The changes in 
arterial elastic properties may precede the actual development of an overt clinical disease. Therefore 
arterial stiffness might be an early manifestation of the disease process and or precisely linked with 
the progression of vascular disease. Increased levels of arterial stiffness were observed in patients 
with diabetes, renal failure and hypertension. (Glasser et al., 1997).  
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Table 4.1. The commonly used indices of arterial stiffness and their definitions (derived from 
(Mackenzie et al., 2002)  
Terms Definition 
Elastic modulus Represents the change in pressure needed for a theoretical 100% 
stretch from baseline diameter at rest; (ΔPxD, mm of Hg) / ΔD  
 
Young’s modulus Represents elastic modulus/unit area 
(ΔPxD, in mm of Hg) / (ΔDxh, in cms)  
 
Arterial distensibility Represents the relative diameter change for a given change in 
pressure; ΔD / (ΔPxD, in mm of Hg)  
 
Arterial compliance Represents absolute change in diameter or area for a given step in 
pressure; (ΔD, in cms) / (ΔP, mm of Hg) 
 
Pulse wave velocity Represents the velocity required for the pulse to travel down a 
length of the artery; (Distance, in cm/Δt, in seconds) 
 
Augmentation index The difference between the first and second systolic peaks,  
represented as percentage of pulse pressure 
 
Stiffness index (β) Represented as a ratio between In (systolic/diastolic pressures) 
and the relative diameter change; β= In (Ps/Pd)/ (Ds-Dd)/Dd 
 
D=diameter; P= pressure; h=wall thickness; t=time; s=systolic; d=diastolic 
 
4.2.  Non-invasive assessment of arterial stiffness 
4.2.1. Pulse pressure 
Pulse pressure (PP) represents the absolute difference in systolic (SBP) and diastolic blood pressures 
(DBP), and may reflect the buffering function of the large arteries. However, a number of other 
factors can affect the PP, including aortic valve insufficiency, presence of arterio-venous fistula and 
myocardial contractility. Unsurprisingly, PP has only modest correlation with other measures of 
arterial stiffness. It is rather evident that ageing is associated with a proportional increase in systolic 
and diastolic blood pressures, up to a certain age.  Interestingly no further intensification in DBP is 
observed after the age of 50-60 years, however paradoxically in a majority DBP showed a reduction 
and as a consequence widens the pulse pressure. (Franklin et al., 1997) To an extent, reliable 
assessment of PP can be performed with routine sphygmomanometers. However, the measurement of 
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PP from peripheral resistant arteries (radial or brachial) might not always represent true central aortic 
pulse pressure, which is limitation with this technique. (Pauca, Wallenhaupt, Kon, & Tucker, 1992) 
Elevated central aortic pulse pressure is often associated with the development of LVH and the later 
independently predicts CV mortality. (Deague, Wilson, Grigg, & Harrap, 2001) 
 
Results from the Framingham Heart Study revealed that PP was superior in predicting patients with 
higher coronary risk compared to SBP or DBP individually. (Franklin, Khan, Wong, Larson, & Levy, 
1999) In the MRC Mild hypertension trial, PP independently predicted both fatal and non-fatal 
coronary events in untreated hypertensives male subjects compared to SBP, DBP or MBP; however 
stroke was better predicted by MBP. (Millar, Lever, & Burke, 1999) Similar results were seen in a 
French study, where PP remained an independent significant predictor of all cause, cardiovascular 
mortality in males between 40-69 years. (Benetos et al., 1997) In the Systolic Hypertension in Elderly 
Program (SHEP), for every 10 mm of Hg increase in PP, there was a subsequent 11% increase in 
stroke risk and 16% increase in all-cause death noted in elderly patients with isolated systolic 
hypertension. (Domanski, Davis, Pfeffer, Kastantin, & Mitchell, 1999) In the community-based East 
Boston Senior Health project, PP remains an independent predictor of congestive heart failure (even 
after adjusting for confounders including sex, age, MAP, presence of diabetes, prior history of 
coronary disease, valvular heart disease and AF). For every 10-mm Hg rise in pulse pressure, there 
was a 14% increased risk of congestive heart failure observed in this study. (Chae et al., 1999) 
 
4.2.2. Pulse wave velocity 
The pulse wave velocity (PWV) in simple terms represents the rate at which the pressure wave travels 
within the vasculature. PWV can be measured by calculating the distance travelled by the wave 
between two points within the vascular tree divided by the time taken for the wave to travel that 
distance (metres/sec or centimetres/sec). Simultaneous assessment of two sites within the vasculature 
as a single operator can be technically challenging; nonetheless ECG gated readings taken separately 
in relation to a fixed point of cardiac cycle (normally R wave in the ECG) often helps in overcoming 
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this limitation. Both invasive and non-invasive techniques have been tried in the assessment of PWV, 
albeit with its own limitations. Also to avoid the conceptual problems related to ‘wave reflection’ 
conventionally foot-to-foot method is used to measure PWV. A few major pitfalls associated with this 
technique include: (i) Anatomy of the central aorta and its poor accessibility therefore the nearest 
available superficial arteries (radial, brachial, carotid, femoral) are often used; (ii) the arterial distance 
calculated between the two recording sites can only be approximated by the measurements from the 
surface, therefore might not be accurate. (Asmar et al., 1997) PWV is a segmental measurement, 
providing information only on a segment of the large artery. The Bramwell and Hill equation 
expresses PWV as a product of arterial distensibility, using the formula below: 
PWV = √ ΔPV/ΔVp = √1/±pD,  
(D=distensibility; ΔPV/ΔV=relative volume elasticity of the vessel segment and p=density of the 
blood) 
  
Figure 4.1. Assessment of pulse wave velocity using applanation tonometry (calculated by measuring 
distance between carotid-femoral divided by time, PWV = L / t in m/sec) 
 
 
 
The technique involved in the assessment PWV has been well validated and often easily reproducible. 
A small study, illustrated the potential use of magnetic resonance imaging (MRI) technique in the 
Common carotid 
artery 
Common femoral 
artery 
∆t 
∆L 
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assessing PWV from the arteries, which are not routinely accessible. (Mohiaddin, Firmin, & 
Longmore, 1993) 
 
The recent systematic review and meta-analysis of longitudinal studies evaluating brachial-ankle 
PWV or brachial-ankle elasticity index (baEI) suggested that an increase of baEI by 1m/s correspond 
with an increased risk of total cardiovascular events by 12%, cardiovascular mortality by 13% and all-
cause mortality by 6%. (Vlachopoulos, Aznaouridis, Terentes-Printzios, Ioakeimidis, & Stefanadis, 
2012) The Framingham Heart study, reported that higher carotid-femoral PWV (PWVcf) was 
associated with a 48% increase in cardiovascular risk; however no associations noted between the 
augmentation index, central pulse pressure, and pulse pressure amplification. (Mitchell et al., 2010) 
Similarly, in the offspring cohort data from the Framingham Heart study, revealed a positive 
correlation between carotid-femoral PWV and systolic BP related to exercise. (Thanassoulis et al., 
2012) Recently, Bortel and colleagues have published an expert consensus document on the 
measurement of aortic stiffness in clinical practice using carotid-femoral pulse wave velocity towards 
standardisation of the technique. (Van Bortel et al., 2012) The measurement of carotid-femoral PWV 
is now considered as the gold standard for the assessment of aortic stiffness in clinical practice.  
 
4.2.3. Pressure Waveform analysis 
Since the early pressure waveforms obtained using sphymograph, various invasive and non-invasive 
methods have been established for analysing arterial waveforms. A typical ‘arterial waveform’ 
consists of the forward pressure wave due to ventricular contraction and a reflected wave from the 
peripheries (predominantly at branching points); notably morphology of the waveform varies 
throughout the vascular tree. The velocity of the pressure wave is directly proportional to the stiffness 
of the arterial wall. In elastic and complaint arteries with lower PWV, the reflected wave tends to 
reach the aortic root late in diastole; thereby amplifying both diastolic pressure and coronary blood 
flow. On the contrary, in resistant and stiffer arteries the reflected wave reaches the aortic root earlier 
than expected, augmenting systolic pressure. In effect it lowers diastolic pressure, reduces forward 
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flow and increases systolic load on the heart. The magnitude of arterial stiffness is directly 
proportional to the wave amplification on reflection, thereby enhances the central pressure as well as 
the systolic load on the heart.  
 
Non-invasive measurement of arterial stiffness can be performed using pulse wave analysis (PWA). 
The technique remains simple and well validated, using applanation tonometry pressure waveforms 
obtained from peripheral arteries (radial or femoral or carotid artery).  Subsequently, an analogous 
central estimated wave form can be derived using a validated generalised transfer factor 
(Sphygmacor, AtCor Medical). From the derived central wave form, augmentation index can be 
assessed. Augmentation pressure (AP) = difference in first (P1) and second (P2) systolic peaks in 
forward pressure wave (P1-P2); Augmentation Index = a ratio between the AP and PP, represented in 
percentage; (AI = P1 – P2 / PP)]. (M. F. O'Rourke & Gallagher, 1996)  
 
Figure 4.2. Assessment of pulse wave analysis using applanation tonometry (PWA)  
 
 
Pulse wave analysis derived central aortic pressure (Sphygmocor version 7, Atcor) from radial artery 
using applanation tonometry has been shown to be predictive of clinical outcomes in the Conduit 
Artery Function Evaluation (CAFE-BPLA) study. Despite having identical effects on brachial BP, 
central aortic pressure was significantly lower in the amlodipine ± perindopril arm compared to 
Pulse Pressure 
Augmentation pressure (P2) 
Time 
Systolic pressure (P1) 
Diastolic pressure (P3) 
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atenelol ± thiazide diuretic arm in patients with treated hypertension. (Williams et al., 2006) However 
in the CAFE-LLA study, treatment with atorvastatin did not show any effect on the central aortic 
pressures or hemodynamics. (Williams et al., 2009) Similarly, measurement of augmentation index 
was prospectively used in both FIELD study to assess the long-term impact of fenofibrate therapy in 
subjects with type 2 diabetes (Hiukka et al., 2008) as well as in the SEARCH of diabetic in youth 
study towards assessing arterial stiffness. (Wadwa et al., 2010) Nevertheless, in a study of elderly 
patients with acute ischaemic stroke, a higher augmentation index was associated with lower in-
hospital mortality. National Institutes of Health stroke Scale (NIHSS) score, AF and augmentation 
index were independent predictors of in-patient mortality. (Tziomalos et al., 2014) 
 
4.3. Arterial stiffness in atrial fibrillation 
The results from the observational Framingham cohort suggested that increase in PP is associated 
with higher risk of AF. The cumulative 20-year incidence of AF was 5.6 % for PP of ≤ 40 mm of Hg 
and rose exponentially to 23.3% for PP ≥ 61 mmHg. There was a significant 1.3-fold increased risk of 
AF with every 20 mm of Hg increase in PP, (after adjusting for diabetes, smoking, BMI, valvular 
heart disease, treatment for hypertension, LVH, MI and cardiac failure). These data suggest that 
alteration in arterial physiology may be associated with increased risk of developing AF. (Mitchell et 
al., 2007) Similar results seen in the French PARTAGE elderly cohort study, low brachial and aortic 
pulse pressure amplification (percentage of increase in PP in brachial artery relative to central PP) is 
associated with higher risk of heart disease (cardiac failure, AF or coronary disease). (Salvi et al., 
2010) In the LIFE study (The Losartan Intervention For Endpoint reduction in Hypertension), PP 
independently predicts the development of new onset AF, over a mean follow-up of 4.9 years. 
(Larstorp et al., 2012) In an Italian study of patients with type-2 diabetics (with a mean follow-up 10-
years), baseline PP is an independent predictor of the risk of AF (after adjusting for sex, BMI, age, 
diabetes, treatment for hypertension, LVH, coronary disease, renal failure, valvular heart disease and 
cardiac failure. (Valbusa et al., 2012) Recently, in the Multi-Ethnic Study of Atherosclerosis for every 
1-SD increase in PP there was a 29% increased risk of AF observed over a mean follow-up of 7.8 
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years. Similarly, each 1-SD increase in aortic distensibility (assessed using magnetic resonance 
imaging) was associated with 9% increased risk of AF in this study. (Roetker et al., 2014) 
 
Increased arterial stiffness may impose an abnormal haemodynamic load on the left ventricle. In 2008 
Lantelme and colleagues, in their study with hypertensives patients (n=310, mean age = 54 years) 
found a significant association between LA diameter (LAD) and PWVcf. Similarly significant 
association observed between LAD and 24-hour PP even after adjusting for confounders including left 
ventricular remodelling and filling pressures. This was postulated as one of the likely mechanisms that 
poorly controlled hypertensive patients with diastolic dysfunction have further increased risk of stroke 
by the virtue of developing AF, due to adverse cardiac remodelling. (Lantelme et al., 2008) In another 
study assessing the relationship between arterial stiffness and LV diastolic function, there was a 
positive correlation observed between aortic PP, brachial PP, PWVcf, augmentation pressure (AP, 
using applanation tonometry) with left atrial volume and diastolic functional grading, even after 
adjusting for age, gender, and clinical and echocardiographic covariates. Interestingly, PWV and 
aortic and brachial PP were superior to AP in discriminating subjects with the highest risk of having 
new cardiovascular events. (Abhayaratna et al., 2006) Even in patients with obstructive sleep apnoea, 
PWVcf significantly correlated with LA diameter, after adjusting for confounders and proposed as a 
possible mechanism of atrial remodelling contributing the higher risk of AF in these patients. (Drager, 
Bortolotto, Pedrosa, Krieger, & Lorenzi-Filho, 2010) 
 
A Korean study assessing patients with hypertension reported higher PWVhf (pulse wave velocity 
heart-femoral) in patients with AF compared to those in sinus rhythm. The study concluded that 
presence of AF was significantly correlated with a higher PWV, independent of age and blood 
pressure. (S. H. Lee, Choi, Jung, & Lee, 2008) Recently Kaji and colleagues demonstrated an 
independent correlation between increased augmentation index (AI, measured from Cardio-Ankle 
Vascular Index, CAVI) and raised B-type natriuretic peptide levels in patients with PAF compared to 
those in sinus rhythm. (Kaji et al., 2009) It was postulated that the change in arterial stiffness with its 
progressive LV remodelling in patients with PAF might account for the elevated levels of BNP in 
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their study. Similarly, the same group of researchers demonstrated that augmentation index (measured 
using radial arterial waveform using applanation tonometry) was noted to be significantly higher in 
patients with PAF compared to gender matches controls without PAF, even after adjusting to age, sex, 
heart rate and medical therapy. Also increase in augmentation index was significantly correlated with 
LVH and LA enlargement, suggesting that enhanced wave reflection may be related to the 
development of AF. (Doi et al., 2009) In a small study of AF patients, Fumagalli et al demonstrated 
an association between CAVI and age, duration of AF and left atrial diameter immediately post 
DCCV. (Fumagalli et al., 2014) In a study, Chen et al demonstrated an association between increased 
carotid intima-media thickness and arterial stiffness (measured using carotid-femoral pulse wave 
velocity) with lone AF. Notably, persistent AF patients were found to have higher arterial stiffness 
compared to paroxysmal AF patients in this study. (Chen et al., 2013) In a small study of lone AF 
patients, both baseline higher central PP and augmentation pressure were associated with increased 
AF recurrences during one-year follow-up post-catheter ablation. (D. H. Lau et al., 2013) These 
studies confirm the potential role of arterial stiffness in the development of AF as well as in its disease 
progression over time.  
  
4.4. The Future 
Indeed it is rather evident that higher arterial stiffness independently predicts future cardiovascular 
risk. Nevertheless, until recently this concept remained unexplored. At present, we are privileged to 
have numerous cheap and simpler techniques to assess arterial stiffness non-invasively; although the 
full clinical impact of these measurements are not yet clear. The prognostic value of these 
measurements have been investigated in relatively small studies and focussed on specific high-risk 
groups. Larger studies will be required to understand the effect of drugs and treatment on these 
parameters as well as their impact on the clinical outcomes. With substantial improvement in the non-
invasive techniques, the assessment of arterial stiffness could be made routine and might play an 
integral role in the evaluation of our patients in the near future. 
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CHAPTER FIVE 
 
5. A review on the effects of right ventricular apical pacing and atrial fibrillation 
5.1.  Introduction 
Over a century ago, McWilliam (1899) reported in the British Medical Journal that application of an 
electrical impulse to a human heart in asystole caused a ventricular contraction and proposed that a 
heart rhythm of 60-70 beats per minute could be evoked by impulses. The New York based 
cardiologist, Dr Hyman with his colleagues in 1930’s were the first to construct an electro-mechanical 
device and reportedly tested on experimental animals also popularised the term ‘artificial 
pacemakers’.  Despite these, it was only in 1958 Mr. Arne Larsson became the first human to receive 
a fully implantable pacemaker in Sweden. However over the years, there has been a significant 
improvement in the technology of the pacemakers and the new generation pacemakers has more 
sophisticated inbuilt arrhythmic algorithms, often multi-functional, considerably smaller with 
prolonged battery life. 
 
For managing symptomatic bradyarrhythmia, cardiac pacing remains an effective way of treatment. 
(Epstein et al., 2008) Common indications for cardiac pacing includes sinus node disease (SND) and 
AV-nodal conduction disturbances (Mond, Irwin, Morillo, & Ector, 2004) Notably for AV-block 
patients, treatment with cardiac pacing has shown to improve the symptoms as well as prognosis. 
(Barold, 1996) Also in selected patients, cardiac pacing can be used to improve LV systolic function 
(Brecker, Xiao, Sparrow, & Gibson, 1992) and for symptom control in chronic AF patients following 
AV-nodal ablation. (Brignole et al., 1997) Unsurprisingly, over the years there has been a steep rise in 
pacemaker implantations and the incidence continue to increase with development of 
resynchronisation therapy for heart failure patients. (Uslan et al., 2008) Permanent pacemaker 
implantation involves transvenous placement of one or more endocardial pacing lead(s) within the 
right atria or right ventricle (single chamber) or both (dual chamber). Traditionally pacing from RV 
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apex has proven to be effective and often better tolerated; however it was proposed that RV apical 
pacing, both in short and long term may pose deleterious effects to the cardiac function.  
 
5.2. The effects of RV pacing on the myocardium 
During RV apical pacing, the triggered electrical wave propagates through a non-specialised tissue 
slowly within the myocardium instead via fast His-Purkinje fibres; (Vassallo et al., 1986) as a result 
causing delayed electrical activation (broad QRS complexes on the surface ECG resembling left 
bundle branch block). This abnormal delayed pattern of electrical activation has been well 
demonstrated between the interventricular septum and the infero-posterior basal segment of LV from 
RV apical pacing. (Auricchio et al., 2004; Leclercq et al., 1995; Rodriguez, Timmermans, Nabar, 
Beatty, & Wellens, 2003) 
 
Nevertheless similar abnormal sequence of mechanical activation has been established with RV apical 
pacing. Interestingly, changes are observed in both the onset as well as the mode of mechanical 
activation with RV apical pacing. (Prinzen, Augustijn, Arts, Allessie, & Reneman, 1990) Regional 
differences in the work load within the ventricles were observed with acceleration of systolic 
shortening of myocardial tissues closer to the site of pacing causing abnormal pre-stretch in particular 
at the areas of delayed mechanical activation. Thus the presence of multiple unusual contractile 
stimuli within the myocardium might compromise cardiac function. Using MRI, Prizen et al 
demonstrated altered myocardial strain patterns within the ventricles as well as changes in the 
regional peak strain from pacing (mechanical dyssynchrony). (Prinzen, Hunter, Wyman, & McVeigh, 
1999)  
 
In canine experimental models, changes in cardiac metabolism and abnormal perfusion in epicardial 
arteries have been demonstrated with RVOT pacing. (Prinzen et al., 1990) Even without any 
established CAD, abnormalities in myocardial perfusion were observed in patients with RV pacing in 
long-term. (Skalidis et al., 2001; Tse & Lau, 1997) Long term RV pacing may induce structural 
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changes at both intra-cellular and cellular levels, manifested by abnormal fibrosis and also with 
variations in the mitochondrial structure (Karpawich, Rabah, & Haas, 1999).  Long-term RV pacing 
resulted in abnormal asymmetrical septal hypertrophy, progressive LV dilatation (correlating with the 
increase in duration of QRS complexes) (van Oosterhout et al., 1998; Vernooy, Dijkman, Cheriex, 
Prinzen, & Crijns, 2006) and mitral insufficiency as well as abnormal LA remodelling (Barold & 
Ovsyshcher, 2005; Maurer, Torres, Corday, Haendchen, & Meerbaum, 1984) The possible deleterious 
effects associated with RV apical pacing are summarised in TABLE 5.1. Adapted from (Tops, Schalij, 
& Bax, 2009) 
 
Table 5.1. Short- and Long-term effects of RV pacing on cardiac structure 
Effects on perfusion and metabolism Abnormal regional perfusion with cardiac tissues 
Variations in the metabolic demand 
 
Abnormal cardiac remodelling Development of asymmetrical LV hypertrophy 
Development of LV cavity dilatation 
Development of mitral insufficiency 
Development of LA dilatation and fibrosis 
 
Effects on the cardiac hemodynamics Results in reduced cardiac output  
Results in raised  LV diastolic pressures 
 
Effects on the mechanical function Abnormal regional myocardial strain pattern 
Results in inter-ventricular mechanical dyssynchrony 
Results in intra-ventricular mechanical dyssynchrony 
 
5.3. RV pacing related mechanical dyssynchrony 
RV pacing can lead to intra-ventricular (within the LV regional walls) as well as inter-ventricular 
dyssynchrony (in between LV and RV). The development of mechanical dyssynchrony with long- 
term RV pacing is associated with LV dilatation, deterioration of systolic LV function and symptoms 
of heart failure. (Tops et al., 2006) It was proposed that functional impairment of LV may be the 
result of abnormal electrical activation pattern (resembling LBBB) or mechanical dyssynchrony with 
RV pacing. Echocardiography plays an important role in the assessment of mechanical dyssynchrony 
using Doppler, TDI, strain imaging and 3-D techniques.  
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5.3.1. Inter-ventricular dyssynchrony 
Time from the start of the QRS complex to the start of systolic aortic flow (assessing LV) or systolic 
pulmonary flow (assessing RV), is used to determine electro-mechanical delay using traditional 
Doppler techniques. The ‘inter-ventricular dyssynchrony’ is represented in milliseconds; it is the time 
difference between the electromechanical delay of LV and RV; (Rouleau et al., 2001) it is more 
pronounced whilst pacing at RV apex. (Schmidt et al., 2007; Tops et al., 2006) 
 
Figure 5.1. Diagrammatic representation of the assessment of inter-ventricular dyssynchrony  
 
5.3.2. Intra-ventricular dyssynchrony 
In detail, mechanical delay in the activation of individual regional walls within the LV due to RV 
pacing is expressed as ‘Intra-ventricular dyssynchrony’. This can be calculated as the time difference 
between the individual walls of LV at peak systole from the start of QRS complexes in surface ECG 
and represented in milliseconds. The later appears to be more evident and marked between the septal 
and LV lateral or posterior walls. Notably, the interventricular septum exhibits a premature fast 
inferior decent (in the pre-ejection phase); whereas the posterior wall remains slow to contract. 
(Gomes et al., 1977) Furthermore various echocardiographic studies consistently demonstrated that 
intra-ventricular dyssynchrony is promoted by RV apical pacing both in short- and long-term; also has 
been postulated as one of the possible mechanism(s) associated with the impairment of cardiac 
function. (Albertsen et al., 2008; Liu et al., 2008; Lupi et al., 2006) 
Pulmonary artery 
   ECG 
  Aorta 
Systolic flow 
Inter-ventricular dyssynchrony 
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Figure 5.2. Diagrammatic representation of the assessment of intra-ventricular synchrony between 
LV-septal and lateral wall.  
 
The presence of intra-ventricular dyssynchrony is associated with at least 3-fold increase in 
hospitalisations for decompensation in patients with stable non-ischaemic heart failure; independent 
of EF and the duration of QRS complexes. (Bader et al., 2004; Cho et al., 2005) Nevertheless, 
treatment with cardiac resynchronisation therapy (CRT) might aid in the complete recovery of systolic 
LV function, in heart failure patients. (Castellant, Fatemi, Bertault-Valls, Etienne, & Blanc, 2008; 
Ypenburg et al., 2009) 
 
5.3.  Relationship between risk of AF and the mode of pacing  
Various randomised controlled trials assessing the mode of pacing revealed that single chamber 
ventricular based (VVI) pacing is associated with unfavourable outcomes compared to dual chamber 
pacing (DDD). In the Mode Selection Trial (MOST) in Sinus-Node dysfunction study (n=2010), 
patients were randomised to either DDD or VVI based pacing. There were no significant differences 
noted in the primary end point (all cause death or nonfatal stroke) between DDD (21.5%) and VVI 
groups (23%) over a median-FU of 33 months. Despite no differences observed between the study 
groups in other secondary end points including death, stroke or hospitalisation for heart failure; 
however patients in DDD group were observed to have lower risk of AF (HR 0.79, p=0.008), 
improved symptoms from heart failure and quality of life compared to VVI pacing. (Lamas et al., 
2002) 
LV Septal wall 
   ECG 
  LV Lateral wall 
Longitudinal 
strain 
Intra-ventricular dyssynchrony 
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The Canadian Trial of Physiological Pacing (CTOPP, n=2568) randomised symptomatic bradycardia 
patients to either “physiological pacing” (i.e., AAI / DDD) or VVI based pacing. The primary end 
point (composite of stroke and CV death) did not differ significantly between the physiological 
(5.5%) vs. ventricular pacing (6.1%), over a mean-FU of 6 years. Nevertheless, a significant reduction 
in the risk of AF with an absolute risk reduction of 6.9% was noted in patients with physiological 
pacing compared to VVI pacing. (Kerr et al., 2004)  
 
In the Pacemaker Selection in the Elderly (PASE) study (n=407) patients with symptomatic 
bradycardia were randomised to either DDDR or VVIR pacing. Notably in SND patients, VVIR 
pacing was associated with significantly increased risk of AF (28%) compared to DDDR pacing 
(16%), over a median-FU of 18 months. On multivariate regression analysis (adjusting for clinical 
variables) VVI pacing independently predicted the development of AF (HR 2.6, p=0.01). (Stambler et 
al., 2003) Similarly, higher incidence of AF, mitral regurgitation and left atrial enlargement were 
observed in patients who were paced in VVI compared to non-VVI mode (AAI/DDD) over a mean 
follow-up of 6 years. (Said et al., 2014) 
 
Hemodynamic consequences of ventricular pacing compared to physiological pacing 
The negative haemodynamic and electrophysiological changes associated with VVI pacing (in 
patients in sinus rhythm) were attributed to loss of AV and or VA synchrony, induction of ventricular 
mechanical dyssynchrony, development of functional mitral regurgitation, promotion of arrhythmic 
substrate as well as activation of neuroendocrine pathways. Of note, the presence of retrograde VA 
conduction with VVI pacing potentiates adverse cardiac remodelling via ‘negative atrial kick’ (atrial 
contraction against the closed AV valves), increase in the LA pressure and subsequent LA dilatation. 
These progressive changes within the left atrium related to pacing might serve as a likely trigger for 
the development of AF. (Berglund et al., 1996; Cannan, Higano, & Holmes, 1997; Ishikawa et al., 
1996) 
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Multiple pacing RCT’s consistently revealed that the percentage of ventricular pacing (%Vp) is 
associated with adverse outcomes; despite preserving AV synchrony. In the sub-analysis of the data 
from MOST study, Sweeney et al demonstrated that cumulative %Vp is independently predictor of 
heart failure admissions and development of AF, irrespective of the pacing modes (DDDR or VVIR). 
In the DDDR mode, those who had cum%Vp >40% was associated with 2.6-fold increased risk of 
heart failure hospitalisations compared to cum%Vp <40%. On the other hand in VVIR mode, those 
with cum%Vp >80% had a 2.5-fold increase in heart failure hospitalisations compared to the patients 
with cum%Vp <80%. In this study, higher %Vp is associated with increased risk of developing AF in 
both pacing modes.  The cumulative risk of AF in DDDR group increased by 1% for every 1% 
increase in the cum%Vp up to 85%; however in VVIR mode, the increase was 0.7% for every 1% 
increase in the cum%Vp up to 80%. (Sweeney et al., 2003) 
 
The controversial DAVID (Dual Chamber and VVI Implantable Defibrillator) trial compared patients 
with physiological pacing (DDDR, with minimal ventricular rate 70bpm) to ventricular pacing 
(VVIR, minimal ventricular rate of 40 bpm) over a median follow-up 8.4 months (trial was halted 
early). All the patients recruited in this trial have had typical indications for defibrillator therapy 
rather than for symptomatic bradycardia. The primary composite end point (time to death and first 
hospitalisation for heart failure) was significantly lower in VVIR-40 compared to DDDR-70 group. 
Patients with DDDR pacing were noted to have 1.6-fold increased risk of mortality or requiring 
hospitalisations for decompensated heart failure compared to VVIR group. Notably, higher percentage 
of %Vp is associated with increased risk of AF as well as tendency towards survival decline. 
Therefore the non-inferiority observed with physiological pacing in this study was thought to be 
related to the net effects of higher resting mean heart rate as well as less optimal AV coupling 
intervals. (Wilkoff et al., 2002) 
 
In a study of patients with sick sinus syndrome (SSS) and preserved AV conduction (n=177), Nielsen 
et al compared AAIR vs.  DDDR pacing either with short AV delay (DDDR-s) or programmed long 
AV-delay (DDDR-l) and investigated the effects on cardiac remodelling. Patients in the DDDR 
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group(s) were noted to have significant increase in LAD and higher risk of AF compared to AAIR, 
during 2.9 years of mean-FU. Also patients in the DDDR-l group were found to have significant 
reduction in LV fractional shortening compared to AAIR group. However, there were no significant 
differences observed in thromboembolic complications, heart failure and all-cause mortality between 
the study groups. (Nielsen et al., 2003) There was a 77% relative risk reduction in AF observed in 
patients with AAIR compared to DDDR-s group. Both prior history of thromboembolism and 
presence of tachy-brady syndrome are associated with increased risk of thromboembolic 
complications. (Kristensen et al., 2004; Nielsen et al., 2003) 
 
The observed worse outcomes from physiological pacing (despite preserving AV synchrony) may be 
a result of programmed short AV delay and thereby subsequently more frequent but avoidable RV 
pacing. Notably, the subsets of patients who are more vulnerable to the ill effects of long term RV 
pacing include those with conduction disturbances, (Varma, 2008) ischaemic heart disease and 
impaired LV systolic function. (Sweeney & Hellkamp, 2006) Therefore, it is optimal to keep the 
percentage of Vp as minimal as required to curtail the unfavourable effects from RV apical pacing. 
(Sweeney & Prinzen, 2006) 
 
Newer generation pacemakers are incorporated with distinct pacing algorithms in order to reduce and 
avoid needless RV pacing. The precise objective is to maintain and facilitate normal intrinsic AV 
conduction as much as possible, thereby averting RV pacing related LV dyssynchrony. Both Search 
AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction (SAVE 
PACe) and Inhibition of Unnecessary RV Pacing with AVSH in ICDs (INTRINSIC RV) studies 
assessed specifically the outcomes related to minimising ventricular pacing. SAVE PACe trial 
(n=1065), randomised SND patients with preserved AV conduction to routine DDDR or DDDR with 
minimal ventricular pacing (DDDR-minVp). Over a mean follow-up of 1.7 years, there was a 
significant difference observed in the %Vp between conventional DDDR (99%) vs. DDDR-minVp 
(9%) groups. Patients assigned to DDDR-minVp mode showed a significant reduction in the 
development of AF (7.9% vs. 12.7%, p=0.004) compared to DDDR group. There was a 40% relative 
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risk reduction in the development of AF with DDD-minVp (HR 0.60, p=0.009] and %Vp remains an 
independent predictor of persistent AF. The authors suggested that the lower risk of new onset AF 
with minVp noted in this study might be a result of reduced RV pacing as well as improved AV 
coupling. (Sweeney et al., 2007) 
 
Similarly the INTRINSIC RV study assessed ICD patients (n=988) with backup VVI-40 pacing vs. 
DDDR-AVSH 60-130 and the potential benefits with AV search hysteresis programming 
(prolongation of the AV delay to promote normal intrinsic conduction). Over a mean follow-up 11.6 
months, the primary end point (a composite of all cause death and heart failure admissions) was 
significantly higher in the DDDR-AVSH 60-130 (9.5%) compared to VVI-40 group (6.4%). In 
general terms, higher percentage of RV pacing is associated with increased risk of clinical events 
(mortality and hospitalisations from heart failure). (Olshansky et al., 2007) In the post-hoc analysis of 
data from this study, almost a 3-fold increased mortality risk observed in patients with new onset AF. 
(Bunch et al., 2009) 
 
The recent prospective PACE study (Pacing to Avoid Cardiac Enlargement) randomised patients 
(n=177) with bradycardia and preserved LV function (EF ≥45%) to RV apical pacing or biventricular 
pacing (BiV). The results suggested that chronic RV pacing was associated with progressive 
deterioration of LVEF (53 ± 10.1% vs. 61.5 ± 6.6 %, p<0.001) as well as increase in LVESV (38.3 ± 
20.3 mls vs. 28.4 ± 10.7 mls, p<0.001) compared to the baseline parameters over a follow-up period 
of 2 years. However, there were no significant changes observed in the BiV pacing group in both 
these parameters. Both the changes in the LVEF and LVESV correlated with progressive worsening 
in dyssynchrony index in the RV apical pacing group from baseline at first year (p<0.001) and second 
year follow-up (p<0.001). With the results of this study, it is possible that the adverse cardiac 
remodelling associated with RV apical pacing could be prevented by CRT, even in patients with 
preserved EF. (Chan et al., 2011) In a recent study, decrease in left atrial reservoir function 
(angiographic assessment of left atrial ejection fraction) with acute RV pacing was associated with AF 
recurrences post catheter ablation in paroxysmal AF patients. (Park et al., 2014) 
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5.4. Relationship between AF and atrial high rate episodes / events 
AF remains silent and paroxysmal in a quarter of patients and its clinical presentation often extremely 
heterogeneous. (Hart et al., 2000) Irrespective of the pattern of arrhythmia whether paroxysmal or 
persistent or permanent, the stroke risk linked with the disease appears quite comparable. (Hughes, 
Lip, Guideline Development Group, Secondary Care, & Clinical, 2008) Initial studies revealed 
asymptomatic recurrences with AF were frequent compared to symptomatic episodes; however 
uncertainty prevailed over the assessment of their stroke risk. (Page, Wilkinson, Clair, McCarthy, & 
Pritchett, 1994) In a majority of patients with asymptomatic AF, the initial manifestation of 
arrhythmia could be catastrophic and even fatal with clinical manifestations like stroke or systemic 
thromboembolism. (Rho & Page, 2005) The post hoc analysis of AFFIRM data revealed increased 
risk of stroke in asymptomatic AF patients in the rhythm control group in comparison to rate control; 
possibly due to lack of appreciation of the true thromboembolic risk and therefore inadequate 
anticoagulation or inappropriate antithrombotic therapy with asymptomatic PAF.  (Flaker et al., 2005) 
 
Traditional dual chamber pacemakers are integrated with a lead inside the right atria, through which 
we can precisely monitor, detect as well as store atrial arrhythmias and atrial high-rate events or 
episodes (AHRE). An accurate assessment of true AF arrhythmic burden can be obtained from 
repeated device interrogations. Nonetheless, variations in the atrial lead position and its configuration, 
limitations in the pacemaker settings (P-wave sensitivity, P-wave amplitude, blanking periods and 
AHR detection zones) could influence the reliability of the device identified AHRE during the AF 
paroxysms. (Nowak et al., 2001; Passman et al., 2004; Purerfellner, Gillis, Holbrook, & Hettrick, 
2004) 
 
Device identified atrial rates greater than 250 complexes per minute with events lasting for more than 
five minutes have been demonstrated to be highly specific (93-98%) and sensitive (94-100%) in 
detection of AF and also verified by ambulatory cardiac monitoring. (Pollak et al., 2001) Data from 
AIDA (Automatic Interpretation for Diagnostic Assistance) study, revealed that atrial rates greater 
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than 220 beats per minute with at least 10 consecutive beats during onset and terminated by 20 
consecutive beats are similarly highly specific (94.2%) and sensitive (93%) in detecting supra 
ventricular arrhythmias and correlates well with Holter monitoring. (Defaye, Dournaux, & Mouton, 
1998; Limousin et al., 1997) Better diagnostic yield for AHRE can be obtained by optimising the 
device as well as its programming features with precise mode switching algorithms and better atrial 
sensing thresholds (Fitts, Hill, Mehra, & Gillis, 2000; Passman et al., 2004) From the available 
literature, the reported incidence of device detected AHRE appears to be quite varied, ranging 
between a minimum of 24% to as high as 88%. However, patients with previous history of AF appear 
to have higher AF burden and increased frequency of recurrent AHRE during device interrogations 
and routine follow-ups. As similar to AF patients, a significant proportion of pacemaker patients 
remain asymptomatic during the AHRE episodes. (Cheung et al., 2006)  In contrast, clinical symptom 
is a poor indicator of AF occurrence. 
 
5.5. Clinical significance of atrial high rate episodes /events 
Consistently data from various studies revealed a close association between device identified AHRE 
and adverse outcomes. In the sub group analysis of patients from MOST trial, (where AHRE defined 
as at least 1 episode >220bpm over 10 consecutive beats but >5 minutes) there was a 2.5 fold 
increased risk of total mortality, 2.8 fold increased risk of death or non-fatal stroke and a 5-fold 
increased risk of AF observed in patients with AHRE compared to no AHRE (irrespective of the 
mode of pacing), during a median-FU 27 months. (Glotzer et al., 2003) The prospective observational 
TRENDS study evaluated the stroke risk in relation to AF burden. AT/AF burden is defined as the 
longest duration of arrhythmia on a given day in the last 30 days with detection of an atrial rate of 
more than 175bpm lasting for more than 20 seconds. In patients with at least > 1 stroke risk 
(hypertension or age ≥65years or heart failure or diabetes or previous history of thromboembolism), 
higher AF burden (>5.5hrs) has a 2-fold increased annualised risk for thromboembolism compared to 
zero AF burden. (Glotzer et al., 2009) 
 
  61 
In the more recent ASSERT study, device detected subclinical AF (atrial rate >190bpm for >6min) 
was associated with a 3.8-fold increased risk of AF and a 2.5-fold increased risk of ischaemic stroke 
or thromboembolism (after adjusting for stroke risk factors) over a mean follow-up of 2.5 years. 
(Healey et al., 2012) Data from the Italian AT500 Registry Investigators, revealed a 3-fold increased 
risk of thromboembolism with device identified AF (where AF duration at least longer than 24 hours) 
in patients with dual chamber pacemakers over a median-FU of 22 months. The overall incidence of 
thromboembolism in this study was 1.9%. (Capucci et al., 2005) Heart failure patients without any 
previous history of atrial arrhythmias following CRT-D implantation (mean-FU 32 months), a quarter 
of patients developed new onset AHRE (atrial rate more than 180bpm for more than 10 minutes per 
day)  and unsurprisingly received more inappropriate device shocks, less improvement in systolic LV 
function as well as more hospital admissions for heart failure decompensation. (Borleffs et al., 2009)  
  
5.6. Conclusion 
Consistent evidence from various trials revealed an association between high percentage of RV apical 
pacing and adverse clinical outcomes. However, the deleterious effects associated with RV apical 
pacing are often heterogeneous and cumulative.  Also it is rather unclear whether is there any safe 
ideal mode and or specific percentage of RV pacing, which can be more effective. The proposed ill 
effects from RV apical pacing were often due to the development of mechanical dyssynchrony and 
subsequent systolic dysfunction, mitral regurgitation and LA dilatation. Devices identified AHRE 
corresponds well with AF on Holter monitoring and are associated with poor outcomes. The 
combination of sophisticated AF detection algorithms and stored data from devices may be the most 
reliable method of assessing arrhythmic burden in AF, thereby identifying patients at higher 
thromboembolic risk. 
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CHAPTER SIX 
 
6. MD Proposal/plan overview 
6.1. Cardiac pacing from the right ventricular (RV) apex is associated with a higher incidence of 
AF. In a study of patients with sick sinus syndrome and preserved AV conduction, worsening LA 
dilatation (Nielsen et al., 2003)  and higher risk of new onset AF were observed in DDDR group 
compared to AAIR group. (Kristensen et al., 2004) However, this increased risk of AF does not result 
from the loss of atrio-ventricular (AV) synchrony alone, as evidenced by an analysis of the MOST 
trial, which demonstrated linearly increasing risk of AF with cumulative percentage ventricular pacing 
whether in DDDR or VVIR modes. (Sweeney et al., 2003) The magnitude of increased risk was 1% 
for each 1% increase in cumulative percentage ventricular pacing and was similar between pacing 
modes. These data suggest that RV apical pacing, even with preservation of atrio-ventricular 
synchrony, may be related to an increased risk of AF. Newer pacemaker algorithms which minimise 
ventricular pacing in dual chamber pacemakers (9% ventricular pacing compared to 99%) has been 
shown to reduce risk of AF compared to conventional dual chamber pacemakers, but the incidence of 
persistent AF remains considerable at about 8% over 1.6 years of follow-up. (Sweeney et al., 2007) 
 
6.1.1. The role of arterial stiffness in the pathophysiology of AF in cardiac pacing  
The increased incidence of AF is generally believed to be a result of abnormal ventricular activation 
with pacing from the apex of the RV to the base and from the right to the left ventricle through non-
specialised conduction tissue. (Vassallo et al., 1986) The resulting alteration in mechanical activation 
is associated with dyssynchronous ventricular contraction, which is associated with adverse regional 
myocardial loading, increased myocardial work, (Borlaug et al., 2007) impaired hemodynamic 
performance, (Rosenqvist et al., 1996) increasing mitral regurgitation (Maurer et al., 1984) and left 
atrial pressures (Barold & Ovsyshcher, 2005). 
 
  63 
However, this pathophysiological model neglects the intrinsic interaction between ventricular 
contraction and the arterial system. Arterial stiffening increases pulse wave velocity (PWV), which 
may result in earlier return of wave reflection, augmenting aortic pressure in late systole (instead of 
diastole) and increases late systolic load. (M. F. O'Rourke & Hashimoto, 2007; M. F. O'Rourke & 
Kelly, 1993) In the setting of pacing from the RV apex, which increases iso-volumetric contraction 
(and relaxation) time at the expense of shortening diastolic filling time, the onset of LV ejection is 
delayed, I propose that earlier arterial wave reflection especially in the setting of increased PWV may 
be more likely to augment the outgoing systolic pressure wave and exacerbate the adverse regional 
mechanical loading already imposed by the dyssynchronous ventricular contraction. Increased pulse 
pressure (a surrogate measure of arterial stiffness) is associated with new-onset AF. (Mitchell et al., 
2007) 
 
Previous studies of arterial physiology (e.g., by PWV and pulse wave analysis) in patients with 
permanent pacemakers were small, consisted of heterogeneous groups of patients with atrial and dual 
chamber pacing modes and were designed primarily to evaluate the interaction between heart rate, 
PWV and pressure augmentation.  The interaction between RV pacing, arterial stiffness and wave 
reflection has not been studied and the long-term effect of wave reflection on the left atrium (LA) and 
the incidence of AF and AF burden are not known. 
 
6.1.2. Endothelial function and arterial stiffness  
The vascular endothelium is effectively a large endocrine and paracrine organ that detects 
hemodynamic changes and circulating signal factors, and responds by producing vasoactive 
substances. The critical balance between these factors plays a major role in vascular homeostasis: 
endothelial dysfunction has been associated with failure to regulate blood pressure (BP) or 
haemostasis. (S. Verma & Anderson, 2002) Therefore, abnormal arterial physiology (and blood 
pressure) may be associated with imbalance in the endothelial production of relaxing/vasodilating 
(e.g. Nitric Oxide (NO)) and contracting/vasoconstricting factors (e.g. endothelin-1 (ET-1)). Hence, 
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impairment of vascular endothelial function would be expected to reduce arterial compliance, increase 
wave reflections and result in greater pressure augmentation. Indeed, Wilkinson et al have 
demonstrated this in a study of patients with hypercholesterolemia compared to normal controls. 
(Wilkinson et al., 2002)  
 
Felmeden et al, reviewed the established methods of assessing endothelial (dys) function and damage 
(Felmeden & Lip, 2005). The most commonly applied method to assess large artery endothelial 
function in clinical research is the use of FMD. (Corretti et al., 2002) The measurement of vWf has 
also been used as a plasma marker of endothelial damage/dysfunction. (Mannucci, 1998) Unlike 
FMD, Laser Doppler Flowmetry (LDF) has been used to assess small artery (‘micro-vascular’) 
endothelial function. The relationship between these different measures of endothelial function – 
circulating markers (e.g.: vWf), micro-vascular (LDF) and large artery physiology – is not clear.  
 
6.2. Aims 
My thesis will investigate (i) the inter-relationships between the different measures of macro-vascular 
and micro-vascular endothelial (dys) function; (ii) the relationship between these macro- and micro-
vascular measures of endothelial function, cardiac remodelling and arterial stiffness in patients with 
atrial fibrillation; and (ii) the relationship between these macro- and micro-vascular measures of 
endothelial function with the development of atrial fibrillation in patients with dual chamber 
pacemakers. 
 
6.3. Hypotheses to be tested 
1. AF is associated with greater micro- & macro-vascular endothelial dysfunction 
2. Endothelial dysfunction is associated with measures of increased arterial stiffness 
3. Increased arterial stiffness and endothelial dysfunction are associated with adverse LA / 
LV remodelling in AF 
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4. Greater endothelial dysfunction is associated with increased risk of cardiovascular events 
in AF  
5. Greater endothelial dysfunction and arterial stiffness are associated with LA / LV 
remodelling and higher AF burden during one-year follow-up in patients with DDD 
pacemakers  
 
Thesis plan chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Cross-sectional study 
 
 Relationship between arterial stiffness and macro-vascular, micro-vascular endothelial 
function in PAF 
 
 Relationship between arterial stiffness and cardiac remodelling in patients with PAF 
 
 Assessment of vWf and soluble E-Selectin in patients with AF  - A predictor of cardiovascular 
events 
(2) Prospective longitudinal study with patients with dual chamber pacemakers 
 
Baseline study 
 Relationship between atrial high rate episodes, arterial stiffness and endothelial dysfunction  
 
 Relationship between atrial high rate episodes, arterial stiffness and cardiac remodelling 
 
 
One-year follow-up study 
 Relationship between the changes in arterial stiffness, endothelial function and atrial high rate 
episodes 
 
 Relationship between the changes in arterial stiffness, cardiac remodelling and atrial high rate 
episodes 
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Study patients 
Cross-sectional study 
 
55 patients with paroxysmal AF (with hospitalisation due to atrial fibrillation confirmed on ECG 
within the last 12 months); who were compared to 55 patients with documented hypertension (without 
paroxysmal AF, as disease controls’) and 55 healthy controls.  For the study, paroxysmal AF patients 
were recruited from the specialist out-patient arrhythmia follow-up clinic and hypertensive controls 
from out-patient hypertension follow-up clinics, both based at City Hospital, Birmingham, UK from 
January 2009 to August 2010. 
 
Paroxysmal AF (as described in NICE guidelines, published 2014) – usually recurrent, but with 
spontaneous termination less than 7 days, more often < 48 hours. The frequency of the paroxysms 
may vary individually depending on the aetiology predisposing to the arrhythmia. Paroxysmal AF 
also may degenerate into persistent AF. 
 
Exclusion criteria include age<18 years, clinically significant valvular heart disease; malignancy; 
immune disease; untreated thyroid disease; chronic liver disease; renal failure (estimated GFR < 
30ml/min); pregnancy; refusal of consent.  
 
Prospective study 
101 consecutive patients with dual chamber pacemakers implanted within the preceding 12 months 
recruited from the pacemaker clinic based at City Hospital, Birmingham, UK.  Notably all of the 
consecutive 101 patients (100%) agreed to participate in this follow-up study from August 2008 to 
August 2009. All patients had assessment at baseline and one-year to determine the changes in 
endothelial function, cardiac remodelling and AF burden. The indications of pacing include sick sinus 
node disease, advanced second degree or third degree atrio-ventricular block, as well as to allow the 
up-titration of anti-arrhythmic drugs in the presence of paroxysmal AF where treatment had been 
limited by bradycardia.  
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Healthy controls 
‘Healthy controls’ were recruited from the members of hospital staff and patient’s relatives. Healthy 
controls were assessed by careful history, clinical examination, ECG (and echocardiography if 
needed) and routine blood tests.  
 
6.4. Study methods 
All subjects were invited to attend the research unit at City Hospital, Birmingham, UK for an initial 
visit, during which the study was explained and informed consent obtained. I collected, a detailed 
clinical history, including dyspnoea scoring and NYHA class, past medical history, cardiovascular 
risk factors (hypertension - defined as BP >140/90mmHg or treatment with antihypertensive drugs; 
smoking; etc.). Clinical examination included BP measurement, cardiac and pulmonary auscultation, 
assessment of venous pressure and presence of peripheral oedema, 12-lead ECG. Patients with 
borderline random glucose levels could have diabetes and therefore this was either 
confirmed/excluded by an oral glucose tolerance test. Patients were advised not to take any vaso-
active medications (including caffeine) for at least 12- hours prior to the study. All the tests were 
conducted after fasting and abstaining from smoking from midnight of the preceding day. Hence, the 
study was conducted >18 hours free of therapy (assuming the last dose of drugs were taken the 
previous morning at approximately 8am). There may be a ‘hang over’ effect of some cardiovascular 
drugs with longer duration of action but it was considered unethical to stop therapy for prolonged 
periods in view of the risk of clinical deterioration. The average of three blood pressure (BP) readings 
was taken using a validated, semi-automated oscillometric device (Omron) from the non-dominant 
brachial artery after a 10-minute period of rest. Examinations were carried out in a quiet temperature 
controlled room. 
 
6.4.1. Pacemaker programming for the detection of atrial fibrillation 
Current dual chamber pacemakers have sophisticated algorithms for AF detection. The software is 
tailored to detect the common mechanisms through which episodes of paroxysmal AF are initiated by 
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premature atrial complexes (PAC), by bradycardia or immediate re-initiation of AF. Pacemaker 
detection algorithms were programmed to detect AF as atrial high rate events (AHRE) of greater than 
220 beats per minute for at least one minute, lasting more than 10 consecutive beats. The above 
programming has been demonstrated to be highly sensitive (93-98%) and specific (94-100%) in 
identifying AF, verified by ambulatory monitoring. (Pollak et al., 2001) Termination of AF was 
defined as the occurrence of 20 beats below the ARHE detection rate to ensure the exclusion of short 
episodes of atrial premature beats. Due to differences in arrhythmia detection algorithms between the 
manufacturers, this study only included patients’ with Vitatron (T-series) or Medtronic (Sensia) 
pacemakers as these were the most commonly implanted pacemaker systems in our hospital over the 
study period. The device was appropriately set with optimal post-ventricular atrial blanking (PVAB) 
periods to reduce far field R-wave over sensing and lower P-wave sensitivities to identify atrial 
activity during AHRE. Patients with atrial sensing abnormalities were excluded.  Patients with 
permanent pacemakers were then invited to attend for a second visit after a period of one-year for the 
follow-up (i.e., for prospective longitudinal study). 
 
6.4.2. Assessment of macro-vascular endothelial function 
6.4.2.1. Carotid artery pulse wave analysis  
Brachial blood pressure (BP) was measured using a semi-automated oscillometric device (Omron 
705CP, Omron). Following 10 minutes of rest in a supine position BP was measured 3 times over 5 
minutes and the mean of the last 2 measurements was used as the brachial BP. After measuring the BP 
and PWVcf, carotid artery waveforms were sampled over 10 seconds with Atcor tonometer (SPT 304, 
Atcor Medical) using SphygmoCor (Version 8, Atcor Medical) and calibrated to the average BP. The 
waveforms were then continuously stored into an interfaced laptop (Toshiba Satellite) and 
subsequently post-processed using dedicated software (SphygmoCor CvMS) to obtain pulse wave 
analysis (PWA). The integral system software was used to calculate an averaged carotid artery 
waveform and to derive a corresponding central aortic pressure waveform using a previously 
validated generalised transfer function. Aortic pressure waveforms were subjected to further analysis 
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by the SphygmoCor software to identify the time to peak/shoulder of the first and second wave 
components (T1, T2) during systole. The pressure at the peak/shoulder of the first component was 
identified as P1-height and the pressure difference between this point and the maximal pressure 
during systole was identified as augmented pressure (AP, due to peripheral reflection). Using the data 
obtained, all the below three indices were quantified in adherence to the expert consensus document 
on arterial stiffness. (Laurent et al., 2006) 
(i) Measurement of Carotid-Femoral Pulse Wave Velocity 
Carotid-to-femoral pulse wave velocity (PWVcf) was measured using applanation tonometry after the 
patients had been rested in supine posture for 15 minutes. Measurements were taken immediately after 
obtaining the brachial BP. PWVcf was obtained by measuring the arterial pressure waves from carotid 
and femoral arteries simultaneously using pressure sensitive transducers (SPC-301, Millar 
Instruments). The surface distance from the suprasternal notch to the femoral recording site is 
measured. The pressure wave transit time was calculated using foot-of-the-wave to foot-of-the-wave 
method. PWVcf was calculated by dividing the distance to the distal site by the pressure wave transit 
time as distance/time (m/s). The mean of at least two PWVcf recordings were taken from each subject 
and the average was taken.  
 
Figure 6.1.  Measurement of carotid-femoral pulse wave velocity using applanation tonometry (SPC-
301, Millar Instruments post-processed using dedicated software (SphygmoCor CvMS) 
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In Figure 6.1, the top strip Site A, is the pulse wave form analysis from carotid artery and the bottom 
strip Site B, from femoral artery and both are ECG gated. The distance between the carotid and 
femoral artery is measured and described in mms. The right bottom panel gives the carotid-femoral 
reference range. 
 (ii) Augmentation index  
Augmentation Index (AIx) was defined as the ratio of AP and PP. [AIx= (AP/PP) %] expressed in 
percentage. Macro-vascular endothelial function was assessed by measuring the changes in AIx in 
response to inhaled salbutamol (200micrograms, technique supervised) and sublingual glyceryl-
trinitrate (GTN, 200micrograms, technique supervised). The subsequent readings were taken every 
five minutes from the same carotid artery and the changes in the individual components of arterial 
wave forms were recorded including AP, AIx and P1-height. Systemic endothelial function is defined 
as the ratio of the change in response to salbutamol relative to GTN. (McEniery et al., 2006) 
Endothelial dysfunction has been shown to be associated with PWV and augmentation index in 
patients with hypertension using this technique. (Wallace et al., 2007) 
 
Figure 6.2. Diagrammatic representation of pulse-wave analysis using applanation tonometry (SPT 
304, Atcor Medical) post-processed using dedicated software (SphygmoCor CvMS) 
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In Figure 6.2, Left top: 10-second snap shot of carotid artery wave form; Right top: Operator index 
demonstrating the reproducibility of individual wave forms throughout the recording; Left bottom: 
Averaged carotid artery pulse wave form with amplitude in mm of Hg (Y-axis) and duration in 
milliseconds (X-axis); Left bottom: SphygmoCor software derived ascending aortic pressure wave, 
equivalent to the pressure wave measured by an invasive catheter. From the aortic pressure wave, a 
number of valuable cardiovascular measurements are determined, including central aortic systolic 
pressure, aortic augmentation index and central pulse pressure. 
 
(iii) Reservoir pressure 
A novel concept of ‘aortic cushioning’ has been proposed by Parker and colleagues, who proposed its 
role in maintaining a smooth pulsatile pressure and flow following ventricular contraction. (Tyberg et 
al., 2009) Reservoir pressure (Pr), is a measure of the elastic compliance of the artery considered to be 
another surrogate of measuring arterial stiffness in compliant arteries like the aorta. Using the custom 
MATLAB algorithm (The Math Works, Inc. R2007a), Pr is derived from the raw data (exported as 
text files) from the stored pulse wave analysis (Atcor Medical) obtained from applanation tonometry. 
The integral software system averages the stored central aortic pressure waveform and deduces the Pr 
using a validated generalised transfer function.  
 
Figure 6.3. Measurement of reservoir pressure using applanation tonometry (using Atcor Medical) 
with custom MATLAB algorithm (The Math Works, Inc. R2007a). The aortic pressure in blue from 
applanation tonometry and the derived reservoir pressure in red.  
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Reproducibility of Pulse wave analysis 
Intra-observer variability was assessed in 25 patients (randomly selected hypertensive controls) by 
repeating the measurements on 2 occasions (1-2 days apart) under the same basal conditions. To test 
the inter-observer variability, the measurements were repeated by a second operator (1 and 2 days 
apart) who was unaware of the results of first examination. Variability was calculated as the mean 
percent error, derived as the difference between the 2 sets of measurements, divided by the mean of 
the observations. Intra- and inter-observer variabilities for pulse wave analysis (augmentation index) 
and PWVcf were <5% and <10% respectively. (Data presented in TABLE 6.1) 
 
Table 6.1. Reproducibility of pulse wave analysis (pulse wave velocity and augmentation index) 
Variables 
 
Intra-observer Inter-observer 
PWVcf 
 
0.041 0.048 
Augmented pressure 
 
0.05 0.062 
Augmentation Index 
 
0.042 0.055 
 
6.4.2.2.  Microvascular endothelial function (using Laser Doppler Flowmetry, LDF) 
The laser Doppler technique is established as a non-invasive reliable and effective method for the 
assessment of micro vascular circulation.  LDF provides a continuous, real time measurement without 
disturbing the normal physiological state of microcirculation. It uses the traditional Doppler frequency 
effect principle with reflection of signals from static and moving blood cells to assess the blood flow 
in the microvasculature.  
 
Micro vascular perfusion (RED BLOOD CELL FLUX, RCF) = Mean red blood cell concentration 
in the sample volume x mean velocity of the cells, expressed in blood perfusion units (BPU) an 
arbitrary unit. The volume of tissue sampled is 0.5 – 1 mm3. The skin blood flow motion (SBF) can 
be explored using spectral Fourier analysis of forearm skin laser Doppler. This is combined with the 
non-invasive iontophoresis using endothelium dependent and independent vasodilators to assess the 
endothelial function. In normal subjects the RCF rises in a cumulative fashion to acetyl choline (Ach) 
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or sodium nitroprusside (SNP) allowing the response to each pulse and the maximum to be 
quantitatively assessed. LDF has been used in the assessment of endothelial dysfunction and blunted 
SBF could be the early sign of micro- vascular dysfunction in chronic kidney disease patients.(Rossi 
et al., 1996) A blunted response is also seen in patients with hypertension, (Rossi et al., 1997) 
diabetes, (Skrha, Prazny, Haas, Kvasnicka, & Kalvodova, 2001) dyslipidaemia (Rossi et al., 2009) 
and smoking (Rossi, Carpi, Di Maria, Galetta, & Santoro, 2007). 
 
LDF was used to directly assess endothelial function at the level of the microcirculation. A laser-
Doppler meter, which emits a beam of low power laser light at a wavelength of 780 nm, was used to 
measure skin red blood cell flux (RCF) recorded as perfusion units (PU). This instrument can be used 
successfully irrespective of skin colour. This was combined with the non-invasive technique of 
iontophoresis, which allows the local transfer of charged substances across the skin using a small 
electrical current from a purpose-designed chamber into which the LDF probe is placed will deliver 
the current. All studies were carried out with established protocols in our department at City Hospital, 
Birmingham, UK.   
 
Endothelium-dependent and –independent vasoresponse of the skin forearm circulation were 
evaluated using cutaneous Laser Doppler Flowmetry (LDF) system in combination with iontophoresis 
(Perimed AB, Periscan PIM II Laser Doppler Perfusion Imager, Sweden). The LDF outputs were 
recorded continuously by an interfaced computer (Dell Dimension DIM 4600 Intel (R)) equipped with 
Perisoft dedicated software (LDPIwin Software 2.6). This software allows measurement of skin blood 
flux in conventional perfusion units (PU): 1PU=10mV. Endothelial-dependent response was assessed 
using 2% acetylcholine (ACh) and endothelial-independent response using 1% sodium nitroprusside 
(SNP). Both the ACh and SNP were delivered to the skin by iontophoresis.  
 
A drug delivery chamber (Code L1611, Perimed, Sweden) was filled with 0.5ml of 2% ACh and 
positioned on the anterior aspect of the right forearm. Thereafter the ACh was delivered to the skin 
using drug delivery electrode attached to the drug delivery chamber. An indifferent electrode was 
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attached to the anterior aspect of the right forearm 10 cm from the drug delivery electrode. Ach was 
delivered by means of one iontophoretic pulse of 0.1mA for one minute continuously (using 382b 
Perilont Power Supply, Perimed, Sweden). Basal skin flux was determined in PU as median value two 
minutes before iontophoresis. The higher skin blood flux value reached following iontophoresis 
procedure was measured in PU, using repeated continuous mode measurements obtaining high 
resolution images (25 x25 mm, with a minimum background threshold of 7V) for five minutes and 
seven minutes with ACh and SNP respectively.  
 
Skin RCF increased in a cumulative manner to ACh or SNP allowing the response to each pulse and 
the maximum to be quantitatively assessed. The skin vasodilator response to ACh was expressed as 
skin blood flux percentage change from baseline (∆%LDF Ach). Similarly the endothelial-
independent response was measured using 1% SNP and the change in skin blood flux is recorded 
(∆%LDF SNP). Figure 6.4, represents the LDF perfusion image at baseline and at hyperaemia with 
acetyl choline; Table 6.2, shows the progressive changes in perfusion with hyperaemia from baseline, 
using a validated transfer function. 
 
Figure 6.4. Assessment of micro-vascular endothelial function with Laser Doppler flowmetry 
 
     
In figure 6.4, Image 1 is the Laser Doppler flowmetry picture of the baseline perfusion at 00:00 prior 
to Acetyl choline Iontophoresis and Image 3 is the Laser Doppler flowmetry picture of maximal 
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hyperaemia elicited using iontophoresis with acetyl choline at 0120 minutes.  The white circled area is 
the field of interest to assess hyperaemia. 
Table 6.2. The changes in perfusion with Acetyl choline in LDF using Iontophoresis [will be 
tabulated as follows using integrated Perisoft software system (LDPIwin Software 2.6)]. Images 1, 2 
&3 are the three baseline perfusion data; Image 6 reflects the peak change in perfusion data with 
Acetyl choline. 
  Item  Min  Max  Mean  Change  % Change  Median  
Image 1  0.34  1.05  0.68  ref  ref  0.67  
Image 2  0.36  1.28  0.66  -0.01  -2.01  0.66  
Image 3  0.31  1.05  0.67  -0.01  -1.53  0.66  
Image 4  0.44  1.68  0.95  0.28  40.92  0.91  
Image 5  0.44  1.84  1  0.33  48.42  0.96  
Image 6  0.42  1.78  1.01  0.33  49.07  1  
Image 7  0.33  1.63  0.93  0.26  38.06  0.91  
Image 8    0.39    1.63    0.93    0.25    37.01    0.86  
 
6.4.2.3. Echocardiography 
All patients underwent standard trans-thoracic echocardiographic studies (IE33, Phillips System) in 
the University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham at 
baseline and at one year follow-up. All studies were performed as per British Society of 
Echocardiography (BSE) standards and all the images were stored in a dedicated computer and 
subsequently used for post-processing to derive the required data. 
(i) Doppler measurement of mitral inflow (E-wave, A-wave, E/A ratio, IVRT, Deceleration 
time), pulmonary venous flow, M-mode assessment of longitudinal function of LV 
(MAPSE) and RV (TAPSE), calculation of LVEF by Simpson’s biplane method and 
assessment of LV diastolic function with tissue Doppler at the mitral annulus (EM, AM, SM 
and E/EM ratio) and colour M-mode velocity propagation (CMM Vp) across the mitral 
inflow were routinely done. All the images were appropriately optimised to highest frame 
rates possible. (Dalsgaard et al., 2007; Vogel et al., 2003) 
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(ii) LA diameter (LAD) was assessed using M-mode in parasternal long axis view and using 
prolate-ellipsoid method LA volume was derived; LAV= πxD1xD2xD3/6 (D1 = 
represents longitudinal diameter of LA in the apical four chamber view; D2 = represents 
horizontal diameter of LA in the apical four chamber view; D3 = represents vertical 
diameter of LA in parasternal long axis view). (Ujino et al., 2006) 
Reproducibility of Doppler measurements 
Intra-observer variability was assessed in 10 patients (randomly selected hypertensive controls) by 
repeating the measurements on 2 occasions (1 and 5 days apart) under the same basal conditions. To 
test the inter-observer variability, the measurements were performed off-line from video recordings by 
a second observer unaware of the results of the first examination. Variability was calculated as the 
mean percent error, derived as the difference between the 2 sets of measurements, divided by the 
mean of the observations. Intra- and inter-observer variabilities for conventional 2-D Doppler 
measurements, assessment of LA, LV measurements and TDI derived parameters from mitral annulus 
velocity (EM,) were all below 5% and 10% respectively. (Data presented below) 
 
Table 6.3. Reproducibility of the echocardiographic parameters 
Variables 
 
Intra-observer Inter-observer 
LA dimension 
 
0.022 0.034 
Ejection fraction 
 
0.044 0.066 
E-wave velocity 
 
0.035 0.023 
A-wave velocity 
 
0.035 0.023 
Deceleration time 
 
0.047 0.079 
EM velocity 
 
0.035 0.023 
 
6.4.2.4.  Blood samples  
From the study subjects 20 mls of venous blood was taken at the index visit and during the follow-up. 
After centrifugation at 3000 revolutions per minute per 1000g for 20 minutes at 4ºC of the venous 
sample, citrated plasma was obtained. The gathered plasma was then separated into aliquots and 
stored at -70ºC to allow batch analysis in the dedicated laboratory of University of Birmingham 
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Centre for Cardiovascular Sciences Unit, City Hospital, Birmingham, UK. All enzyme-linked 
immunosorbent assays (ELISA) were performed in duplicates. The intra- and inter-assay coefficients 
of variation for all ELISA assays were <5% and <8% respectively. All laboratory work was 
performed in a blinded fashion with respect to the identity of the samples and occurrence of clinical 
events. 
Laboratory assays were performed for the following plasma markers. 
(i) vWf [ELISA, Dako, Glostrup, Denmark]. The reference unit for vWf is international units 
per decilitre (IU/dl), standardized by National Institute for Biological Standards and 
Controls, Blanche Lane, South Mimms, Potter Bar, Hertfordshire, UK. The lower limits 
of detection: 0.5 IU/dl. 
(ii) Soluble E-Selectin [ELISA, R&D systems, Oxon]. The reference unit for sE-Selectin is 
nanogram per millilitres (ng/ml). 
 
6.5.  General statistical methods 
The Anderson-Darling test was applied to data of continuously variable to define distribution. Results 
are expressed as mean and standard deviation (SD) or as median with inter-quartile range (IQR), 
dependent on the distribution. Between or inter-group comparison were made using the Chi-2 test for 
categorical variables and using the unpaired t-test and 1-way ANOVA or the Mann-Whitney U test 
and Kruskal-Wallis test for continuous data, with between group comparison by Tukey’s post-hoc test 
(after log transformation) as appropriate. Within groups comparisons were analysed using paired 
Student’s t or Wilcoxon signed-rank tests. Correlations were performed by Spearman’s correlation 
methods. All tests were 2-tailed, and probability valves were considered significant at the 0.05 level. 
All statistical analyses will be performed using SPSS software version 22 (SPSS INC., Chicago, 
Illinois, USA). 
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6.6. Ethical Considerations 
All studies were conducted in accordance with the declaration of Helsinki and following ethical 
approval by the Ethics committee of City Hospital, Birmingham and the North Staffordshire Research 
and Ethics Committee. All patients and healthy control subjects provided written informed consent. 
 
6.7. Expected outcomes and clinical value 
Although the impact of AF on thrombogenesis and cardiac function has been well established, the 
data on the processes leading to its development and the consequent arrhythmia burden are sparse. 
Pacing from the RV apex has been identified as a risk factor for AF but the risk of AF remains 
significant in the pacemaker population despite reduction in ventricular pacing. This thesis will study 
micro- and macro-vascular endothelial function and arterial physiology in patients with AF and in the 
pacemaker population, which will provide novel insight into the pathophysiology of AF and possibly 
new targets for therapy. 
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CHAPTER SEVEN 
 
7. Relationship between arterial stiffness, macro-vascular and micro-vascular endothelial 
function in patients with paroxysmal atrial fibrillation 
7.1. Introduction 
Pulse pressure (PP), a surrogate of arterial stiffness is a predictor of cardiovascular events including 
stroke (Laurent et al., 2003) and heart failure (Chae et al., 1999). The prospective population-based 
Framingham study, suggested that an increase in PP is associated with higher incidence of AF. 
(Mitchell et al., 2007) The cumulative 20-year incidence of AF was 5.6 % for ≤ PP of 40 mm of Hg 
and rose exponentially to 23.3% for PP ≥ 61 mmHg. There was a significant 1.3-fold increased risk of 
AF with every 20 mm of Hg increase in PP, even after adjusting for cardiovascular risk factors. These 
data suggest that alteration in arterial physiology may be associated with increased risk of developing 
AF. 
 
7.2. Hypothesis 
Whilst higher PP has been associated with increased risk of AF, it is not clear if arterial stiffness is 
mediated by endothelial dysfunction (ED) and (or) related to co-existent cardiovascular risk factors. I 
therefore hypothesized that: (i) patients with PAF will have greater macro- and micro-vascular 
endothelial dysfunction and measures of arterial stiffness, compared to patients with hypertension and 
no known AF (disease controls) and healthy controls, and (ii) macro- and micro-vascular endothelial 
dysfunction is associated with measures of arterial stiffness. A cross-sectional study of patients with 
PAF compared to disease controls (patients with hypertension without PAF) and healthy controls was 
performed to test these hypotheses.  
 
7.3. Patients and methods 
Patients were recruited as described in Chapter Section 6.4. Fifty five patients with PAF in sinus 
rhythm (with hospitalisation due to atrial fibrillation confirmed on electrocardiogram within the last 
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12 months), 55 age- and sex-matched patients with clinically stable hypertensives, who were on 
established standard anti-hypertensive therapy and 55 healthy controls were recruited for this study.  
 
As per laboratory protocol, patients or controls with the following were excluded: History of 
malignancy, connective tissue or inflammatory disorders, renal or liver disease, venous thrombo-
embolism, recent infections or those who were taking regular non-steroidal anti-inflammatory drugs, 
immunosuppressive drugs and hormone replacement therapy. All subjects were asked to abstain from 
tobacco, alcoholic and caffeine containing beverages during the night before the study. Other 
exclusion criteria in this study also included heart failure (LVEF <40%), significant valvular heart 
disease and hypertrophic cardiomyopathy. 
 
Following verbal and written informed consent, patients underwent detailed history and physical 
examination. Patients were advised to refrain from vaso-active medications (including caffeine) at 
least 12 hours prior to the study and an average of three blood pressure (BP) readings was taken using 
a validated, semi-automated oscillometric device (Omron) from the non-dominant brachial artery after 
a 10-minute period of rest. Examinations were carried out in a quiet temperature controlled room. 
 
Measurement of Carotid-Femoral Pulse Wave Velocity 
As described in Chapter section 6.4. PWVcf was measured using applanation tonometry by measuring 
the arterial pressure waves from carotid and femoral arteries simultaneously using pressure sensitive 
transducers (SPC-301, Millar Instruments) as per protocol. 
 
Carotid artery Pulse Wave Analysis (PWA) 
As described in Chapter section 6.4. PWA was measured using applanation tonometry from the 
sampled carotid artery waveforms using SphygmoCor (Version 8, Atcor Medical) and calibrated to 
the average BP. The waveforms were then continuously stored into an interfaced laptop and 
subsequently post-processed using dedicated software (SphygmoCor CvMS). The integral system 
software was used to calculate an averaged carotid artery waveform and to derive a corresponding 
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central aortic pressure waveform using a previously validated generalised transfer function and 
subsequently Augmentation Index (AIx). Macro-vascular endothelial function was assessed by 
measuring the changes in AIx in response to inhaled salbutamol (200micrograms, technique 
supervised) and sublingual glyceryl-trinitrate (GTN, 200micrograms, technique supervised). The 
subsequent changes in the individual components of arterial wave forms were recorded including AP, 
AIx and P1-height. 
 
Reservoir pressure 
As described in Chapter section 6.4. from the carotid artery PWA data obtained from the applanation 
tonometry, reservoir pressure (Pr) is derived using the custom MATLAB algorithm (The Math Works, 
Inc. R2007a).(Tyberg et al., 2009) 
 
Laser Doppler flowmetry 
Endothelium-dependent and –independent vasoresponse of the skin forearm circulation were 
evaluated using cutaneous Laser Doppler Flowmetry (LDF) system in combination with iontophoresis 
(Perimed AB, Periscan PIM II Laser Doppler Perfusion Imager, Sweden). The LDF outputs were 
recorded continuously by an interfaced computer equipped with Perisoft dedicated software (LDPIwin 
Software 2.6). Endothelial-dependent response was assessed using 2% acetylcholine (ACh) and 
endothelial-independent response using 1% sodium nitroprusside (SNP). Both the ACh and SNP were 
delivered to the skin by iontophoresis and the subsequent skin vasodilator response to ACh was 
expressed as skin blood flux percentage change from baseline (∆%LDF Ach). Similarly the 
endothelial-independent response was measured using 1% SNP and the change in skin blood flux is 
recorded. (∆%LDF SNP).  
 
Blood samples and laboratory analysis 
Analysis of both vWf and sE-Sel levels were performed as per protocol as described in section 6.4. 
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Power calculations 
There is no published data on arterial stiffness (measurement of augmentation index or pulse wave 
velocity) in atrial fibrillation. However, Hayward et al demonstrated that patients with coronary artery 
disease have impaired endothelial dysfunction with increased AIx and impaired salbutamol induced 
changes in AIx compared to healthy controls of 0.5 SD (p<0.01) (Hayward, Kraidly, Webb, & Collins, 
2002) Similarly Freestone et al, showed abnormal FMD in atrial fibrillation patients compared to 
controls in sinus rhythm of 0.5 SD (p<0.001). (Freestone, Chong, et al., 2008) I propose, at least a 
similar magnitude of ED with AIx would be raised in AF patients, probably even higher than disease 
controls.  Therefore to detect a 0.5 SD difference in AIx with a power (1- ) of 80% and a p-value of 
<0.05, a minimum of 32 patients per group were required for the study. From my pilot data 
(unpublished) to identify a 20% difference in AIx with the average value of 30±12 (80% power and 
p<0.05), I aimed to recruit 55 patients in each group for this cross-sectional study.  
 
Statistical analysis 
Following a test of statistical normality, data were expressed as mean with standard deviation (SD) or 
as median with inter-quartile range (IQR) for the normally distributed data and non-parametrically 
distributed data respectively. Patient characteristics were compared between groups with a χ2 test for 
categorical variables, independent-Samples T-test for continuous variables and Mann-Whitney U test 
for non-continuous variables. Both univariate and multivariate logistic regression analysis were used 
to identify features independently associated with higher PP, PWVcf and Pr. Statistical analyses were 
undertaken with SPSS 22.00 software (SPSS Inc), and significant was accepted at the 0.05 level (2-
sided).  
 
7.4. Results 
The clinical and demographic details of all the subjects are summarised in Table 7.1, whilst the PP 
PWVcf and Pr data are summarised in Table 7.2. There was no statistical difference in the age, gender, 
body mass index (BMI), heart rate and mean BP between individual study groups. However systolic 
BP (SBP) was significantly higher in patients with PAF compared to healthy controls (136 ±15 vs. 
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125 ± 10 mm of Hg, p<0.001); but not between patients with PAF and hypertension. Similarly, PP (59 
±12 vs. 48 ± 7 mm of Hg, p<0.001); PWVcf (6.8 ± 1.3 vs. 5.8 ± 1.0 m/s, p<0.001) and Pr (130 ± 12 vs. 
119 ± 13 mm of Hg, p<0.001) were significantly higher in patients with PAF compared to healthy 
controls, but not between patient groups.  
 
Table 7.1.  Characteristics of the study groups 
Variables 
 
Healthy     
(n=55) 
Disease controls 
(n=55) 
PAF           
(n=55) 
p 
Age (in years) 55 ± 10 58  ± 9 59  ± 13 0.09 
Males (%) 35 (63.6) 34 (61.8) 36 (65.5) 0.93 
HTN (%)  50 (90.9) 48 (87.3) 0.55 
Diabetes (%)  16 (29.1) 14 (25.5) 0.67 
IHD (%)  13 (23.6) 13 (23.6) 1.00 
Stroke (%)  8 (14.5) 7 (12.7) 0.78 
PVD (%)  5 (9.1) 3 (5.5) 0.47 
Dyslipidaemia (%)  35 (63.6) 35 (63.6) 1.00 
Smoker (%)  13 (23.6) 15 (27.3) 0,63 
ACE inhibitors (%)  21 (38.2) 24 (43.6) 0.57 
ARBs (%)  8 (14.5) 13 (23.6) 0.23 
Beta blockers (%)  14 (25.5) 23 (41.8) 0.07 
Calcium blockers 
(%) 
 23 (41.8) 25 (45.5) 0.70 
Diuretics (%)  17 (30.9) 13 (23.6) 0.40 
Statins (%)  38 (69.1) 32 (58.2) 0.24 
BMI (Kg/m2) 29 ± 3 27  ± 4 28  ± 5 0.86 
Heart rate (bpm) 63 ± 10 64  ± 11 60  ± 10 0.52 
Systolic BP  125 ± 10* 134  ± 16 136 ± 15 <0.001 
Diastolic BP  78 ± 8 81 ± 11 77 ± 8 0.95 
Mean BP 99 ± 8 103 ± 11 102  ± 10 0.38 
*p<0.05, statistically significant between healthy controls and PAF      
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Table 7. 2. Measures of arterial stiffness between the study groups 
Variables 
 
Healthy      
(n=55) 
Disease controls 
(n=55) 
PAF            
(n=55) 
p 
PP(mm of Hg) 48 ± 7* 54  ± 14 59  ± 12 <0.001 
PWVcf (m/s) 5.8  ± 1.0* 6.7  ± 1.3 6.8  ± 1.3 <0.001 
Pr (mm of Hg) 
 
119  ± 13* 132 ± 13 130  ± 12 <0.001 
*p<0.05, statistically significant between healthy controls and PAF 
 
With regard to the assessment of micro-vascular endothelial function using LDF, the median 
percentage of change in perfusion with Ach from baseline (∆%LDF Ach) was significantly lower in 
patients with PAF compared to healthy controls (77 vs. 123 PU, p<0.001). However no significant 
differences were detected between the disease groups. There were no significant differences observed 
in the changes in perfusion with SNP (endothelial-independent response, ∆LDF SNP) between the 
individual study groups. [Table 7.3] 
 
On the assessment of macro-vascular endothelial function, baseline AP (20 ± 9 vs. 18 ± 6 mm of Hg, 
p=0.29) and AIx (34 ± 10 vs. 27 ± 7, p<0.001) were higher in patients with PAF compared to healthy 
controls. Changes in AIx in response to salbutamol (∆AIx Sal, 5 vs 9, p<0.001) and the median 
percentage change in AIx with salbutamol from baseline (∆%AIx Sal, 13 vs 34, p<0.001), were 
significantly lower in patients with PAF compared to healthy controls, but not between the disease 
groups [Table 7.3].  
 
The baseline plasma levels of vWf was significantly higher in patients with PAF compared to healthy 
controls (103 ± 24 vs. 90 ± 12 IU/dl, p=0.005), although no differences were observed between the 
disease groups. There were no differences noted in plasma levels of sE-Sel between the study groups.  
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Table 7.3. Baseline values of micro-vascular and macro-vascular endothelial function including 
plasma markers in between the study groups 
Variables 
 
Healthy       
(n=55) 
 
 
Disease controls 
(n=55) 
PAF            
(n=55) 
p 
Ach baseline (PU) mean ± SD 0.6 ± 0.1 0.6 ± 0.2 0.6 ± 0.1 0.74 
Ach Peak (PU) mean ± SD 1.4 ± 0.4* 1.1 ± 0.3 1.1 ± 0.3 <0.001 
∆%LDF Ach (PU) median (IQR) 123 (97-155)* 72 (45-110) 77 (55-105) <0.001 
SNP baseline mean ± SD 0.6 ± 0.2 0.7 ± 0.1 0.6 ± 0.1 0.77 
SNP peak (PU) mean ± SD 1.4 ± 0.4 1.2 ± 0.3 1.2  ± 0.3 0.62 
∆%LDF SNP (PU) median (IQR) 109 (92-140)* 75 (45-99) 88 (67-122) <0.001 
AP (mm of Hg) mean ± SD  18 ± 6 22 ± 7 20 ± 9 0.29 
AP-Sal (mm of Hg) median (IQR) 12 (6-17) 15 (11-21) 14 (7.3-21) 0.74 
AP-GTN (mm of Hg) median (IQR) 7 (0-12) 3(-2 – 13) 4 (-3 -13) 0.40 
AIx baseline mean ± SD 27 ± 7 34 ± 10 35 ± 10 0.06 
AIx Sal median (IQR) 17 (12-25)* 29 (23-37) 29 (21-38) <0.001 
AIx GTN median (IQR) 10 (-2 – 18) 3 (-5 -20) 9.5 (0.5-25) 0.19 
∆AIx Sal median (IQR) 9 (5-12)* 5 (2-8) 5 (2-8) <0.001 
∆AIx GTN median (IQR) 18 (13-25) 29 (17-36) 22 (14-30) 0.18 
∆% AIx Sal median (IQR) 34 (21-48)* 16 (5.6-23) 13 (6-24) <0.001 
∆% AIx GTN median (IQR) 67 (41-108)* 91 (47-115) 71 (37-99) 0.16 
vWf (IU/dl)  mean ± SD 90 ± 12* 99 ± 23 103 ± 24 0.005 
sE-Sel (ng/ml) median (IQR) 
 
20 (14-25) 18 (13-28) 18 (14-22) 0.70 
*p<0.05, statistically significant between healthy controls and PAF; SD=standard deviation; IQR= 
interquartile ratio 
 
Assessment of relationship between arterial stiffness and endothelial function 
On correlation analysis in PAF patients, there was a significant negative relationship between arterial 
stiffness (PP and Pr) and markers of macro-vascular endothelial function (ΔAIx Sal and Δ%AIx Sal) 
(Table 7.4). A significant negative correlation was noted between PP and ΔAIx Salbutamol (r=-0.34, 
p=0.01), PP and Δ%AIx Salbutamol (r=-0.38, p<0.01), Pr and ΔAIx Salbutamol (r=-0.26, p=0.05) and 
between Pr and Δ%AIx Salbutamol (r=-0.32, p=0.02). However no significant relationship was 
observed between arterial stiffness and markers of micro-vascular endothelial function (ΔLDF Ach, 
Δ%LDF Ach) in PAF patients.  
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Table 7.4. Correlations between arterial stiffness and endothelial function in PAF 
 
On univariate regression analysis, the predictors of ΔAIx Sal were sex, history of diabetes and PP.  
Sex, diabetes, PP and Pr were predictive for Δ%AIx Sal. On multivariate analysis even after 
adjustment for age, sex and diabetes, PP remained significantly associated with both ΔAIx Sal 
(p=0.05) and Δ%AIx Sal, (p=0.05) and similarly Pr with Δ%AIx Sal (p=0.05) 
 
Table 7.5. Univariate analysis of predictors of change in Augmentation Index with salbutamol    
(ΔAIx Sal) in PAF 
Variables B ± SE β p 
Age -0.06 ± 0.05 -0.16 0.26 
Sex  -3.90 ± 1.28 -0.40 0.004* 
Hypertension 0.43 ± 2.047 0.03 0.84 
Diabetes mellitus 3.51 ± 1.43 0.33 0.02* 
Ischaemic heart disease 2.00 ± 1.53 0.18 0.20 
Stroke -2.31 ± 2.02 -0.16 0.26 
Dyslipidaemia 0.58 ± 1.36 0.06 0.67 
PVD -1.64 ± 2.80 -0.08 0.56 
Smoking -0.58 ± 1.46 -0.06 0.69 
Pulse pressure -0.12 ± 0.05 -0.31 0.03 
Reservoir pressure -0.07 ± 0.04 -0.23 0.10 
On multivariate analysis     
Pulse pressure* -0.10 ± 0.05 -0.25 0.05* 
Reservoir pressure -0.05  ± 0.04 -0.17 0.23 
*adjusted for age, gender and diabetes mellitus 
 
 
 
 
Variables 
 
ΔAIx Salbutamol Δ% AIx Salbutamol ΔLDF Acetylcholine Δ% LDF Acetylcholine 
r p r p r p r p 
PP -0.34 0.01* -0.38 0.005* 0.05 0.70 0.05 0.75 
PWVcf -0.06 0.66 -0.20 0.15 -0.08 0.56 -0.12 0.39 
Pr -0.26 0.06 -0.33 0.02* 0.82 0.56 0.09 0.53 
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Table 7.6. Univariate analysis of predictors of percentage change in Augmentation Index with 
salbutamol (Δ% AIx Sal) in PAF 
Variables B ± SE β p 
Age -0.30 ± 0.16 -0.25 0.07 
Sex -16.01 ± 4.03 -0.49 <0.001* 
Hypertension -6.03 ± 6.73                -0.13 0.37 
Diabetes mellitus 8.30 ± 4.86 0.24 0.09 
Ischaemic heart disease 4.19 ± 5.11 0.12 0.42 
Stroke -10.47 ± 6.62 -0.22 0.12 
Dyslipidaemia 0.06 ± 4.50 0.002 0.99 
PVD -7.79 ± 9.23 -0.12 0.40 
Smoking -7.23 ± 4.72 -0.21 0.13 
Pulse pressure -4.97 ± 0.17 -0.38 0.005* 
Reservoir pressure -0.26  ± 0.13 -0.28 0.04* 
On multivariate analysis     
Pulse pressure* -0.38 ± 0.19 -0.29 0.05* 
Reservoir pressure* -0.22  ± 0.11 -0.24 0.05* 
*adjusted for age, gender and diabetes 
 
7.5. Discussion 
This study demonstrated increased measures of arterial stiffness (PP, PWVcf and Pr) in patients with 
AF compared to healthy controls. These findings are consistent with the Framingham Heart study, 
which showed significantly increased risk of developing AF with increasing PP, even after adjusting 
for clinical risk factors and mean arterial pressure. These findings suggest an association between AF 
and increased arterial stiffness. 
 
Increased arterial stiffness may impose an abnormal haemodynamic load on the left ventricle. 
Lantelme et al, in their study with hypertensive patients (n=310, mean age = 54 years) found a 
significant association between LA diameter (LAD) and PWVcf. Similarly, there was a significant 
association between LAD and 24-hour PP even after adjusting for left ventricular remodelling and 
filling pressures. (Lantelme et al., 2008) The authors postulated that poorly controlled hypertensive 
patients with diastolic dysfunction may develop adverse cardiac remodelling and have increased risk 
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of developing AF and stroke.  Also, Lee et al reported higher PWVhf (pulse wave velocity heart-
femoral) in patients with AF compared to those in sinus rhythm. (S. H. Lee et al., 2008) 
 
Similarly higher levels of sE-Sel were found in patients with AF (paroxysmal, persistent, permanent 
and lone) compared to subjects in sinus rhythm. (Freestone et al., 2007) Interestingly, a lower baseline 
sE-sel level appeared to predict the successful maintenance of sinus rhythm at 6 months in AF 
patients’ post-electrical cardioversion. (Tveit et al., 2007) Impaired FMD (endothelium-dependent) 
was observed in AF patients and corresponds to similar variations in the plasma levels of vWf and sE-
Sel levels compared to those in sinus rhythm. (Freestone, Chong, et al., 2008) Indeed, there was an 
improvement noted in FMD with patients in AF after restoring sinus rhythm following cardioversion. 
(Guazzi et al., 2007; Skalidis et al., 2007) Recently Kaji et al demonstrated an independent correlation 
between increased augmentation index (AI, measured from Cardio-Ankle Vascular Index, CAVI) and 
raised B-type natriuretic peptide levels in patients with PAF compared to those in sinus rhythm 
(r=0.47, p<0.01). (Kaji et al., 2009) Therefore, this study is consistent with and extends these previous 
findings by demonstrating lower endothelial-dependent changes with acetyl-choline (micro-vascular) 
and salbutamol (macro-vascular) in patients with PAF compared to healthy controls, suggesting both 
macro- and micro-vascular endothelial dysfunction.  
 
In the present study, there was a significant negative correlation observed between PP and Pr with 
macro-vascular endothelial function (ΔAIx Sal, Δ% AIx Sal) in patients with PAF. However, there 
was no significant difference between the disease groups in almost all the parameters of arterial 
stiffness and measures used for the assessment of endothelial function in this study. Therefore, the 
results of this study suggest that the arterial stiffness is likely to be mediated by macro-vascular 
endothelial (dys) function, which is related to co-existent cardiovascular conditions (hypertension, 
diabetes, ischaemic heart disease and dyslipidaemia) in patients with PAF rather than the arrhythmia 
per se.  
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The association between PP/Pr, but not PWV and macro-vascular endothelial function probably 
reflects the nature of these measurements. Both PP and Pr (derived from pulse waveform) are affected 
by vascular tone in resistance vessels, which in turn is regulated by endothelial function. Pulse wave 
velocity (PWVcf) in contrast, is dependent on the arterial wall properties (Young’s modulus of 
elasticity) between the carotid and femoral arteries. 
 
7.6. Study limitations 
The main limitation of this study is its cross-sectional design, which does not provide insight into 
prognostic value of the study markers of details of (patho)physiological pathways implicated. Indeed, 
it is a small study of patients with PAF and is also limited by multiple testing. However the study 
benefits from having a healthy control group as a comparator. Predictably, most of the patients with 
PAF do have co-existent medical conditions like hypertension, diabetes and ischemic heart disease 
and therefore the assessment of endothelial function in these patients might not reflect the true 
endothelial perturbation related to the arrhythmia per se.  
 
7.7. Conclusion 
The present analysis demonstrated an association between arterial stiffness and macro-vascular 
endothelial function in patients with PAF. The greater endothelial dysfunction and increased arterial 
stiffness in patients with paroxysmal atrial fibrillation is related to co-existent cardiovascular diseases 
like hypertension, diabetes and coronary artery disease rather than the arrhythmia per se. Targeting 
these risk factors with early intervention and treatment may help in preventing the development of AF 
and its complications.  
 
 
 
 
 
 
  90 
CHAPTER EIGHT 
 
8. Relationship between arterial stiffness and cardiac remodelling in patients with paroxysmal 
atrial fibrillation 
8.1. Introduction 
The association between left atrial (LA) enlargement and AF is well recognised. In a study of 1655 
older subjects from Olmsted County, Tsang et al demonstrated a 48% increased risk of AF with 30% 
increase in LA volume and the latter independently predicted ischemic strokes. (Tsang et al., 2001) 
The Framingham Heart Study also observed a 39% higher risk of AF with every 5 mm increase in LA 
diameter(Vaziri et al., 1995), with the latter independently predicting the risk of stroke and death. 
(Benjamin, D'Agostino, Belanger, Wolf, & Levy, 1995) Similar results were observed in the 
Cardiovascular Health Study which has demonstrated that the incremental increase in the LA diameter 
was associated with higher risk of AF. (Psaty et al., 1997) 
 
8.2. Hypothesis 
Abnormal LA remodelling is associated with increased risk of AF, but it is unclear to what extent 
arterial stiffness contributes to LA remodelling. This study tested the hypothesis that (i) patients with 
PAF will have increased arterial stiffness and (ii) measures of arterial stiffness are associated with 
greater abnormal cardiac remodelling in PAF compared to ‘disease controls’ (patients with essential 
hypertension) and healthy controls.  
 
8.3. Patients and methods 
Patient’s recruitment, assessment of arterial stiffness including PP, PWVcf and Pr are as described in 
Chapter section 6.4. 
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Echocardiogram 
A detailed and comprehensive trans-thoracic echocardiogram was performed in all the patients using 
Philips IE33. Standard M-mode, 2-dimensional, colour Doppler imaging were carried out in 
parasternal and apical views. Measurements were averaged over three cardiac cycles. However 
particular attention was given to the measurement of left atrial (LA) dimension, LA volume, LV 
systolic assessment by calculating ejection fraction (EF, %) using biplane Simpson’s technique; 
diastolic parameters including E, A velocity across mitral inflow using pulse wave Doppler (cm/s), 
E/A ratio, iso-volumetric relaxation time (IVRT, ms), deceleration time (DT, ms), colour M-mode 
propagation velocity (CMM-Vp, cm/s), pulmonary vein systolic flow velocity (PVs-vel, cm/s), 
pulmonary vein diastolic flow velocity (PVd-vel, cm/s), pulmonary vein flow systolic and diastolic 
velocity ratio (PVs/d ratio) and mitral annular plane systolic excursion (MAPSE, cm). Using tissue 
Doppler imaging (TDI), EM, AM and SM (cms/s) velocities were measured on the mitral valve septal 
annulus at appropriate echocardiographic settings (sample volume 2-5 mm, sweep speed 50 to 100 
mm/s with filters and baseline adjusted to low velocity range -20 to 20 cm/s) . The linear antero-
posterior (AP) LA dimension was measured (in cm) by conventional 2-dimensional echocardiography 
in the parasternal long axis view using M-mode modality. LA volume was measured using bi-plane 
dimensional method, a simplified version of ellipsoid method.  Using the formula π/6 (LxD1xD2, LA 
volume was calculated and represented in millilitres; where L is long-axis from apical four-chamber, 
D1 is the AP dimension from the parasternal long-axis and D2 is the septo-lateral dimension from 
apical four-chamber view). 
 
Power calculations 
There is no published data on arterial stiffness (measurement of augmentation index or pulse wave 
velocity) in atrial fibrillation. However, Hayward et al demonstrated patients with coronary artery 
disease have impaired endothelial dysfunction with increased AIx and impaired salbutamol induced 
changes in AIx compared to healthy controls of 0.5 SD (p<0.01) (Hayward et al., 2002) Similarly 
Freestone et al, showed abnormal FMD in atrial fibrillation compared to controls in sinus rhythm of 
0.5 SD (p<0.001). (Freestone, Chong, et al., 2008) I propose, at least a similar magnitude of ED with 
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AIx would be raised in AF patients, probably even higher than disease controls.  Therefore to detect a 
0.5 SD difference in AIx with a power (1- ) of 80% and a p-value of <0.05, a minimum of 32 patients 
per group were required for the study. From my pilot data (unpublished) to identify a 20% difference 
in AIx with the average value of 30±12 (80% power and p<0.05), I aimed to recruit 50 patients in each 
group for this cross-sectional study.  
 
Statistical analysis 
Following a test of statistical normality, data were expressed as mean with standard deviation (SD) or 
as median with inter-quartile range (IQR) for the normally distributed data and non-parametrically 
distributed data respectively. Patient characteristics were compared between groups with a χ2 test for 
categorical variables, independent-Samples T-test for continuous variables and Mann-Whitney U test 
for non-continuous variables. Both univariate and multivariate logistic regression analysis were used 
to identify features independently associated with higher LAD and LAV. Statistical analyses were 
undertaken with SPSS 22.00 software (SPSS Inc), and significant was accepted at the 0.05 level (2-
sided).  
 
8.4. Results 
There were no statistical differences in the age, gender, body mass index (BMI), heart rate and mean 
BP between individual study groups [Table 7.1]. Mean systolic BP (SBP) was significantly higher in 
patients with PAF compared to healthy controls (p<0.001); but not between patients with PAF and 
hypertension.  Mean PP (59 ± 12 vs. 48 ± 7 mm of Hg, p<0.001); PWVcf (6.8 ± 1.3 vs. 5.8 ± 1.0 m/s, 
p<0.001) and Pr (130 ± 12 vs. 119 ± 13 mm of Hg, p<0.001) were significantly higher in patients with 
PAF compared to healthy controls, but not between patient groups. [Table 7.2] 
 
With respect to the echocardiographic measurements, both mean LAD (p<0.001) and LAV (p<0.001) 
were significantly higher in patients with PAF compared to healthy controls. There was no difference 
observed in the LAD between disease groups; however, there was a significant difference in the LAV 
between PAF and hypertensive subjects (p=0.05).  Similarly IVRT (p<0.001) and DT (p<0.001) were 
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noted to be significantly higher in patients with PAF compared to healthy controls, but no differences 
seen between disease groups. Nevertheless, CMM-Vp was significantly lower in patients with PAF 
compared to healthy subjects (49 ± 10 vs. 63 ± 12 cm/s, p<0.0001), but not between patient groups.   
EM velocity was lower and the E/EM ratio significantly higher in patients with PAF compared to 
healthy controls (p=0.001); but no differences were observed between disease groups.  
 
There were no other differences in the other echocardiographic parameters of systolic and diastolic 
function between patients with PAF and healthy controls or between disease groups.  [Table 8.1]  
 
Table 8.1. Baseline values of echocardiographic parameters in between the study groups. 
Variables 
 
Healthy      
(n=55) 
Disease controls 
(n=55)        
PAF 
(n=55) 
P 
LA diameter (cm) 3.6 ± 0.5* 3.9 ± 0.5 4.1 ± 0.6 <0.001 
LA volume (ml) 30 ± 9* 38.± 13φ 45 ± 11 <0.001 
EF (%) 67 ± 8 68 ± 10 65 ± 11 0.49 
E velocity (cm/s) 73 ± 15 74 ± 19 78 ± 21 0.45 
A velocity (cm/s) 70 ± 14* 79 ± 18 75 ± 17 0.04 
E/A ratio 1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.4 0.09 
IVRT (ms) 93 ± 11* 111 ± 18 109 ± 12 <0.001 
DT (ms) 184 ± 18* 223 ± 55 236 ± 62 <0.001 
CMM Vp (cm/s) 63 ± 12* 51 ± 10 49 ± 10 <0.001 
MAPSE (cms) 
PVs (cm/s) 
PVd (cm/s) 
1.7 ± 0.3 
58.4 ± 12.6 
43 ± 8.8 
1.8 ± 1.4 
54.5 ± 13.8 
43.8 ± 13.8 
1.8 ± 0.3 
54.7 ± 10.9 
41.9 ± 9.4 
0.63 
0.22 
0.70 
PVs/d ratio 1.3 ± 0.3 1.3 ± 0.4 1.3 ± 0.2 0.64 
E/EM ratio 9.1 ± 2.5* 11.5 ± 3.9 11.5 ± 5.2 0.001 
EM velocity (m/s) 8.7  2.4* 6 9 2.3 7.5 ± 2.0 0.001 
AM velocity (m/s) 9.9 ± 2.2 10.3 ± 2.3 9.2 ± 2.5 0.58 
SM velocity (m/s) 8.7 ± 2.4 8.5 ± 2.4 8.5 ± 1.8 0.80 
*p<0.05, statistically significant between healthy controls and PAF 
φp<0.05, statistically significant between disease controls and PAF 
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Assessment of relationship between arterial stiffness and LA remodelling 
On correlation analysis in patients with PAF (Table 8.2), a significant positive relationship was noted 
between PP and LAV (r=0.28, p=0.04), Pr and LAV (r=0.29, p=0.04) as well as with PWVcf and LAD 
(r=0.31, p=0.03). 
 
Table 8.2. Correlation between arterial stiffness and LA remodelling 
 
On univariate regression analysis, the predictors of LAD were age, hypertension and PWVcf (Table 
8.3). Similarly age, hypertension, PP and Pr were predictors of LAV (Table 8.4) On multivariate 
analysis, there were no significant association observed between PWVcf and LAD (p=0.14) or PP and 
LAV (p=0.32) or Pr and LAV (p=0.07), after adjusting to age and hypertension.  
 
Table 8.3. Univariate analysis of predictors of left atrial diameter (LAD) in patients with PAF 
Variables B ± SE β p 
Age 0.02 ± 0.01 0.37 0.007 
Gender -0.05 ± 0.17 -0.04 0.79 
Hypertension 0.58 ± 0.24                0.32 0.02 
Diabetes mellitus 0.32 ± 0.18 0.24 0.08 
Ischaemic heart disease -0.06 ± 0.19 -0.04 0.77 
Stroke -0.06 ± 0.24 -0.04 0.81 
Dyslipidaemia 0.13 ± 0.17 0.11 0.44 
PVD -0.14 ± 0.35 -0.06 0.69 
Smoking 0.25 ± 0.18 0.19 0.17 
Pulse wave velocitycf 0.14 ± 0.06 0.34 0.02 
On multivariate analysis     
Pulse wave velocitycf* 0.09 ± 0.63 0.23 0.14 
*adjusted for age and hypertension 
 
Variables 
 
Left atrial diameter Left atrial volume 
r p r p 
PP 0.16 0.26 0.28 0.04* 
PWVcf 0.31   0.03* 0.06            0.67 
Pr 0.12 0.40 0.29 0.04* 
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Table 8.4. Univariate analysis of predictors of left atrial volume (LAV) in patients with PAF 
Variables B ± SE β p 
Age 0.39 ± 0.20 0.27 0.05 
Gender -1.77 ± 5.62 -0.04 0.75 
Hypertension 15.44 ± 8.24                0.25 0.07 
Diabetes mellitus 3.53 ± 6.10 0.08 0.57 
Ischaemic heart disease -1.85 ± 6.27 -0.04 0.77 
Stroke -1.57 ± 7.97 -0.03 0.85 
Dyslipidaemia 3.47 ± 5.68 0.09 0.54 
PVD -6.93 ± 11.64 -0.08 0.54 
Smoking 8.75 ± 5.87 0.21 0.14 
Pulse pressure 0.48 ± 0.23 0.28 0.05 
Reservoir pressure 0.44  ± 0.17 0.35 0.01 
On multivariate analysis     
Pulse pressure* 0.29 ± 0.29 0.16 0.32 
Reservoir pressure* 0.34  ± 0.19 0.27 0.07 
*adjusted for age and hypertension 
 
8.5. Discussion 
This study demonstrated increased PP, PWVcf and Pr in patients with AF compared to healthy 
controls with parallel increase in LA remodelling. Similar findings were observed in the Framingham 
Heart study, which demonstrated a significant higher risk of developing AF with increasing PP, even 
after adjusting to clinical risk factors and mean arterial pressure. These findings suggest an association 
between AF and increased arterial stiffness. (Mitchell et al., 2007) 
 
Increased arterial stiffness may impose an abnormal pulsatile workload on the left ventricle, (Mitchell 
et al., 2004) thereby promoting ventricular hypertrophy (Gardin et al., 1997) and subsequent reduced 
ventricular compliance (Leite-Moreira, Correia-Pinto, & Gillebert, 1999; Zile & Gaasch, 1990). The 
higher ventricular stiffness and the increase in left ventricular filling pressures may result in abnormal 
left atrial remodelling (Vaziri et al., 1995), dilatation and fibrosis – all of which may contribute to the 
pathogenesis of AF. The above mechanisms are evident with the echocardiographic findings of the 
present study that patients with PAF have higher IVRT, DT, E/EM ratio and lower CMM-PV, EM-
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velocity all suggestive of higher left ventricular stiffness, increased filling pressures and diastolic 
dysfunction. The significantly higher LAV and increased LAD in patients with AF compared to 
healthy subjects and disease controls may also represent diastolic dysfunction.  
 
In a study with hypertensive patients, Lantelme et al found a significant association between LA 
diameter (LAD) and PWVcf. A similar significant association observed between LAD and 24-hour PP 
even after adjusting for confounders including left ventricular remodelling and filling pressures. 
(Lantelme et al., 2008) Also Lee et al reported higher PWVhf (pulse wave velocity heart-femoral) in 
patients with AF compared to those in sinus rhythm. (S. H. Lee et al., 2008) In the Framingham Heart 
Study, the level of systolic BP and duration of hypertension was predictive of adverse LA 
remodelling. Patients with an 8-year average systolic BP of ≥ 140 mm of Hg were twice as likely to 
have LA enlargement compared to those with levels ≤ 110 mm of Hg. (Vaziri et al., 1995)In the 
present study, there was a significant correlation observed between the arterial stiffness and abnormal 
cardiac remodelling (LAV and LAD) in patients with PAF. However, there were no significant 
differences observed between the disease groups in the markers of LA remodelling including LAD 
and LAV. Therefore the results of this study suggest that arterial stiffness may ‘drive’ the abnormal 
cardiac remodelling in PAF patients; but further LA remodelling appears to be related to co-existent 
cardiovascular conditions and the development of AF.   
 
8.6. Conclusion 
Abnormal cardiac remodelling in patients with PAF is related to higher arterial stiffness (PP, PWVcf 
and Pr), but the increased arterial stiffness is related to co-existent cardiovascular risk factors. The 
development and perpetuation of the arrhythmia may be related to greater LA remodelling driven by 
higher arterial stiffness.  
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CHAPTER NINE 
 
9. von Willebrand factor and soluble E-selectin levels in patients atrial fibrillation: A predictor 
of future cardiovascular events  
9.1. Introduction 
The pathophysiological mechanisms associated with the prothrombotic tendency in AF are highly 
complex and multifactorial. Atrial fibrillation confers a ‘hypercoaguable state’ by fulfilment of 
Virchow’s triad for thrombogenesis. (Watson, Shantsila, & Lip, 2009) ‘Blood vessel wall 
abnormalities’ were recognised as ‘endothelial damage or dysfunction’. (Freestone & Lip, 2008) A 
continuum of endothelial activation, dysfunction and (ultimately) damage, has been proposed towards 
the perpetuation and progression of the arrhythmia and its complications. (Blann, Choudhury, 
Freestone, Patel, & Lip, 2008) 
 
von Willebrand factor (vWf) is a glycoprotein secreted by vascular endothelial cells as a response to 
endothelial damage into the systemic circulation. (Bowie et al., 1986) Under the normal physiological 
state, circulating plasma vWf is derived predominantly from endothelial cells; but platelets do 
contribute to the circulating pool in pathological states. (Blann & Taberner, 1995) Although vWf has 
been described as an acute phase protein, various studies have shown higher vWf levels in the absence 
of other indicators of acute phase response and may be more suggestive of endothelial damage or 
injury. (Blann, 1991)  Thus, the measurement of plasma vWf has commonly been used to assess 
endothelial damage/dysfunction. Multiple studies have consistently reported higher levels of vWf in 
patients with AF.   
 
Adhesion molecules are expressed on endothelial cell surfaces that promote leukocyte adhesion. 
Whilst soluble E-Selectin (sE-Sel) is specific for endothelial cells and not expressed under normal 
physiological states (Gearing & Newman, 1993), its expression may be increased under pathological 
conditions, and raised plasma levels of sE-Sel (measured using ELISA) are believed to reflect 
endothelial activation. (Blann & Lip, 1998) Higher plasma levels of sE-Sel have been noted in AF 
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patients compared to healthy controls in sinus rhythm. However, no significant differences in the 
levels of sE-Sel observed between disease sub-groups of AF. (Freestone et al., 2007) Interestingly, 
low baseline sE-sel levels predicted the successful maintenance of sinus rhythm at 6 months in AF 
patients. (Tveit et al., 2007) Circulating sE-sel levels in AF patients also correlated well with 
endothelial-dependent vasodilatation in the brachial artery using FMD. (Freestone, Chong, et al., 
2008) In one study of patients with systolic heart failure, plasma sE-Sel levels were not significantly 
different in AF patients compared to those in sinus rhythm, despite increased vWf levels. (Freestone, 
Gustafsson, et al., 2008) 
 
9.2. Hypothesis 
This study tested the hypothesis that higher levels of baseline vWf and sE-Sel are associated with 
increased clinical adverse events (a composite of ischaemic stroke or transient ischaemic attack (TIA), 
acute myocardial infarction (AMI) and all-cause mortality), in a ‘real world’ community cohort of AF 
patients during their routine follow-up, irrespective of the anti-thrombotic therapy used. 
 
9.3. Patients and methods 
Four hundred and twenty three consecutive patients with non-valvular AF were recruited from our 
outpatient clinic. Atrial fibrillation was confirmed on electrocardiogram (ECG). Exclusion criteria 
included any condition(s) that may affect the endothelium (e.g., recent stroke, myocardial infarction 
and thromboembolism within 6 months, uncontrolled hypertension), patients with significant cardiac 
abnormalities (valvular disease, hypertrophic cardiomyopathy), inflammatory or connective tissue 
disorders, active infection, malignancy, pregnancy, hepatic or renal impairment and on long-term 
immunosuppressive therapy. Following verbal and written informed consent, patients underwent 
detailed history taking and physical examination. Patients were advised not to take any vaso-active 
medications (including caffeine) 12-hours prior to the study. Blood samples were collected within 7 
days of enrolment, one sample per patient were included in these analysis. Examinations were carried 
out in a quiet temperature controlled room. The Cardiac failure, Hypertension, Age, Diabetes, Stroke 
[Doubled] (CHADS2) score was calculated, as was the CHA2DS2-VASc score (Cardiac failure or 
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dysfunction, Hypertension, Age ≥75[Doubled], Diabetes, Stroke[Doubled] – Vascular disease, Age 
65-74 and Sex category [Female]), whereby 2 points are assigned for a history of stroke or age ≥75; 
and 1 point each for age 65-74 years, a history of hypertension, diabetes, cardiac failure and vascular 
disease).  The study was approved by the local research ethics committee, and conducted in 
concordance with the declaration of Helsinki. 
 
Follow-up 
Patients were followed-up for clinical adverse events, with the primary endpoint being a composite of 
stroke/TIA, acute myocardial infarction (MI) and all-cause mortality.  All the patients were offered 
routine 6-monthly follow-up in the specialist arrhythmia clinic. Clinical events were ascertained using 
hospital electronic patient record event tracker and or patient reporting systems and or contacting 
patients or family. The mortality data were obtained from hospital event statistics or the Office for 
National Statistics. As per World Health Organisation (WHO), stroke was defined as a focal (or at 
times global) neurological impairment of sudden onset, and lasting more than 24 hours (or leading to 
death), and of presumed vascular in origin (Sacco et al., 2013). Myocardial infarction (MI) was 
defined as the detection of rise and or fall of cardiac biomarkers (usually troponin) with at least one 
value above the 99th percentile of the upper reference limit (URL) together with evidence of 
myocardial ischaemia with at least one of the following; (i) symptoms of ischaemia, (ii) ECG changes 
indicative of new ischaemia [new ST-T changes or new left bundle branch block (LBBB)], (iii) 
development of pathological ‘Q’ waves in the ECG, (iv) imaging evidence of new loss of viable 
myocardium or new regional wall motion abnormality. (Thygesen et al., 2012) 
 
Laboratory tests 
Venous blood was drawn at baseline from the ante-cubital vein ensuring minimal stasis and trauma 
into Vacutainer ® tubes (Becton Dickinson, UK) each containing 0.5 ml of 3.8% sodium citrate and 
EDTA. Blood was kept on ice and processed within 30 minutes of sampling by centrifugation at 1,500 
cycles for 20 minutes at 4·C. The resultant supernatant plasma was then collected and stored at -70’C 
until later batch processed by enzyme–linked immunosorbent assay (ELISA) to measure vWf (Dako, 
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Glostrup, Denmark) and sE-Selectin (R&D Systems). The reference unit for vWf is international units 
per decilitre (IU/dl), which was standardized by reference vWf from National Institute for Biological 
Standards and Controls, Blanche Lane, South Mimms, Potter Bar, Hertfordshire, UK. Similarly the 
reference unit for sE-Selectin is nanogram per millilitres (ng/ml). The intra and inter-assay coefficient 
of variations were <5% and <8% respectively, for both assays.  
 
Statistical analysis 
Following a test of statistical normality, data were expressed as mean with standard deviation (SD) or 
as median with inter-quartile range (IQR) for the normally distributed data and non-parametrically 
distributed data respectively. Patient characteristics were compared between groups with a χ2 test for 
categorical variables, independent-Samples T-test for continuous variables and Mann-Whitney U test 
for non-continuous variables. Both univariate and multivariate binary logistic regression analysis were 
used to identify features independently associated with higher biomarker levels.  In the above 
regression analysis, both vWf and sE-sel variables were used as continuous variables. In the 
multivariate analysis, both the CHADS2 ≥2 and CHA2DS2-VASc ≥2 clinical variables were not 
included on addition to other individual variables which comprised the above stroke risk schemata. 
Survival analysis of time to clinical events was performed using the Kaplan-Meier estimate of the 
survival function. Statistical analyses were undertaken with SPSS 22.00 software (SPSS Inc), and 
significant was accepted at the 0.05 level (2-sided).  
 
9.4. Results 
In this study of 423 patients (55.6% male) with non-valvular AF, paroxysmal AF was present in 
55.1% (n=233) and permanent AF in 44.9% (n=190), whilst 85.5% (n=361) had treated hypertension, 
19.4% (n=82) diabetes, 26.5% (n=113) prior history of stroke or TIA, 19.9% (n=84) heart failure 
(ejection fraction <55%) and 9.9% (n=42) were smokers. Of the whole cohort, 75.2% (n=318) were 
on treatment with vitamin K antagonists (VKA) compared to 19.4% (n=82) on aspirin and 5.4% 
(n=23) were not on any antithrombotic treatment. The median CHADS2 score was 2 (1-3), whilst the 
median CHA2DS2-VASc score was 3 (2-4). At baseline, median vWf levels for the 423 patients were 
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85 (IQR 66-115) IU/dl [range 36 to 215 IU/dl]. Mean sE-Sel levels were 14.8 ± SD 5.4 ng/ml [range 4 
to 32 ng/ml]. Baseline levels of vWf and sE-Sel according to patient characteristics are shown in 
Table 9.1.    
 
Table 9.1. Baseline plasma levels of vWf and soluble E-Selectin according to patient characteristics 
 All 
patients 
(n=423) 
% 
VWf (IU/dl) 
Median              
(IQ range) 
 
p 
sE-Sel (ng/ml) 
Mean ± SD 
 
p 
Overall  85 (66-115)  14.8 ± 5.4  
Age in years       
>75 43.5 85 (67.3-120.8) 0.28 14.9 ± 5.2 0.65 
<75 56.5 84 (64-114)  14.6 ± 5.5  
Sex      
Women 44.4 85 (68-115) 0.23 14.3 ± 5.1 0.69 
Men 55.6 84.5 (60.8-115.3)  15.2 ± 5.5  
Hypertension      
Yes 85.5 84 (64-117) 0.84 14.7 ± 5.4 0.53 
No 14.5 87 (64.8-117)  15.2 ± 5.5  
Diabetes      
Yes 19.4 80.5 (66-110) 0.75 13.6 ± 4.9 0.03* 
No      80.6 85 (64.8-117)  15.1 ± 5.5  
Previous stroke/TIA      
Yes 26.5 100 (70-129) 0.03 15.2 ± 5.6 0.36 
No 73.5 82.5 (62.3-111.8)  14.6 ± 5.3  
Heart failure (EF<55%)      
Yes 19.9 96.5 (68.3-133) 0.07 15.3 ± 6.1 0.30 
No 80.1 84 (64-114)  14.6 ± 5.2  
Smoker      
Yes 9.9 81 (60.5-117) 0.89 14.9 ± 5.6 0.93 
No 90.1 85 (66-115)  14.8 ± 5.3  
Statin treatment      
Yes 30.3 80 (63-115) 0.38 14.4 ± 5.5 0.40 
No 69.7 85 (67-115)  14.9 ± 5.3  
VKA treatment      
Yes 75.2 84 (63-114) 0.06 14.6 ± 5.3 0.37 
No 24.8 88 (71.5-123.5)  15.2 ± 5.5  
Aspirin treatment      
Yes 19.4 88.5 (72-122.5) 0.50 15.4 ± 5.6 0.52 
No 5.4 84 (61-127.5)  14.5 ± 4.8  
CHADS2 ≥ 2      
Yes 63.6 86 (68-124.5) 0.02* 14.8 ± 5.4 0.71 
No 36.4 84 (58-110)  14.8 ± 5.2  
*p<0.05, statistically significant between the groups 
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There were 94 clinical events (22.2%) over a median follow-up period of 19 (9-31) months - 44 
(10.4%) acute MI events, 25 ischaemic stroke/TIAs (5.9%) and 25 (5.9%) deaths. The drop-out rate 
was a 2.4 % (n=10) and one patient was excluded due to the development of malignancy.  
 
Relationship to risk factors for stroke and cardiovascular disease 
Bivariate analyses found no significant associations between the increased levels of vWf and the 
following stroke risk factors: advanced age (p=0.80), female sex (p=0.23), history of hypertension 
(p=0.84), diabetes (p=0.75) and smoking (p=0.90). Patients with prior ischaemic stroke or TIAs were 
associated with increased levels of vWf (r=0.142, p=0.004). Similarly, higher vWf levels were found 
in patients with heart failure but this was non-significant (r=0.88, p=0.07).  There was a significant 
association between diabetes and the levels of sE-Sel (r=-0.113, p=0.02) but no other significant 
associations were observed.  
 
Relationship to CHADS2 and CHA2DS2-VASc scores 
Median vWf levels in patients who had a CHADS2 score of ≥2 was 86 (67.5-122.5), compared to. 84 
(60-110) with those CHADS2<2 (p=0.005). Median vWf levels in patients with a CHA2DS2-VASc 
score ≥2 was 85 (66-117) compared to 84 (55-103) with those CHA2DS2-VASc<2 (p=0.13). sE-Sel 
levels did not show any significant correlations to the CHADS2 or CHA2DS2-VASc scores.    
 
Relationship to age 
Patients who were ≥ 75 years old had a higher rate of clinical events compared those age 65-74 years 
[RR 1.1, 95% (1.01-1.09), p=0.01] and <65 years [RR 1.1, 95% CI (1.01-1.09), p=0.006]. However, 
there was no difference between patients aged 65-74 years compared to those age<65 years [RR 1.0, 
95% CI 0.96-1.08), p=0.48]. On multivariate analysis, the relationship between advancing age and 
clinical events remained statistically significant between the individual age groups [RR 1.1, 95% (1.0-
1.17), p=0.09 for age<65 years vs. age 65-74 years); RR 1.1, 95% CI (1.03-1.1.4), p=0.002 for <65 
years vs. age ≥75 years); RR 1.1, 95% CI (1.01-1.12), p=0.02 for 65-74 years vs. age ≥75 years)]. 
[Figure 9.1] 
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Figure 9.1. Kaplan-Meier estimates of time to clinical events in AF patients according to age (<65 
years vs. 65-74 years vs. ≥ 75 years) 
 
 
 
Relationship to anti-thrombotic therapy 
There were no significant differences in vWf (84 vs. 88.5 vs. 84 IU/dL; p=0.14) or sE-Sel (14.4 vs. 
15.8 vs. 15.2 ng/ml; p=0.55) levels with VKA, aspirin, or no antithrombotic therapy, respectively.  
 
Patients on VKA therapy had significantly less clinical adverse events compared to those receiving 
aspirin or no antithrombotic treatment [RR 0.51, 95% CI (0.31-0.84), p=0.008] [Figure 9.2]. Patients 
receiving aspirin had a significantly higher number of clinical adverse events compared to those not 
receiving antithrombotic therapy [RR 6.38, 95% CI 1.40-29.11; p=0.017] [Figure 9.3].  
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Figure 9.2. Kaplan-Meier estimates of time to clinical events in AF patients with and without 
anticoagulation therapy 
 
 
 
Figure 9.3. Kaplan-Meier estimates of time to clinical events in AF patients with aspirin and no 
antithrombotic therapy 
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Clinical adverse events on follow-up 
Bivariate analyses demonstrated significantly higher vWf levels in patients who had a clinical 
outcome (composite of ischaemic stroke/acute myocardial infarction/all-cause mortality) compared to 
those without an event (134 vs. 80 IU/dl, p<0.001). Plasma vWf levels were also higher in patients 
who had acute MI (163 vs. 80 IU/dl, p<0.001) and ischaemic stroke or TIA (139 vs. 80 IU/dl, 
p<0.001) compared to those event-free. sE-Sel levels were significantly higher in patients who have 
had an adverse event (19.2 vs. 13.5ng/ml, p<0.001) compared to those event-free.   
 
Higher sE-Sel levels were also noted in patients who had an acute MI (20.6 vs. 13.5 ng/ml, p<0.001) 
and ischaemic stroke or TIAs (20.3 vs. 13.5 ng/ml, p<0.001). No significant differences in vWf (105 
vs. 80 IU/dl, p=0.14) or sE-sel (15.4 vs. 13.5 ng/ml, p=0.72) levels were seen in relation to all-cause 
mortality.  
 
Table 9.2. Baseline plasma levels of vWf and soluble E-Selectin according to individual clinical 
outcomes 
 
Outcomes All 
patients 
(n=423) % 
vWf (IU/dl) 
Median (IQ 
range) 
 
p 
sE-Sel (ng/ml) 
Mean ± SD 
 
p 
Overall clinical events      
Yes (n=94) 22.2 134 (105-176.8) <0.001* 19.2 ± 4.8 <0.001* 
No (n=329) 77.8 80 (59.8-100.3)  13.5 ± 4.8  
AMI (n=44) 10.4 163 (120.3-185) <0.001* 20.6 ± 3.4 <0.001* 
Ischaemic stroke (n=25) 5.9 139 (112-176) <0.001* 20.3 ± 3.8 <0.001* 
All cause death (n=25) 5.9 105 (74.5.127) 0.14 15.4 ± 5.9 0.72 
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Figure 9.4. Relationship between baseline plasma levels of vWf and overall clinical events 
 
 
Table 9.5. Relationship between baseline plasma levels of sE-sel and the individual clinical events 
 
 
On multivariate logistic regression analysis, independent predictors of the clinical adverse events were 
vWf [p<0.001], sE-Sel [p<0.001], age [p=0.001] and treatment with aspirin [p=0.002]. Using 
multivariate Cox regression analyses, only age, vWf and sE-Sel levels were found to be the 
independent predictors of survival. [Table 9.3] 
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Table 9.3. Cox regression analyses for overall clinical adverse events   
Variable Unadjusted hazard ratios Adjusted hazard ratios* 
(95% CI) p (95% CI) p 
Age 1.05 (1.02-1.08) <0.001 1.05 (1.02-1.08) <0.001 
Sex 1.00 (0.67-1.51) 0.99 1.24 (0.80-1.91) 0.34 
Hypertension 1.30 (0.71-2.39) 0.40 1.53 (0.81-2.89) 0.19 
Diabetes 0.66 (0.35-1.23) 0.66 0.64 (0.33-1.25) 0.19 
Smoker 0.77 (0.36-1.66) 0.50 0.92 (0.42-2.05) 0.84 
Heart failure 1.14 (0.71-1.81) 0.59 0.91 (0.52-1.61) 0.75 
Previous stroke or TIA 1.17 (0.77-1.80) 0.46 1.31 (0.79-2.18) 0.30 
CHADS2 ≥2 1.29 (0.83-2.01) 0.26   
CHA2DS2VASc ≥ 2 4.50 (1.11-18.31) 0.04   
Aspirin treatment 4.74 (1.13-19.94) 0.03   
Anticoagulant therapy 0.69 (0.45-1.05) 0.08 0.87 (0.55-1.37) 0.56 
von Willebrand factor 1.019 (1.014-1.024) <0.001 1.012 (1.007-1.018) <0.001 
Soluble E-Selectin 1.14 (1.10-1.18) <0.001 1.12 (1.07-1.16) <0.001 
*Adjusted for age, sex, hypertension, diabetes, smoking, heart failure, previous stroke or TIA, aspirin 
treatment, anticoagulant therapy, von Willebrand factor, soluble E-selectin. 
 
 
Kaplan-Meier curves according to the tertiles of vWf are shown in Figure 9.6. Significantly higher 
clinical adverse events occurred in the upper tertile of vWf [RR 1.03, 95% CI (1.02-1.04), p<0.0001 
[lowest vs. upper tertile]; RR 1.04, 95% CI (1.03-1.05), p<0.001 [middle vs. upper tertile] 
respectively].   
 
On multivariate analyses, tertiles of vWf were significantly associated with overall clinical events 
[RR 1.04, 95% CI (1.03-1.05), p<0.001 [lowest vs. upper tertile]; RR 1.05, 95% CI 1.03-1.06), 
p<0.001 [middle vs. upper tertile].  
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Figure 9.6. Kaplan-Meier estimates of time to clinical events in AF patients with vWf levels in 
tertiles 
 
 
 
Kaplan-Meier curves according to the tertiles of sE-Sel are shown in Figure 9.7. The higher tertiles of 
sE-Sel were associated with more adverse events [RR 1.2, 95% CI (1.04-1.40), p=0.02 [middle vs. 
lowest tertile]; RR 1.3, 95% CI (1.19-1.39), p<0.001 [middle vs. upper tertile]]. On multivariate 
analyses, tertiles of sE-Sel were significantly associated with overall clinical adverse events (RR 1.3, 
95% CI (1.06-1.48), p=0.008 [middle vs. lowest tertile]; RR 1.3, 95% CI (1.19-1.42), p<0.001 
[middle vs. upper tertile]).  
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Figure 9.7. Kaplan-Meier estimates of time to clinical events in AF patients with sE-sel levels in 
tertiles
 
  
9.5. Discussion 
The present study suggests that vWf and sE-Sel are independent predictors of clinical adverse events 
(MI, ischaemic stroke, but not all-cause mortality) in this community based, prospective cohort. In the 
present study, only prior history of stroke or TIA and heart failure were independently associated with 
higher levels of vWf. Also, diabetes was the only major clinical risk factor associated with reduced 
plasma levels of sE-Sel in patients with AF; however, this observation could be related to the down 
regulation of sE-Sel expression on active treatment of diabetes. In the SPAF III (Stroke Prevention in 
Atrial Fibrillation III) study, higher plasma vWf levels were independently associated with previous 
history of stroke, ageing, presence of diabetes and established heart failure (all with p<0.001). 
(Conway, Pearce, et al., 2003) In the Rotterdam study, there was a positive linear relationship 
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between vWf level and the presence of AF among women but not among men. Indeed, female gender 
is independently associated with increased risk of stroke and thromboembolism with AF, even after 
adjusting for other confounders. (Lane & Lip, 2009) There were no associations observed between 
either VKA treatment or aspirin with the vWf or sE-sel levels, consistent with previous studies.(Li-
Saw-Hee et al., 2000)  
 
The most striking finding in this study is the independent association between the plasma levels of 
vWf, sE-Sel and overall clinical adverse outcomes. The Stoke Prevention in Atrial Fibrillation (SPAF) 
study, revealed a significant relationship between vWf levels and CV events. For every 20U/dl 
increase in the levels of vWf the risk of stroke increased by 1.2% in absolute terms in this study. 
(Conway et al., 2002) This is consistent with other data suggesting that raised levels of vWf predicts 
future cardiovascular events (stoke, myocardial infarction and death) and a poor prognosis in patients 
with coronary artery disease. (Jansson et al., 1991) In an early Swedish study, Gustafsson et al also 
demonstrated higher levels of vWf in patients with AF with or without stroke, when compared to 
controls in sinus rhythm. (Gustafsson et al., 1990)  In an early cross-sectional study, Lip et al 
demonstrated raised vWf levels in patients with chronic AF, independent of underlying structural 
heart disease. (Lip et al., 1995) More recently, Freestone et al reported significantly higher levels of 
plasma vWf in patients with systolic heart failure who were in AF compared to those in sinus rhythm. 
(Freestone, Gustafsson, et al., 2008) 
 
In the present study, there was a significant negative correlation between the VKA use and overall 
clinical adverse events, consistent with the efficacy of anticoagulation therapy in reducing the risk of 
stroke and mortality in AF patients. (Hart, Pearce, & Aguilar, 2007)  In keeping with the evidence, 
aspirin treated patients were associated with more adverse clinical outcomes.  Patients with a higher 
thromboembolic risk, calculated with both the CHADS2 and CHA2DS2VASc scores (European Heart 
Rhythm et al., 2010) had significantly higher vWf levels. Given that those with higher CHADS2 and 
CHA2DS2VASc score(s) are likely to have more co-existent cardiovascular risk factors either in 
isolation or in combination, they would be expected to have higher endothelial damage/dysfunction.  
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Unsurprisingly, it has been proposed that the addition of plasma vWf levels to the clinical stroke risk 
factors may potentially improve risk stratification of patients with AF. (Lip et al., 2006; Roldan et al., 
2011)  
 
9.6.  Study limitations 
The study is limited by its small sample size as well as lacked a sinus rhythm control group from the 
same population to address the effect of AF per se on the levels of vWf and sE-Sel levels. Some 
patients with AF during their follow-up period may well have developed additional concurrent 
cardiovascular risk factors which could have affected the results of the above plasma markers. 
However, this ‘real world’ population study was to assess the relationship between the baseline levels 
of vWf and sE-sel towards the parameters of clinical outcomes in AF patients and extends previous 
work in trial based populations. 
 
9.7.  Conclusion 
Higher levels of vWf and soluble E-Selectin at baseline are independently associated with an 
increased risk of clinical adverse events (acute myocardial infarction, ischaemic stroke but not all-
cause mortality) in ‘real world’ AF patients, and may aid clinical risk stratification towards predicting 
patients at greater risk of complications associated with this common arrhythmia. 
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CHAPTER TEN 
 
10. Association between atrial high rate episodes, arterial stiffness and endothelial function in 
patients with dual chamber pacemakers 
10.1. Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and a major 
healthcare burden (Wolowacz, Samuel, Brennan, Jasso-Mosqueda, & Van Gelder, 2011), due to its 
increased mortality and morbidity due to its complications such as stroke, thromboembolism and heart 
failure. (Benjamin et al., 1998; Miyasaka et al., 2006) The stroke risk associated with AF is largely 
non-homogenous and is associated with clinical and echocardiographic risk factors. (Lip, 2008) The 
risk of thromboembolism may also increase proportionally with duration of AF, thereby precipitating 
greater blood stasis due to mechanical and structural changes within the left atrium (LA). In 
experimental models, a shorter duration of AF results in less electrical and structural LA remodelling. 
(Allessie et al., 2002) In one study assessing LA appendage function post-electrical cardioversion, the 
duration of AF was related to the duration of atrial stunning even after restoring sinus rhythm. 
(Mitusch et al., 1995) 
 
‘AF burden’ describes the time spent in AF. The significance of arrhythmia duration has been very 
difficult to demonstrate because of the difficulty in measuring and reliably estimating the AF burden. 
Various modalities of monitoring including 24-hr and 7-day Holter recordings, event monitors and 
trans-telephonic monitoring have their own limitations, including the surveillance period and the 
quality of the tracings. The probability of detecting the transient arrhythmia proportionally increases 
with the duration of the monitoring period. Event monitors may only detect symptomatic events, 
although a significant proportion of patients with AF remain asymptomatic during their recurrences. 
(Rho & Page, 2005) Atrial Holter function, beat-to-beat detection of atrial high rate episodes (AHRE), 
intra-cardiac markers and electrograms (EGM) in patients with implanted pacemakers are currently 
the most reliable and robust methods of monitoring and evaluating AF burden. (Purerfellner et al., 
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2004; A. Verma et al., 2007) In clinical studies, AHRE or device detected AF was associated with 
higher risk of stroke, embolic events and death (Capucci et al., 2005; Glotzer et al., 2009); as well as 
increased hospitalisations for heart failure. (Borleffs et al., 2009)  
 
10.2. Hypothesis 
Studies have demonstrated a higher risk of developing AF in patients with pacemakers irrespective of 
preserving AV synchrony, but there are no studies evaluating the association between arterial 
stiffness, endothelial function and atrial high rate episodes (AHRE) in patients with pacemakers. I 
tested the hypothesis that patients with dual chamber pacemakers with AHRE will have higher arterial 
stiffness and greater micro-vascular/macro-vascular endothelial dysfunction.  
 
10.3. Patients and methods 
Consecutive 101 patients with permanent pacemakers implanted within the preceding 12 months, 
incorporating advanced AF detecting algorithms were recruited for this study. These patients were 
selected from the outpatient pacemaker clinic. This population of patients was selected to allow 
accurate assessment of the AHRE without the need for prolonged ambulatory monitoring. Exclusion 
criteria included any condition(s) that may affect endothelium (e.g., recent stroke, myocardial 
infarction, thromboembolism, uncontrolled hypertension), patients with inflammatory or connective 
tissue disorders, active infection, malignancy, pregnancy, hepatic or renal impairment and on long-
term immunosuppressive therapy. We also excluded patients with significant cardiac abnormalities 
(valvular disease, hypertrophic cardiomyopathy, LV ejection fraction <55%). 
 
Following verbal and written informed consent, patients underwent detailed history taking and 
physical examination. Patients were advised not to take any vaso-active medications (including 
caffeine) 12-hours prior to the study and an average of three blood pressure (BP) readings was taken 
using a validated, semi-automated oscillometric device (Omron) from the non-dominant brachial 
artery after a 10-minute period of rest. Examinations were carried out in a quiet temperature 
controlled room. The approval for the study was obtained from the local research ethics committee 
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and was conducted in concordance with the declaration of Helsinki. Pacemaker interrogation was 
performed at baseline to establish the presence or absence of AHRE. Patient groups were categorized 
on the basis of pacemaker interrogation as follows:  absence of AHRE [AHRE (-)] and presence of 
AHRE [AHRE (+)]. Episodes relating to atrial over sensing were rejected. 
 
Device characteristics 
Newer generation dual chamber pacemakers have more sophisticated algorithms for AF detection and 
therapy algorithms. These devices are software tailored to detect the common mechanisms through 
which episodes of paroxysmal AF are initiated by premature atrial complexes (PAC), by bradycardia 
or immediate re-initiation of AF. Pacemaker detection algorithms were programmed to detect AF as 
atrial high rate events (AHRE) of greater than 220 beats per minute for at least one minute, lasting 
more than 10 consecutive beats. The above programming has been demonstrated to be highly 
sensitive (93-98%) and specific (94-100%) in identifying AF, verified by ambulatory monitoring. 
(Glotzer et al., 2003; Seidl et al., 1998) Termination of AF was defined as the occurrence of 20 beats 
below the ARHE detection rate to ensure the exclusion of short episodes of atrial premature beats. 
Due to differences in arrhythmia detection algorithms between the manufacturers, this study only 
included patients with Vitatron (T-series) and Medtronic (Sensia) pacemakers as these are the most 
commonly implanted pacemaker systems in our hospital over the study period. The device was 
appropriately set with optimal post-ventricular atrial blanking (PVAB) periods to reduce far field R-
wave over sensing and lower P-wave sensitivities to identify atrial activity during AHRE. Patients 
with atrial sensing abnormalities were excluded.  
 
Assessment of arterial stiffness and endothelial function 
Measurement of arterial stiffness including PP, PWVcf, Pr as well as assessment of macro-vascular 
and micro-vascular endothelial function and laboratory analyses were performed as described in 
Chapter section 6.4.  
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Power calculations 
There is no published data on arterial augmentation index and the development of atrial fibrillation in 
the pacemaker population. Hayward et al previously reported significant difference in augmentation 
index (83.6 + 4.6 vs. 62.7 + 4.0%) and in the response to salbutamol (-2.4 + 1.9 vs. 13.2 + 2.3%) 
between patients with coronary disease and controls. (Hayward et al., 2002) Therefore to achieve a 
modest difference in augmentation index of <1SD, 28 patients will provide 80% power at p<0.05 
between patients with pacemakers who develop atrial fibrillation and patients who do not. My data, 
from a local audit, (unpublished), revealed an annual incidence of atrial fibrillation of 30% (diagnosed 
from atrial high rate episodes) in patients with dual chamber pacemakers. Therefore, I aim to recruit 
100 patients with dual chamber pacemaker for the follow-up study.        
 
Statistical analysis 
Following the test of statistical normality, data were expressed as mean with standard deviation (SD) 
or as median with inter-quartile range (IQR) for the normally distributed data and non-parametrically 
distributed data respectively. Comparisons between groups were analysed by 2-sample t-test or Mann-
Whitney or Kruskal-Wallis test as appropriate. Correlations were performed by Spearman’s or 
Pearson’s method as appropriate. Both univariate and multivariate binary logistic regression analysis 
were used to identify those parameters which independently predict AHRE. All the analyses were 
undertaken with SPSS version 22.0 software (SPSS Inc), and significance was accepted at the 0.05 
level (2 sided). 
 
10.4. Results 
The clinical and demographic details of all the subjects are summarised in Table 10.1. From the local 
pacemaker clinic, consecutive 101 dual chamber pacemaker patients were recruited in the study 
[mean age 72.1 ± 10.8 years; 69 (68.3%) males] of which, 23.8% (n=24) patients were noted to have 
AHRE on baseline pacemaker interrogation.  There was no significant difference in the age, gender, 
body mass index (BMI), co-morbidities, heart rate, systolic BP between the study groups. Mean 
diastolic BP (DBP) was higher in patients without AHRE compared to those with AHRE (p=0.05). 
  116 
The indications of pacing include sick sinus node disease, advanced second degree or third degree 
atrio-ventricular block as well as to allow the up-titration of anti-arrhythmic drugs in the presence of 
paroxysmal AF where treatment had been limited by bradycardia. In all the cases, at least 12 months 
had elapsed from the device implantation to the study enrolment. No significant differences observed 
between the percentage of atrial (%Ap) and ventricular (%Vp) pacing between the study groups.  
 
Table 10.1. Baseline characteristics in patients with and without atrial high rate events 
Variables 
 
No AHRE 
(n=77) 
AHRE 
(n=24) 
p 
Age ( in years) 71 ± 11.0 75 ± 10.0 0.19 
Males (n) % 52 (67.5) 17 (70.8) 0.76 
BMI (kg/m2)  26.2 ± 4.2 27.8 ± 4.8 0.09 
Heart rate (bpm) 73 ± 9 75 ± 10 0.27 
Systolic BP (mm of Hg) 138± 24 144 ± 12 0.22 
Diastolic BP (mm of Hg) 77 ± 12 72 ± 10 0.05 
Hypertension (n), % 50 (64.9) 17 (70.8) 0.60 
Diabetes (n), % 12 (15.6) 8 (33.3) 0.06 
Ischaemic heart disease (n), % 32 (41.6) 7 (29.2) 0.28 
Stroke or TIA (n), %  8 (10.4) 2 (8.3) 0.77 
Peripheral vascular disease (n), % 5 (6.5) 1 (4.2) 0.68 
Dyslipidaemia 51 (66.2) 19 (79.2) 0.24 
Smoker (n), % 12 (15.6) 9 (37.5) 0.28 
ACE inhibitors (n), % 28 (36.4) 14 (58.3) 0.06 
Angiotensin II receptor blockers (n), % 17 (22.1) 2 (8.3) 0.14 
Beta -blockers (n), % 24 (31.2) 7 (29.2) 0.85 
Calcium channel blockers (n), % 20 (26) 13 (54.2)* 
* 
0.01 
Diuretics (n), % 25 (32.5) 9 (37.5) 0.49 
Statin treatment (n), % 47 (61) 17 (70.8) 0.36 
Aspirin (n), % 51 (66.2) 14 (58.3) 0.13 
Clopidogrel (n), % 8 (10.4) 1 (4.2) 0.65 
Warfarin (n), % 7 (9.1) 7 (29.2) 0.39 
AF burden (%)  5.1 (2-96)  
%Ap 6.9 (0.1-55) 9.8 (0.1-78) 0.77 
%Vp 1.0 (0.1-52) 4.4 (0.1-94) 0.93 
*p<0.05, statistically significant between the groups 
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There were significant differences in PP (p=0.001); PWVcf (p=0.001) and Pr (p<0.001) between 
patients without AHRE compared to those with AHRE [Table 10. 2]. With regard to LDF, the median 
percentage of change in perfusion with Ach from baseline (endothelial-dependent response, ∆%LDF 
Ach) was lower in patients with AHRE compared to those without AHRE (p=0.05) [TABLE 10.3].  
 
Table 10.2. Measures of arterial stiffness between the study groups (AHRE and no AHRE) 
Variables No AHRE AHRE p 
 (n=77) (n=24)  
Pulse pressure (mm of Hg) 60 ± 16 73 ± 10* 0.001 
Pulse wave velocity (m/s) 7.5 ± 2.3 9.0 ± 1.3* 0.004 
Reservoir pressure (mm of Hg) 122 ± 22 140 ± 12* <0.001 
*p<0.05, statistically significant between the groups 
 
Table 10.3. Baseline values of micro-vascular and macro-vascular endothelial function between the 
study groups (AHRE and no AHRE) 
Variables No AHRE AHRE p 
 (n=77) (n=24)  
AP (mm of Hg) 19 (14-26) 19 (14-25) 0.74 
AIx baseline (%) 36 (26-43) 40 (35-42) 0.19 
AIx salbutamol (%) 25 (15-33) 31.5 (23-38)* 0.01 
AIx GTN (%) 14 (-3-27) 2 (-5-19) 0.15 
ΔAIx Salbutamol (%) 10 (6-15) 7.5 (4.3-10)* 0.03 
Δ%AIx Salbutamol 31 (19-43) 19 (12-28)* 0.003 
ΔAIx GTN 22 (15-30) 36 (22-43)* 0.004 
Δ%AIX GTN 63 (36-111) 95 (56-114) 0.27 
ΔLDF Ach  (PU) 0.50 (0.27-0.69) 0.45 (0.26-0.81) 0.96 
Δ%LDF Ach 77 (43-114) 64 (50-97)* 0.05 
ΔLDF SNP (PU) 0.45 (0.28-0.62) 0.37 (0.31-0.62) 0.64 
Δ% LDF SNP 70 (49-90) 59 (33-103) 0.69 
vWf (IU/dl) 96 ± 18 94 ± 29 0.94 
sE-sel (mg/dl) 17 (13-22) 18 (11-24) 0.71 
*p<0.05, statistically significant between the groups 
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There were no significant differences in the changes in perfusion with SNP (endothelial-independent 
response, ∆LDF SNP) between the study groups.  Similarly, changes in AIx in response to salbutamol 
[∆AIx Sal] and the median percentage change in AIx with salbutamol from baseline [∆%AIx Sal], 
were significantly lower (p=0.03 and p=0.003, respectively) in patients with AHRE compared to no 
AHRE. [Table 10.3] 
 
Correlations and regression analyses 
In patients with AHRE, a significant negative correlation was observed between the levels of %Vp 
and Δ% LDF ACh (r=-0.58, p=0.005). Similarly correlations were observed between PP and Δ%LDF 
Ach (r=-0.43, p=0.05). Δ%AIx Sal Ach did not correlate significantly with markers of arterial 
stiffness or percentage of pacing, and no significant correlation between percentage of ventricular 
pacing and measures of arterial stiffness. [Table 10.4]  
 
Table 10.4. Correlation between arterial stiffness, endothelial function and pacing in patients with 
AHRE 
Variables Δ%AIx Salbutamol Δ%LDF Ach 
 r p r p 
PP -0.03 0.90 -0.43 0.05* 
PWVcf -0.06 0.79 -0.26 0.26 
Pr -0.17 0.42 -0.37 0.09 
%Ap 0.17 0.44 -0.09 0.69 
%Vp 0.29 0.17 -0.58 0.005* 
 
The univariate regression analysis for the presence of AHRE according to patient’s characteristics are 
summarised in Table 10.5. Following a step-wise multiple linear regression analyses, the variables 
associated with AHRE were PP [OR 1.06 (95%CI 1.02-1.092), p=0.02], Pr [OR 1.05 (95%CI 1.02-
1.07), p=0.001], PWVcf [OR 1.37 (95%CI 1.09-1.72), p=0.007], Δ%LDF ACh [OR 0.99 (95%CI 
0.97-0.99), p=0.03] and Δ%AIx Sal [OR 0.96 (95%CI 0.92-0.99), p=0.009] [Table 10.6].  On 
multivariate regression analyses, adjusting for other variables (age, diabetes, treatment with ACEI, 
calcium channel blockers and diastolic BP), PP, Pr, PWVcf and macro-vascular endothelial changes 
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with salbutamol (AIx, ΔAIx and Δ%AIx) were independently associated with the presence of AHRE. 
[Table 10.6] 
 
Discussion 
In this study, PP, PWVcf and Pr were higher in patients AHRE compared to those without AHRE, and 
both higher arterial stiffness and greater endothelial dysfunction independently predicted AHRE, 
irrespective of the degree of pacing. These findings are consistent with the Framingham Heart study, 
which demonstrated an increased risk of developing AF with increasing PP, even after adjusting for 
clinical risk factors and mean arterial pressure. (Mitchell et al., 2007) Another study by Lee et al 
reported higher PWVhf (pulse wave velocity heart-femoral) in patients with AF compared to those in 
sinus rhythm. (S. H. Lee et al., 2008) 
 
Table 10.5. Univariate regression analysis for the presence of AHRE with baseline characteristics 
Variables Unadjusted odds ratios 
(95% CI) p 
Age 1.03 (0.98-1.09) 0.19 
Sex 0.86 (0.32-2.33) 0.76 
Hypertension 1.31 (0.48-3.55) 0.59 
Diabetes 2.71(0.95-7.73) 0.06 
Ischaemic heart disease 0.58 (0.22-1.56) 0.28 
Stroke 0.78 (0.16-3.97) 0.77 
Dyslipidaemia 1.94 (0.65-5.78) 0.24 
Peripheral vas disease 0.63 (0.07-5.64) 0.68 
Smoker 0.76 (0.46-1.25) 0.28 
ACE inhibitors 2.45 (0.96-6.24) 0.06 
Angiotensin II receptor blockers 0.32 (0.07-1.50) 0.32 
Beta blockers 0.91 (0.33-2.48) 0.85 
Calcium blockers 3.37 (1.30-8.72) 0.01 
Diuretics 1.25 (0.48-3.24) 0.65 
Statins therapy 1.55 (0.58-4.18) 0.39 
Systolic blood pressure 1.01 (0.99-1.04) 0.22 
Diastolic blood pressure 0.96 (0.92-1.00) 0.06 
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The endothelial-dependent changes with acetyl-choline (micro-vascular) and salbutamol (macro-
vascular) in patients with AHRE were significantly lower compared to those without AHRE, which 
suggest significant endothelial damage and dysfunction, even after adjusting for potential 
confounding factors. In a small study, the observed impairment in FMD (endothelial-dependent) 
corresponds to the magnitude of change noted with the plasma levels of vWf and sE-Sel in AF 
patients compared to the healthy subjects. (Freestone, Chong, et al., 2008) Furthermore, restoration of 
sinus rhythm with cardioversion appears to show an improvement with FMD with patients in AF 
compared to their baseline values. (Guazzi et al., 2007; Skalidis et al., 2007) A significant positive 
correlation revealed between augmentation index (AI, measured from Cardio-Ankle Vascular Index, 
CAVI) and B-type natriuretic peptide levels in PAF patients compared to healthy controls in sinus 
rhythm (p<0.01). (Kaji et al., 2009) 
 
Table 10.6. Univariate and multivariate analysis of variables as predictors for AHRE 
Variables Unadjusted odds ratios Adjusted odds ratios* 
(95% CI) p (95% CI) p 
PP (mm of Hg) 1.06 (1.02-1.09) 0.002 1.05 (1.01-1.09) 0.01 
Pr (mm of Hg) 1.05 (1.02-1.07) 0.001 1.05 (1.02-1.08) 0.003 
PWVcf (m/s) 1.37 (1.09-1.72) 0.007 1.34 (1.02-1.76) 0.04 
ΔLDF Ach (%) 1.24 (0.31-4.95) 0.76   
Δ%LDF ACh 0.98 (0.97-0.99) 0.03 0.99 (0.97-1.00) 0.09 
ΔLDF SNP (%) 0.46 (0.05-3.98) 0.48   
Δ%LDF SNP 1.00 (0.98-1.01) 0.61   
AP baseline (mm of Hg) 0.99 (0.94-1.04) 0.55   
AIx baseline (%) 1.03 (0.99-1.08) 0.18   
AIx salbutamol (%) 1.07 (1.02-1.13) 0.01 1.10 (1.03-1.17) 0.005 
AIx GTN (%) 0.98 (0.95-1.01) 0.14   
ΔAIx salbutamol (%) 0.91 (0.83-0.99) 0.05 0.90 (0.81-0.99) 0.05 
ΔAIx GTN (%) 1.07 (1.03-1.12) 0.002   
Δ%AIx salbutamol 0.96 (0.92-0.99) 0.009 0.95 (0.91-0.99) 0.007 
Δ%AIx GTN 1.00 (0.99-1.01) 0.62   
vWf 1.00 (0.97-1.02) 0.77   
E-selectin 1.02 (0.99-1.02) 0.61   
%Ap 1.01 (0.99-1.02) 0.39   
%Vp 1.01 (0.99-1.02) 0.47   
*adjusted for age, diabetes, treatment with ACEI, calcium channel blockers and diastolic BP 
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There was a negative correlation between %Vp and micro-vascular endothelial function (Δ%LDF 
ACh), and an inverse relationship between micro-vascular endothelial function (Δ%LDF Ach) and 
arterial stiffness (PP). These findings may suggest a possible link between both arterial stiffness and 
ventricular pacing with endothelial (dys) function in these patients with AHRE. Recently Choy et al 
reported that a higher percentage of right Vp compared to those with minimal Vp (90 vs. 15%) is 
associated with impaired endothelial function (measured using reactive hyperaemia in peripheral 
tonometry) as well as reduced cardiac reserve in patients with pacemakers. (Choy et al., 2011) The 
subsequent prolonged and persistent endothelial damage and dysfunction with Vp in long-term may 
exacerbate the perpetuation of the atrial arrhythmia.  
 
Right ventricular (RV) apical pacing is associated with a greater risk of AF. In a randomised study of 
patients with sick sinus syndrome, significantly worsening LA dilatation (Nielsen et al., 2003) and 
higher incidence of AF observed in DDDR (23%) compared to AAIR group (7%). (Kristensen et al., 
2004)  This increased risk of AF does not appear due to result from the loss of atrio-ventricular (AV) 
synchrony alone, as evidenced by an analysis of the MOST trial. (Sweeney et al., 2003) The latter 
study has demonstrated that a linear increase in the risk of developing AF with cumulative percentage 
ventricular pacing whether in DDDR or VVIR modes. The magnitude of increased risk was 1% for 
each 1% increase in cumulative percentage ventricular pacing and was similar between pacing modes. 
These data suggest that right ventricular apical pacing, even with preservation of atrio-ventricular 
synchrony, may be associated with an increased risk of AF. Newer pacemaker algorithms which 
minimise ventricular pacing in dual chamber pacemakers (9% ventricular pacing compared to 99%) 
have been shown to reduce risk of AF compared to conventional dual chamber pacemakers, but the 
incidence of persistent AF remains considerable at about 8% over 1.6 years of follow-up. (Sweeney et 
al., 2007) 
 
Various studies have suggested that a higher percentage of right apical Vp may be deleterious to 
cardiac morphology and its function(s). Pacing from the RV apex results in abnormal ventricular 
activation from the apex to the base and from the right to the left ventricle via a non-specialised 
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conduction tissue (Vassallo et al., 1986), and generates a pattern resembling left bundle-branch block 
(Leclercq et al., 1995). The altered mechanical activation is associated with dys-synchronous 
ventricular contraction, which is associated with negative regional myocardial loading, augments 
myocardial work, impaired hemodynamic performance (Rosenqvist et al., 1996), worsens mitral 
insufficiency (Maurer et al., 1984) and rises left atrial pressures (M. F. O'Rourke & Kelly, 1993). 
These sequences of events were postulated as the plausible mechanism(s) for the development of AF 
in pacemaker patients. 
 
However, the proposed pathophysiological model neglects the interaction between ventricular 
contraction and the arterial system. Arterial stiffening increases pulse wave velocity (PWV), which 
may result in earlier return of wave reflection, augmenting aortic pressure in systole (instead of 
diastole) and increases late systolic load. (M. F. O'Rourke & Kelly, 1993) (M. F. O'Rourke & 
Hashimoto, 2007) In the setting of pacing from the RV apex, which increases iso-volumetric 
contraction (and relaxation) time at the expense of diastolic filling time, and delayed onset of LV 
ejection, earlier arterial wave reflection especially in the setting of increased PWV may be more likely 
to augment the outgoing systolic pressure wave and exacerbate the adverse regional mechanical 
loading already imposed by the dys-synchronous ventricular contraction. This may explain the current 
finding that markers of arterial stiffness (PP, Pr and PWVcf) independently predict the presence of 
AHRE.  
 
10.5. Study limitations 
The main limitation of this study is its cross-sectional design, but it does have its own control arm 
(patients with no AHRE). Participants had their pacemakers implanted for various durations of time 
and information on their baseline clinical characteristics and cardiac function when initially paced 
were not always available. It is a small study with only 24 patients with AHRE and therefore the 
statistical difference between the study groups should be interpreted with caution. Also, most of the 
above pacemaker patients do have co-existent medical conditions like hypertension, diabetes and 
ischemic heart disease and therefore the assessment of accurate endothelial function in these patients 
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might not reflect the true endothelial perturbation related to the arrhythmia per se or the degree of 
pacing.  
 
10.6. Clinical implications 
The present analysis is the first study to investigate the association between AF, arterial stiffness and 
endothelial function in pacemaker patients. The results suggest that arterial stiffness and endothelial 
dysfunction may contribute to the perpetuation of atrial arrhythmia beyond the adverse effects of 
ventricular pacing alone. Nevertheless, further prospective studies with longer follow-up are needed 
to assess the interaction between long-term ventricular pacing, arterial stiffness, endothelial function 
atrial fibrillation and thromboembolism.   
 
In conclusion, the results of this study with dual chamber pacemaker patients indicate that those with 
AHRE have higher arterial stiffness and greater endothelial dysfunction. Irrespective of modality (Ap 
or Vp) or degree of pacing, both arterial stiffness and macro-vascular endothelial function remain 
independent predictors of AHRE, and may potentially contribute to the perpetuation of atrial 
arrhythmia beyond the adverse effects of ventricular pacing alone. 
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CHAPTER ELEVEN 
 
11. Relationship between atrial high rate episodes, arterial stiffness and cardiac remodelling in 
patients with dual chamber pacemakers 
11.1. Introduction 
Cardiac pacing is an effective treatment in the management of symptomatic bradycardia associated 
with both SND and AV-nodal degenerative conduction disorders. (Mond et al., 2004) Indeed there has 
been a significant increase in pacemaker implantations over the last few decades. (Uslan et al., 2008) 
In general RV pacing is very well tolerated and effective. However recent data from clinical trials 
suggested that chronic RV pacing may have detrimental effects on the heart. These negative effects of 
RV pacing have been attributed to both the abnormal electrical and mechanical activation pattern of 
the ventricles and subsequent ‘ventricular dyssynchrony’, which is associated with adverse clinical 
outcomes. (Bader et al., 2004; Cho et al., 2005) In a small study with sick sinus syndrome patients 
with intact intrinsic AV conduction, patients were randomised to AAIR or DDDR pacing [either with 
short AV delay (DDDR-s) or programmed long AV-delay (DDDR-l)]. (Nielsen et al., 2003) There 
was a significant increase in LAD (p<0.05) and a higher risk of new onset AF noted in the DDDR 
group (p=0.03) compared to AAIR, over a mean-FU 2.9years.  
 
Changes in the arterial elastic properties and the subsequent stiffening are associated with increased 
cardiovascular risk. (Glasser et al., 1997) It is not clear if a change in arterial stiffness is a marker of 
disease or part of the pathophysiology. Arterial stiffening has been implicated in the development of 
isolated systolic hypertension and is associated with considerable excess morbidity and mortality. 
Increased pulse pressure (a surrogate of arterial stiffness) is associated with higher risk of AF. 
(Mitchell et al., 2007) However it is still unclear regarding the contribution of arterial stiffness (if any) 
towards adverse cardiac remodelling and the development of AF in pacemaker patients. 
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11.2. Hypothesis 
Chronic RV pacing may be associated with abnormal cardiac remodelling and higher risk of 
developing AF in patients with pacemakers. However, the association between arterial stiffness, 
cardiac remodelling and pacing has not been studied. This study tested the hypothesis that measures 
of arterial stiffness are associated with abnormal cardiac remodelling in patients with dual chamber 
pacemakers with AHRE.  
 
11.3. Patients and methods 
Patients were consecutively recruited as described in Chapter 6.4. Device characteristics were set at 
baseline as per protocol to detect AHRE.  
 
Assessment of arterial stiffness 
Measurement of arterial stiffness including PP, PWVcf, and Pr was performed as described in Chapter 
section 6.4.  
 
Assessment using echocardiography 
Echocardiographic measurements of LA remodelling (LAD, LAV) and LV remodelling (EF, diastolic 
parameters, TDI measurements at the mitral annulus) were performed as described in Chapter 6.4.  
 
Power calculations 
There is no published data on arterial augmentation index and the development of atrial fibrillation in 
the pacemaker population. Hayward et al previously reported significant difference in augmentation 
index (83.6 + 4.6 vs. 62.7 + 4.0%) and in the response to salbutamol (-2.4 + 1.9 vs. 13.2 + 2.3%) 
between patients with coronary disease and controls. (Hayward et al., 2002) Therefore to achieve a 
modest difference in augmentation index of <1SD, 28 patients will provide 80% power at p<0.05 
between patients with pacemakers who develop atrial fibrillation and patients who do not. My data, 
from a local audit (unpublished), revealed an annual incidence of atrial fibrillation of 30% (diagnosed 
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from atrial high rate episodes) in patients with dual chamber pacemakers. Therefore, I aim to recruit 
100 patients with dual chamber pacemaker for the follow-up study.        
 
Statistical analysis 
Following the test of statistical normality, data were expressed as mean with standard deviation (SD) 
or as median with inter-quartile range (IQR) for the normally distributed data and non-parametrically 
distributed data respectively. Comparisons between groups were analysed by 2-sample t-test or Mann-
Whitney or Kruskal-Wallis test as appropriate. Correlations were performed by Spearman’s or 
Pearson’s method as appropriate. Both univariate and multivariate binary logistic regression analysis 
were used to identify those parameters which independently predict AHRE. All the analyses were 
undertaken with SPSS version 22.0 software (SPSS Inc), and significance was accepted at the 0.05 
level (2 sided). 
 
11.4. Results 
The clinical and demographic details of all the subjects are as summarised in Table 10.1. From our 
local pacemaker clinic, 101 consecutive dual chamber pacemaker patients were recruited in the study 
[mean age 72.1 ± 10.8 years; 69 (68.3%) males] of which, 23.8% (n=24) patients were noted to have 
AHRE on baseline pacemaker interrogation. There was no significant difference observed in the age, 
gender, body mass index (BMI), co-morbidities, heart rate, systolic BP between the study groups. 
Mean diastolic BP (DBP) was higher in patients without AHRE compared to those with AHRE 
(p=0.05). The indications of pacing include symptomatic sick sinus node disease, advanced second 
degree or third degree atrio-ventricular block as well as to allow the up-titration of antiarrhythmic 
drugs in the presence of paroxysmal AF where treatment had been limited by bradycardia. In all the 
cases, at least 12 months had elapsed from the device implantation to the study enrolment. No 
significant differences observed between the percentage of atrial (%Ap) and ventricular (%Vp) pacing 
between the study groups. There were significant differences observed in the PP (p=0.001); PWVcf 
(p=0.001) and Pr (p<0.001) between patients without AHRE compared to those with AHRE 
respectively [Table 10. 2].  
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Table 11.1. Baseline values of echocardiographic variables between study groups 
Variables No AHRE                  
(n=77) 
AHRE                    
(n=24) 
p 
LA diameter (cms) 4.0 ± 0.9 4.1 ± 0.6 0.41 
LA volume (mls) 43 ± 17 46 ± 15 0.36 
EF (%) 57 ± 12 51 ± 15 0.05 
E-vel (cm/s) 78 ± 17 67 ± 21* 0.02 
A-vel (cm/s) 85 ± 20 85 ± 33 0.93 
E/A ratio 1.05 ± 0.6 0.81 ± 0.3* 0.01 
IVRT (ms) 109 ± 22 107 ± 18 0.67 
DT (ms) 256 ± 81 248 ± 57 0.68 
CMM Pv (cm/s) 49 ± 18 46 ±15 0.45 
MAPSE (cm) 1.4 ± 0.4 1.5 ± 0.4 0.67 
PVs/d ratio 1.5 ± 0.3 1.6 ± 0.4 0.09 
TAPSE (cm) 2.3 ± 0.5 2.3 ± 0.5 0.72 
Sep EM vel (cm/s) 6.0 ± 1.8 5.2 ± 1.7* 0.03 
Sep AM vel (cm/s) 7.4 ± 2.9 8.6 ± 2.3* 0.02 
Sep SM vel (cm/s) 6.4 ± 1.8 6.6 ± 1.5 0.69 
E/EM ratio  14.3 ± 7.1 13.5 ± 3.4 0.60 
*p<0.05, statistically significant between the groups 
 
However both LAD and LAV did not show any statistically significant difference between the study 
groups. Left ventricular ejection fraction, E-wave velocity, E/A ratio and EM velocities were 
significantly lower in patients with AHRE compared to no AHRE (p<0.05), whereas AM velocity was 
higher in patients with AHRE (p<0.05) [Table 11.1]. 
 
Correlation and regression analysis 
In those patients who have had AHRE, there was a significant positive correlation observed between 
the LAD and %Vp (r=0.20, p=0.05) but not with LAV (r=0.12, p=0.23). Similarly a positive 
correlation noted between PWVcf and LAV (r=0.48, p=0.02). Furthermore no correlations observed 
between other %Vp or %Ap with all markers of arterial stiffness (PP, PWVcf, Pr). EM showed a 
negative correlation with PWVcf (r=-0.44, p=0.03) [Table 11.2].  
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Table 11.2. Correlation between arterial stiffness, cardiac remodelling and pacing in patients with 
AHRE 
Variables Left atrial diameter Left atrial volume EM Velocity 
 r p r p r p 
PP 0.08 0.70 0.14 0.51 -0.39 0.06 
PWVcf 0.18 0.40 0.48 0.02* -0.44 0.03* 
Pr 0.05 0.82 0.08 0.71 -0.39 0.06 
%Ap 0.06 0.78 0.96 0.65 -0.07 0.74 
%Vp 0.20 0.05* 0.12 0.23 -0.22 0.29 
 
Following a step-wise linear regression analysis, the variables associated with the presence of AHRE 
were PP [OR 1.06, 95%CI (1.02-1.09), p=0.002], PWVcf [OR 1.37, 95%CI (1.09-1.72), p=0.007] , Pr 
[OR 1.05, 95%CI (1.02-1.07), p=0.001], EF [OR 1.04, 95%CI (1.00-1.08), p=0.05], E-vel [OR 1.03, 
95%CI (1.00-1.05), p=0.03], E/A ratio [OR 3.8, 95%CI (1.18-11.04), p=0.02], EM [OR 1.21,      
95%CI (1.01-1.7), p=0.04] and AM [OR 0.8, 95%CI (0.81-0.98), p=0.03].  
 
However on multivariate regression analysis adjusting for other variables (age, diabetes, treatment 
with ACEI and calcium channel blockers) PP, PWVcf, Pr, EF, E/A ratio, EM and AM were 
independently associated with the presence of AHRE. [Table 11.3] 
 
11.5. Discussion 
In this study, patients with AHRE have higher degree of arterial stiffness as evidenced by increased 
PP, PWVcf and Pr. Also both the measures of arterial stiffness and markers of diastolic dysfunction 
independently predicted the presence of AHRE, irrespective of right ventricular pacing. It was 
postulated that as a consequence with persistent increase in the afterload, arterial stiffness directly 
contributes to the development of left ventricular hypertrophy (LVH), diastolic dysfunction, increase 
in left ventricular filling pressure and abnormal left atrial (LA) remodelling thereby increased risk of 
developing AF. 
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Table 11.3. Univariate and multivariate analysis of variables as the predictors for atrial high 
rate events (AHRE) 
Variables Unadjusted odds ratios Adjusted odds ratios* 
(95% CI) p (95% CI) p 
PP (mm of Hg) 1.06 (1.02-1.09) 0.002 1.05 (1.01-1.09) 0.01 
Pr (mm of Hg) 1.05 (1.02-1.07) 0.001 1.05 (1.02-1.08) 0.003 
PWVcf (m/s) 1.37 (1.09-1.72) 0.007 1.34 (1.02-1.76) 0.04 
LA diameter (cms) 1.3 (0.70-2.46) 0.41   
LA volume (mls) 1.04 (0.99-1.04) 0.36   
EF (%) 1.01 (1.00-1.08) 0.05 1.06 (1.01-1.11) 0.02 
E-vel (cm/s) 1.03 (1.00-1.05) 0.03 1.02 (.099-1.05) 0.06 
A-vel (cm/s) 1.00 (0.78-1.02) 0.93   
E/A ratio 3.6 (1.18-11.04) 0.02 4.4 (1.20-16.22) 0.03 
IVRT (ms) 1.00 (0.97-1.02) 0.67   
DT (ms) 1.00 (0.99-1.01) 0.67   
CMM Pv (cm/s) 1.00 (0.96-1.02) 0.45   
MAPSE (cm) 1.34 (0.36-4.9) 0.66   
PVs/d ratio 3.7 (0.78-17.2) 0.10   
TAPSE (cm) 0.84 (0.34-2.1) 0.72   
Sep EM vel (cm/s) 1.31 (1.01-1.7) 0.04 1.52 (1.10-2.1) 0.01 
Sep AM vel (cm/s) 0.8 (0.66-0.98) 0.03 0.79 (0.63-0.98) 0.04 
Sep SM vel (cm/s) 1.06 (0.81-1.39) 0.69   
E/EM ratio  1.00 (0.90-1.06) 0.59   
%Ap 1.01 (0.99-1.02) 0.39   
%Vp 1.01 (0.99-1.02) 0.47   
*adjusted for age, diabetes, treatment with ACEI and calcium channel blockers 
 
In prospective population studies, left ventricular hypertrophy, diastolic dysfunction and LA dilatation 
were associated with adverse cardiovascular events and AF. (Tsang et al., 2004) In Framingham Heart 
Study, the level of systolic blood pressure and duration of hypertension have shown to predict adverse 
LA remodelling. (Vaziri et al., 1995) A close association has been revealed between LA volume and 
the risk of new onset AF. In a study from Olmstead County, for every 30% increase in LA volume 
there was a 48% increased risk of AF observed and LAV independently predicts the risk of ischemic 
strokes. (Tsang et al., 2001) 
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In the present study, measures of diastolic dysfunction including E/A ratio, E-velocity and EM were 
significantly lower in patients with AHRE compared to those with no AHRE. Results from the present 
study suggest that the ill effects of RV pacing may be mediated via the development of diastolic 
dysfunction. However there were no differences in either LAD or LAV between the study groups. 
This may be related to the fact that the pacemakers were implanted only <12-months before the study 
and they were RV paced for only a median duration of 4.4% of the time. Therefore it is likely that 
patients with AHRE develop diastolic dysfunction before any apparent echocardiographic evidence of 
cardiac remodelling   (including LV dilatation or systolic dysfunction or LA dilatation). It appears that 
arterial stiffness contributes to the diastolic dysfunction and subsequent adverse LA remodelling, 
irrespective of pacing. This is more evident with the negative correlation(s) observed between the 
measures of arterial stiffness (PP, PWVcf and Pr) and EM velocities as well as positive correlation 
between PWVcf and LAV in the present study.  
 
It was evident that chronic RV apical pacing may have unfavourable effect on the LV function due to 
the abnormal electro-mechanical activation predisposing to cardiac dyssynchrony via complex 
sequence of events including negative regional myocardial loading, impaired hemodynamic 
performance (Vassallo et al., 1986), worsening mitral insufficiency (Barold & Ovsyshcher, 2005) and 
rise in left atrial pressures and LA dilatation (Maurer et al., 1984). In the PACE trial patients with 
bradycardia and preserved LV function (EF ≥45%) randomised to RV apical pacing or biventricular 
pacing (BiV). The results suggested that chronic RV pacing worsens LVEF (53 ± 10.1% vs. 61.5 ± 
6.6 %, p<0.001) with subsequent increase in LVESV (38.3 ± 20.3 mls vs. 28.4 ± 10.7 mls, p<0.001) 
compared to their baseline values; over a mean-FU of 2 years. However in the BiV group, there were 
no significant differences observed in these parameters. Also the changes in the LVEF and LVESV 
corresponds statistically with deteriorating dyssynchrony index in the RV apical pacing group from 
baseline values compared to those during follow-up at one (p<0.001) and two years (p<0.001). (Chan 
et al., 2011) In a small study, Ahmed et al demonstrated development of mechanical dyssynchrony 
from apex to base when paced from the right ventricular apex (measured using speckle tracking 
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longitudinal strain analysis echocardiogram) and subsequent deterioration in ejection fraction in 
patients post-AV nodal ablation (who had normal pre-pacing  ejection fraction) over a median follow-
up 4-months. (Ahmed et al., 2014) 
 
The positive correlation observed between the %Vp and LAD in the present study is not surprising.  
Similar results were observed in a study of patients with SSS who were randomised to either AAIR or 
DDDR pacing with short AV delay (DDDR-s) or programmed long AV-delay (DDDR-l). Over a 
mean follow-up of 2.9 years, there were significant increase in LAD observed in the DDDR group(s) 
(p<0.05) from baseline; but no differences observed in AAIR groups. Nevertheless, significantly 
higher incidence of AF observed in the DDDR-s group (23.3%) compared to AAIR group (7.4%, 
p=0.03). (Nielsen et al., 2003) Similar results were seen in a study assessing the effects of acute RV 
pacing on LA volumes and function. In this study, Xie et al demonstrated that acute RV pacing 
demonstrated a significant increase in the LA volume (p=0.005) and reduction in LA regional tissue 
velocities in patients with pre-existing diastolic dysfunction compared to those parameters during V-
sensing. (Xie et al., 2012)  
 
Study limitations 
The main limitation of this study is its cross-sectional design, but it does have its own control arm 
(patients with no AHRE). Participants had their pacemakers implanted for differing durations of time 
and information on their baseline clinical characteristics and cardiac function when initially paced 
were not always available. Also given its small sample size, with only 24 patients with AHRE in this 
study, all statistical difference between the study groups should be interpreted with caution. 
Understandably most of the above pacemaker patients do have co-existent medical conditions like 
hypertension, diabetes and ischemic heart disease and therefore the assessment of arterial stiffness in 
these patients might not reflect the true endothelial function related to the arrhythmia per se or the 
degree of pacing.  
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11.6. Conclusion 
The present analysis investigated the association between atrial high rate events, arterial stiffness and 
cardiac remodelling in pacemaker patients. The results highlight the interaction between arterial wave 
reflection and ventricular contraction, which modulates the increased risk of developing AF in 
patients with pacemakers. Nevertheless, further prospective studies with longer follow-up are needed 
to assess the true interaction and contribution of long-term ventricular pacing, arterial stiffness 
towards cardiac remodelling to assess the risk of AF.   
 
To conclude, the results of this study with dual chamber pacemaker patients indicate that those with 
AHRE have higher arterial stiffness and abnormal cardiac remodelling. Irrespective of modality (Ap 
or Vp) or degree of pacing, both arterial stiffness and measures of cardiac remodelling remain 
independent predictors of AHRE, and may potentially contribute to the perpetuation of atrial 
arrhythmia beyond the adverse effects of ventricular pacing alone. 
 
. 
 
 
  133 
CHAPTER TWELVE 
 
12. Assessment of changes in macro-vascular, micro-vascular endothelial function and arterial 
stiffness in patients with atrial high rate episodes with dual chamber pacemakers (One-year 
follow-up study) 
12.1. Introduction 
Higher arterial stiffness may be associated with higher risk of AF (Lantelme et al., 2008) and the 
findings of my cross-sectional study (Chapter 7), revealed an association between arterial stiffness 
and endothelial dysfunction in patients with PAF. However, greater endothelial dysfunction and 
higher arterial stiffness in these patients appears to be related to co-existent cardiovascular risk factors 
rather than the arrhythmia per se.  
 
The current pathophysiological model of the development of AF in pacemaker patients neglects the 
possible interaction between the ventricular contraction and the arterial system. Findings of my study 
with dual chamber pacemaker patients suggested that arterial stiffness and endothelial dysfunction 
might contribute to the perpetuation of AF beyond the adverse effects of ventricular pacing alone. The 
independent predictors of AHRE were arterial stiffness and endothelial dysfunction, irrespective of 
the modality (Ap or Vp) or degree of pacing.  
 
The aim of the present study was to explore the association between the changes in micro-vascular, 
macro-vascular endothelial function, arterial stiffness and the development of atrial high rate episodes 
in dual chamber pacemaker patients over a year of follow-up. 
 
12.2. Hypothesis 
This study tested the hypothesis that greater endothelial dysfunction and higher arterial stiffness were 
associated with the development of atrial high rate episodes over one year of follow-up, irrespective 
of pacing.  
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12.3. Patients and methods 
This was a longitudinal one-year follow-up study of the pacemaker cohort. For the baseline study, 96 
patients with dual chamber pacemakers were recruited from the pacemaker clinic. A total of 101 
patients were recruited, of them 5 patients did not complete follow-up study.  
 
Assessment of micro-vascular and macro-vascular endothelial function, arterial stiffness 
The assessments of micro-vascular and macro-vascular endothelial function as well as arterial 
stiffness were performed as described in Chapter 6.4. The device interrogation was performed at one-
year follow-up and the device characteristics were set up to detect atrial high rate episodes as 
described in Chapter 6.4. Laboratory measurements of vWf and sE-sel were performed as described in 
Chapter 6.4.  
 
Power calculations and statistical analysis 
Power calculations and statistical analysis were performed as discussed in Chapter 10 
 
12.4. Results 
Data were analysed in 77 patients with dual chamber pacemakers (excluding those who had AHRE at 
baseline, n=24, as they were likely to have greater endothelial dysfunction during follow-up) [Table 
12.1]. Changes in micro-vascular, macro-vascular endothelial function and arterial stiffness as well as 
the presence of new onset AHRE were assessed and identified as per study protocol. Over one-year 
follow-up, 14.3% (n=11) patients developed new-onset AHRE. On analysing the baseline 
characteristics, patients with AHRE have significantly higher systolic BP (p=0.02) compared to those 
without AHRE. Nonetheless, the %Ap or %Vp did not differ significantly between the study groups 
during the follow-up study. 
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Table 12.1. Baseline characteristics in patients with and without atrial high rate events in PPM               
one –year follow-up study 
Variables 
 
No AHRE                
(n=66) 
AHRE            
(n=11) 
p 
Age ( in years) 73 ± 11 71 ± 10 0.58 
Males (n) % 44 (66.7) 8 (72.7) 0.69 
BMI (Kg/m2) 27 ± 5 25 ± 4 0.24 
Heart rate (bpm) 67 ± 12 65 ± 4 0.34 
Systolic BP (mm of Hg) 134 ± 29 145 ± 11* 0.02 
Diastolic BP (mm of Hg) 72 ± 15 71 ± 10 0.90 
Hypertension (n), % 42 (63.6) 8 (72.7) 0.57 
Diabetes (n), % 10 (15.2) 2 (18.2) 0.80 
Ischaemic heart disease (n), % 25 (37.9) 7 (63.6) 0.11 
Stroke or TIA (n), %  5 (7.6) 3 (27.3) 0.05 
Peripheral vascular disease (n), % 4 (6.1) 1 (9.1) 0.71 
Dyslipidaemia 42 (63.6) 9 (81.8) 0.24 
Smoker (n), % 26 (39.4) 6 (54.5) 0.15 
ACE inhibitors (n), % 23 (34.8) 5 (45.5) 0.51 
Angiotensin II receptor blockers (n), % 16 (24.1) 1 (9.1) 0.27 
Beta -blockers (n), % 21 (31.8) 3 (27.3) 0.77 
Calcium channel blockers (n), % 16 (24.2) 4 (36.4) 0.40 
Diuretics (n), % 20 (30.3) 5 (45.5) 0.33 
Statin treatment (n), % 39 (59.1) 8 (72.7) 0.40 
Aspirin (n), % 46 (69.7) 5 (45.5) 0.12 
Clopidogrel (n), % 6 (9.1) 2 (18.2) 0.37 
Warfarin (n), % 3 (4.5) 4 (36.4)* 0.001 
AF burden (%)  5 (2-96)  
%Ap 52 (15-84) 75 (1-96) 0.39 
%Vp 98 (4 -100) 90 (1-100) 0.57 
* p<0.05, statistically significant between the groups 
 
 On analysing the data on patients without AHRE in comparison to their baseline measures, Pr was 
significantly lower during one-year follow-up (120 ± 22 vs. 112 ± 17, mm of Hg, p=0.001). Similarly, 
changes in macro-vascular endothelial function with salbutamol (ΔAIx Sal, p<0.001; Δ% AIx Sal, 
p=0.002) and micro-vascular function with Ach (ΔLDF Ach, p=0.01; Δ% LDF Ach, p=0.003) were 
significantly lower during the follow-up compared to the baseline. A significant increase in both %Ap 
(p=0.009) and %Vp (p=0.001) was observed during one-year follow-up compared to baseline.  [Table 
12.2] 
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 Figure 12.2. Differences in the arterial stiffness, micro-vascular/macro-vascular endothelial function 
in patients without AHRE at one-year follow-up compared to baseline.  
*p<0.05, statistically significant during follow-up 
Notably, in those who developed new-onset AHRE over one-year of follow-up, all the measures of 
arterial stiffness including PP (p=0.008), PWVcf (p=0.001) and Pr (p=0.02) were significantly higher 
compared to their baseline values. [Table 12.3] Similarly, the changes in AIx with salbutamol (ΔAIx 
Sal, p=0.01; Δ%AIx Sal, p=0.03) as well as the changes in LDF with acetyl choline (ΔLDF Ach, 
p=0.007; Δ%LDF Ach, p=0.007) were significantly lower during the one-year follow-up study 
compared to the baseline. [Table 12.3] 
 
However, analysis of the entire follow-up cohort (n=77) revealed significant differences in the PP 
(p=0.002), PWVcf (p=0.03) and Pr (p<0.001) between patients with new onset AHRE compared to 
those without AHRE. Similarly, the percentage of change in AIx with salbutamol (Δ%AIx Sal, 
p=0.03) and median percentage of change in LDF with acetyl choline (Δ%LDF Ach, p=0.01) were 
significantly lower in patients with AHRE compared to no AHRE. There were no significant 
differences in the response to GTN or SNP in both groups. [Table 12.4] 
 
 
Variables                           No AHRE (n=66)  
 Baseline 1-year follow-up p 
PP (mm of Hg) 61 ± 16 56 ± 17 0.21 
PWVcf (m/s) 7.5 ± 2.5 7.5 ± 1.7 0.90 
Pr (mm of Hg) 120 ± 22* 112 ± 17 0.001 
AP (mm of Hg) 18 (14-26) 17 (12-28) 0.98 
AIx salbutamol (%) 25 (15-32)* 31 (18-37) <0.001 
ΔAIx Salbutamol (%) 11 (7-15)* 6 (4-9) <0.001 
Δ%AIx Salbutamol 33 (22-44) 22 (14-28) 0.002 
ΔLDF Ach  (PU) 0.44 (0.24-0.72)* 0.37 (0.23-0.55) 0.012 
Δ%LDF Ach 78 (42-112)* 61 (45-90) 0.003 
%Ap 8 (0.1-50) 52 (15-84) 0.009 
%Vp 0.4 (0.1-45) 98 (4-100) 0.001 
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Table 12.3. Differences in the measures of arterial stiffness, micro-vascular and macro-vascular 
endothelial function in patients with AHRE at one-year follow-up compared to baseline 
*p<0.05, statistically significant during follow-up 
 
Table 12.4. Measures of arterial stiffness and macro/micro-vascular endothelial function between 
groups (AHRE vs. no AHRE) in PPM one-year follow-up study 
Variables No AHRE                        
(n=66) 
AHRE                                    
(n=11) 
p
PP (mm of Hg) 58 ± 17* 74 ± 8 0.002 
PWVcf (m/s) 7.5 ± 1.7* 8.7 ± 0.8 0.03 
Pr (mm of Hg) 112 ± 17* 141 ± 6 <0.001 
ΔAIx Salbutamol (%) 6 (4-9)* 4 (4-5) 0.06 
Δ%AIx Salbutamol 22 (14-28)* 13 (11-16) 0.03 
ΔLDF Ach  (PU) 0.37 (0.23-0.55)* 0.21 (0.19-0.25) 0.01 
Δ%LDF Ach 61 (45-90)* 40 (34-48) 0.01 
vWf (IU/dl) 92 ± 1 97 ± 12 0.16 
sE-sel (mg/dl) 16 (12-22) 18 (12-24) 0.79 
*p<0.05, statistically significant between the groups  
 
 
 
Variables AHRE (+) (n=11)  
 Baseline 1-year follow-up p 
PP (mm of Hg) 59 ± 17* 74 ± 8 0.008 
PWVcf (m/s) 7.3 ± 1.1* 8.7 ± 0.8 0.001 
Pr (mm of Hg) 123 ± 23* 141 ± 6 0.02 
AIx baseline (%) 43 (33-47) 41 (35-53) 0.86 
AIx salbutamol (%) 29 (18-38)* 33 (31-43) 0.04 
ΔAIx Salbutamol (%) 9 (6-16)* 4 (4-5) 0.01 
Δ%AIx Salbutamol 29 (18-42)* 13 (11-16) 0.03 
ΔLDF Ach  (PU) 0.56 (0.50-0.65)* 0.21 (0.19-0.25) 0.007 
Δ%LDF Ach 81 (62-126)* 40 (34-48) 0.007 
%Ap 2 (0.1-65) 75 (1-96) 0.08 
%Vp 6 (0.1-100) 19 (1-100) 0.60 
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Correlation and regression analysis 
In patients with new-onset AHRE during follow-up, a significant negative correlation was observed 
between the Pr and Δ%LDF Ach (r=-0.71, p=0.02) as well as between PP and Δ%AIx Sal (r=-0.70, 
p=0.02). However no significant correlations were observed between percentage of pacing and the 
measures of arterial stiffness or markers of endothelial dysfunction. 
Table 12.5. Correlation between arterial stiffness, endothelial function and pacing in patients with 
AHRE 
Variables Δ% AIx Salbutamol Δ% LDF Acetyl choline 
 r p r p 
PP -0.19 0.58 -0.33 0.35 
PWVcf -0.70 0.02* -0.23 0.53 
Pr -0.36 0.28 -0.71 0.02* 
%Ap -0.48 0.28 -0.18 0.70 
%Vp -0.56 0.20 -0.44 0.32 
 
Following a step-wise multiple linear regression analyses, the variables associated with the presence 
of AHRE were PP [OR 1.07 (95%CI 1.02-1.13), p=0.007], Pr [OR 1.17 (95%CI 1.06-1.28), p=0.001], 
PWVcf [OR 1.62 (95%CI 1.03-2.55), p=0.04], Δ%LDF Ach [OR 0.95 (95%CI 0.92-0.99), p=0.02], 
Δ%AIx Sal [OR 0.81 (95%CI 0.68-0.95), p=0.01]. On multivariate regression analyses, adjusting for 
age, stroke, systolic BP and treatment with warfarin, PP, Pr, PWVcf, Δ%AIx Sal and Δ%LDF Ach 
remained as independent predictors of AHRE. [Table 12.6 & Table 12.7] 
 
12.5. Discussion 
In this dual chamber pacemaker study, at one-year follow-up there were significant changes observed 
in both arterial stiffness and endothelial dysfunction compared to their baseline values. Also in 
particular in those who developed new onset AHRE, all the measures of arterial stiffness (PP, PWVcf, 
Pr) were significantly higher and endothelial dependent changes with acetyl-choline (micro-vascular) 
and salbutamol (macro-vascular) were significantly lower compared to those with no AHRE. Even 
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after adjusting for confounders, arterial stiffness (PP, PWVcf, Pr) and endothelial dysfunction 
(Δ%LDF Ach & Δ%AIx Sal) remained independent predictors of AHRE. Therefore, this study 
confirms the findings of my previous cross-sectional study (Chapter 10) that progressive worsening in 
the arterial stiffness and  greater endothelial dysfunction were associated with AHRE at one-year 
follow-up, independent of the mode and degree of pacing, in these dual chamber pacemaker patients. 
 
Table 12.6. Univariate regression analyses for the presence of AHRE with baseline characteristics 
(PPM one-year follow-up study) 
Variables         Unadjusted odds ratios 
(95% CI) p 
Age 0.99 (0.93-1.04) 0.58 
Sex 0.75 (0.18-3.11) 0.69 
Hypertension 1.52 (0.37-6.30) 0.56 
Diabetes 1.24(0.23-6.63) 0.79 
Ischaemic heart disease 2.87 (0.76-10.8) 0.12 
Stroke 4.58 (0.92-22.89) 0.06 
Dyslipidaemia 2.57 (0.51-12.89) 0.25 
Peripheral vas disease 1.55 (0.16-15.32) 0.71 
Smoker 0.72 (0.82-3.63) 0.15 
ACE inhibitors 1.56 (0.43-5.66) 0.50 
Angiotensin II receptor blockers 0.31 (0.04-2.63) 0.29 
Beta blockers 0.80 (0.19-3.34) 0.76 
Calcium blockers 1.79 (0.46-6.89) 0.40 
Diuretics 1.92 (0.52-7.02) 0.33 
Aspirin treatment 0.36 (0.09-1.33) 0.13 
Warfarin 12 (2.22-64.93) 0.004 
Systolic blood pressure 1.03 (1.004-1.065) 0.03 
Diastolic blood pressure 0.99 (0.94-1.05) 0.90 
 
Also in this present follow-up study, there was a significant negative correlation between arterial 
stiffness (PP, Pr) and macro-vascular (Δ%AIx Sal)/microvascular (Δ%LDF Ach) endothelial 
dysfunction suggestive of a possible link between arterial stiffness and endothelial function in these 
pacemaker patients who developed new onset AHRE.  
 
The development of atrial arrhythmias is often attributed predominantly to the adverse effects of 
ventricular pacing alone on the cardiac structure and its function(s). (Maurer et al., 1984; M. F. 
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O'Rourke & Kelly, 1993; Rosenqvist et al., 1996; Vassallo et al., 1986). In this study, the significant 
increase in both Ap and Vp during follow-up was not independently associated with the development 
of AHRE. This would suggest that right ventricular pacing may not be the dominant risk factor in the 
initiation and progression of atrial fibrillation, in those pacemaker patients. This would also imply that 
aggressive management of cardiovascular risk factors associated with arterial stiffness and endothelial 
dysfunction may be more effective in the prevention of atrial arrhythmias in patients with pacemakers 
than strategies aimed at minimising the percentage of ventricular pacing. In this regard, it is 
noteworthy that the major randomised trials of pacemaker therapy did not report baseline or changes 
in blood pressure. (Kristensen et al., 2004; Nielsen et al., 2003; Sweeney et al., 2007; Sweeney et al., 
2003)  
 
Table 12.7: Univariate and multivariate analysis of variables as predictors for AHRE (PPM one –year 
follow-up study) 
Variables Unadjusted odds ratios Adjusted odds ratios* 
(95% CI) p (95% CI) p 
PP (mm of Hg) 1.07 (1.02-1.13) 0.007 1.19 (1.06-1.33) 0.004 
Pr (mm of Hg) 1.17 (1.06-1.28) 0.001 1.57 (1.00-2.46) 0.05 
PWVcf (m/s) 1.62 (1.03-2.55) 0.04 1.80 (1.01-3.23) 0.05 
ΔLDF Ach (%) 0.01 (0.00-0.32) 0.02   
Δ%LDF ACh 0.95 (0.92-0.99) 0.02 0.95 (0.91-0.99) 0.02 
ΔLDF SNP (%) 1.03 (0.03-31.85) 0.99   
Δ%LDF SNP 0.99 (0.98-1.02) 0.86   
AIx baseline (%) 1.03 (0.98-1.09) 0.25   
AIx salbutamol (%) 1.04 (0.98-1.10) 0.21   
AIx GTN (%) 1.01 (0.97-1.05) 0.60   
ΔAIx salbutamol (%) 0.74 (0.54-1.02) 0.07   
ΔAIx GTN (%) 1.04 (0.98-1.11) 0.16   
Δ%AIx salbutamol 0.81 (0.68-0.95) 0.01 0.76 (0.60-0.95) 0.02 
Δ%AIx GTN 1.00 (0.99-1.01) 0.21   
vWf 1.03 (0.99-1.08) 0.16   
E-selectin 1.01 (0.92-1.12) 0.79   
%Ap 1.01 (0.99-1.04) 0.37   
%Vp 1.00 (0.98-1.01) 0.60   
*adjusted for age, stroke, systolic BP and treatment with warfarin 
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As previously discussed in Chapter 10 and from the results of the follow-up study, it is clear that on 
top of the proposed detrimental effects of RV pacing; there appears a complex interaction with 
endothelial dysfunction and the arterial structure with its progressive stiffening over time, also 
contributes to the development of atrial fibrillation in those patients with dual chamber pacemakers. 
 
Study limitations 
This is a very small study of patients with pacemakers and only 11 patients developed AHRE, 
therefore there needs to be caution whilst interpreting statistical significance between study groups. 
However, I believe the study might help us to identify and understand new possible 
pathophysiological mechanisms associated with development of AF. The study is also limited by the 
fact that most of the pacemaker patients do have co-existent medical conditions like hypertension, 
diabetes, ischaemic heart disease and previous stroke as well as on medical treatment therefore the 
assessment of endothelial function in these patients might not be true reflection of endothelial 
dysfunction related to the arrhythmia per se or the degree of pacing. 
 
12.6. Conclusion 
The results of the study suggest that progressive worsening in arterial stiffness and greater endothelial 
dysfunction over time may contribute to the initiation and further progression of the atrial arrhythmia 
beyond the adverse effects of pacing alone. Indeed the long-term effects of the degree and mode of 
pacing, arterial stiffness together with endothelial (dys) function in these patients needs to be well 
elucidated to understand the other pathophysiological mechanisms associated with the development of 
atrial dysarrhythmia and well as its thromboembolic complications. 
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CHAPTER THIRTEEN 
 
13. Relationship between the changes in arterial stiffness, cardiac remodelling and atrial high 
rate episodes in patients with dual chamber pacemakers (One-year follow-up study) 
13.1. Introduction 
Increased arterial stiffness was documented in cardiovascular disease states including diabetes, 
hypertension and renal failure; and associated with increased cardiovascular risk. (Glasser et al., 
1997) Increased PP (a surrogate of arterial stiffness) is associated with greater risk of developing AF. 
(Mitchell et al., 2007) Adverse cardiac remodelling including LV hypertrophy and LA dilatation is 
associated with the development of AF. (Tsang et al., 2001; Vaziri et al., 1995) In the cross-sectional 
study, as discussed in chapter 8 there was a clear association observed between arterial stiffness and 
adverse LA remodelling. However the former appears to be predominantly initiated and driven by the 
co-existent cardiovascular conditions. 
 
RV pacing may have detrimental effects on cardiac structure and function; thus subsequent increased 
risk of developing heart failure and AF. Despite preserving AV synchrony, chronic RV apical pacing 
is associated with increase in LA and LV end systolic dimensions with higher incidences of AF 
(Nielsen et al., 2003) as well as deterioration in LV ejection fraction. (Chan et al., 2011) Concerns 
regarding the adverse effects of RV apical pacing have urged the current practice towards minimising 
the percentage of Vp. However, findings of my cross-sectional study with dual chamber pacemaker 
patients (chapter 11), suggested that higher arterial stiffness might contribute to the development of 
LV diastolic dysfunction, independent of degree and mode of pacing. Also, arterial stiffness and 
markers of LV diastolic dysfunction were associated with the presence of AHRE in dual chamber 
pacemaker patients. These results suggest that abnormal arterial wave reflection may contribute to the 
adverse cardiac remodelling in addition to the effects of RV pacing.  
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The present study will assess the association between the changes in arterial stiffness, cardiac 
remodelling and the development of atrial high rate episodes in patients with dual chamber pacemaker 
over one-year follow-up. 
 
13.2. Hypothesis 
This study tested the hypothesis that higher arterial stiffness and abnormal cardiac remodelling were 
associated with atrial high rate episodes over one-year of follow-up, independent of percentage 
atrial/ventricular pacing.  
 
13.3. Patients and methods 
Patients were consecutively recruited as described in Chapter 6.4. Device characteristics were set at 
baseline as per protocol to detect AHRE.  
 
Assessment of arterial stiffness and echocardiography 
Measurement of arterial stiffness including PP, PWVcf, and Pr was performed as described in Chapter 
section 6.4. Echocardiographic measurements of LA remodelling (LAD, LAV) and LV remodelling 
(EF, diastolic parameters, TDI measurements at the mitral annulus) were performed as described in 
Chapter 6.4.  
 
Power calculations and statistical analysis  
Power calculations and statistical analysis were performed as discussed in Chapter 11.  
 
13.4. Results 
Data were analysed in 77 patients with dual chamber pacemakers (excluding those who had AHRE 
from the baseline study, n=24) longitudinally over one-year period assessing the changes arterial 
stiffness and echocardiographic variables as well as the development of new-onset AHRE. At one-
year follow-up, 14.3% (n=11) patients were noted to have new onset AHRE on device interrogation. 
The clinical and demographic details of all the subjects are summarised in Table 12.1.  
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On analysing the data on those patients without AHRE (n=66) in comparison to their baseline 
measures, Pr was significantly lower during one-year follow-up (120 ± 22 mm of Hg vs. 112 ± 17 mm 
of Hg, p=0.001). With respect to the echocardiographic variables, E/A ratio and IVRT were 
significantly higher during the follow-up compared to the baseline (p<0.05), and EF, TAPSE and Sep 
AM velocity significantly lower compared to the baseline (p<0.05). A significant increase in both 
%Ap (p=0.009) and %Vp (p=0.001) were observed during the one-year follow-up compared to 
baseline study. [Table 13.1] 
 
Table 13.1. Differences in arterial stiffness and the echocardiographic variables in patients without  
AHRE at one-year follow-up compared to baseline.  
 *p<0.05, statistically significant between baseline and during follow-up 
*p<0.05. statistically significant between baseline and during follow-up 
 
Variables                           No AHRE (n=66)  
 Baseline 1-year follow-up p 
PP (mm of Hg) 61 ± 16 56 ± 17 0.21 
PWVcf (m/s) 7.5 ± 2.5 7.5 ± 1.7 0.90 
Pr (mm of Hg) 120 ± 22* 112 ± 17 0.001 
LAD (cm) 3.9 ± 0.9 3.6 ± 1.6 0.32 
LAV(mls) 43 ± 17 47 ± 27 0.16 
EF (%) 51 ± 15* 42 ± 20 0.003 
E-vel (cm/s) 67 ± 21 70 ± 25 0.34 
A-vel (cm/s) 86 ± 19 80 ± 21 0.06 
E/A ratio 0.81 ± 0.3* 0.96 ± 0.6 0.04 
IVRT (ms) 108 ± 21* 122 ± 31 0.004 
DT (ms) 256 ± 80 270 ± 86 0.40 
CMM Pv (cm/s) 48 ± 17 47 ± 20 0.95 
MAPSE (cm) 1.4 ± 0.4 1.4 ± 0.3 0.64 
PVs/d ratio 1.4 ± 0.3 1.4 ± 0.4 0.96 
TAPSE (cm) 2.4 ± 0.6* 2.1 ± 0.6 0.03 
Sep EM vel (cm/s) 5.1 ± 1.6 5.1 ± 0.5 0.90 
Sep AM vel (cm/s) 8.8 ± 2.2* 
 
 
 
7.8 ± 2.4 0.003 
Sep SM vel (cm/s) 6.5 ± 1.7 6.4 ± 1.7 0.84 
E/EM ratio 14 ± 7 15 ± 8 0.79 
%Ap 8 (0.1-50) 52 (15-84) 0.009 
%Vp 0.4 (0.1-45) 98 (4-100) 0.001 
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In patients who developed new onset AHRE during one-year follow-up (n=11), all the measures of 
arterial stiffness including PP, PWVcf and Pr were significantly higher compared to their baseline 
measures. During one-year follow-up, there was a significant increase in LAV compared to its 
baseline value (p<0.001). However, no other significant changes observed in other echocardiographic 
variables during the follow study.  
 
Table 13.2. Differences in arterial stiffness and the echocardiographic variables in patients with 
AHRE at one-year follow-up compared to baseline. 
*p<0.05, statistically significant during the follow-up 
 
On analysing data from the entire follow-up cohort (n=77) there were significant differences in PP, 
PWVcf and Pr between study groups (AHRE vs. no AHRE), (p<0.05). Similarly patients with AHRE 
were found to have larger LAV compared to those without AHRE (p=0.08); although this was not 
statistically significant. DT was significantly lower in patients with AHRE compared to those without 
Variables                            AHRE (+) (n=11)  
 Baseline 1-year follow-up p 
PP (mm of Hg) 59 ± 17* 74 ± 8 0.008 
PWVcf (m/s) 7.3 ± 1.1* 8.7 ± 0.8 0.001 
Pr (mm of Hg) 123 ± 23* 141 ± 6 0.02 
LAD (cm) 3.9 ± 0.7 3.5 ± 1.1 0.33 
LAV(mls) 43 ± 13* 62 ± 16 <0.001 
EF (%) 47 ± 14 47 ± 14 1.00 
E-vel (cm/s) 62 ± 25 65 ± 30 0.64 
A-vel (cm/s) 80 ± 23 71 ± 22 0.12 
E/A ratio 0.8 ± 0.3 1 ± 0.5 0.12 
IVRT (ms) 117 ± 26 118 ± 25 0.92 
DT (ms) 256 ± 91 212 ± 88 0.11 
CMM Pv (cm/s) 55 ± 22 42 ± 13 0.11 
MAPSE (cm) 1.6 ± 0.3 1.4 ± 0.4 0.11 
PVs/d ratio 1.5 ± 0.3 1.2 ± 0.4 0.31 
TAPSE (cm) 2.0 ± 0.5 2.1 ± 0.7 0.62 
Sep EM vel (cm/s) 5.2 ± 2.5 5.0 ± 2.6 0.71 
Sep AM vel (cm/s) 8.3 ± 2.4 7.7 ± 2.2 0.46 
Sep SM vel (cm/s) 6.1 ± 1.7 5.6 ± 1.9 0.20 
E/EM ratio 14 ± 10 15 ± 8 0.72 
%Ap 2 (0.1-65) 75 (1-96) 0.08 
%Vp 5.6 (0.1-100) 19 (1-100) 0.60 
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AHRE (p=0.05). However no other echocardiographic variables showed any significant difference 
between the study groups. 
 
Table 13.3. Baseline values of echocardiographic variables between study groups (AHRE vs. no 
AHRE) one-year follow-up study 
Variables No AHRE                  
(n=66) 
AHRE                            
(n=11) 
p 
PP (mm of Hg) 58 ± 17* 74 ± 8 0.002 
PWVcf (m/s) 7.5 ± 1.7* 8.7 ± 0.8 0.03 
Pr (mm of Hg) 112 ± 17* 141 ± 6 <0.001 
LA diameter (cms) 3.4 ± 1.6 3.5 ± 1.1 0.73 
LA volume (mls) 47 ± 27 62 ± 16 0.08 
EF (%) 42 ± 20 46 ± 14 0.49 
E-vel (cm/s) 70 ± 25 65 ± 30 0.61 
A-vel (cm/s) 80 ± 21 71 ± 22 0.21 
E/A ratio 0.96 ± 0.6 0.99 ± 0.5 0.89 
IVRT (ms) 122 ± 31 118 ± 25 0.73 
DT (ms) 270 ± 86* 212 ± 88 0.05 
CMM Pv (cm/s) 47 ± 20 42 ±13 0.47 
MAPSE (cm) 1.4 ± 0.3 1.4 ± 0.4 0.88 
PVs/d ratio 1.4 ± 0.4 1.2 ± 0.4 0.09 
TAPSE (cm) 2.1 ± 0.6 2.1 ± 0.7 0.93 
Sep EM vel (cm/s) 5.1 ± 1.5 5.0 ± 2.6 0.75 
Sep AM vel (cm/s) 7.8 ± 2.4 7.7 ± 2.2 0.84 
Sep SM vel (cm/s) 6.4 ± 1.7 5.6 ± 1.9 0.17 
E/EM ratio  15 ± 8.0 15 ± 7.6 0.85 
*p<0.05, statistically significant between the groups 
 
Correlation and regression analysis 
In patients who developed new onset AHRE during one-year follow-up, there were no significant 
correlations observed between the indices of arterial stiffness (PP, PWVcf, Pr) and echocardiographic 
variables of cardiac remodelling including LAD or LAV or EF. Similarly there were no significant 
associations noted between mode of pacing (Ap and Vp) and markers of cardiac remodelling as well 
as with arterial stiffness. 
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Table 13.4. Correlation between arterial stiffness, cardiac remodelling and pacing during one-year 
follow-up in patients with AHRE 
Variables LAD LAV EF EM Vel 
 r p r p r p r p 
PP 0.15 0.47 0.28 0.41 0.06 0.87 -0.23 0.51 
PWVcf 0.21 0.41 0.52 0.10 -0.30 0.37 0.03 0.93 
Pr 0.20 0.42 0.31 0.36 -0.91 0.79 -0.56 0.74 
%Ap -0.04 0.93 0.09 0.84 0.46 0.30 -0.43 0.34 
%Vp 0.25 0.51 0.22 0.63 0.06 0.91 -0.33 0.47 
 
Following a step-wise multiple linear regression analyses, the variables associated with the presence 
of AHRE were PP [OR 1.07 (95%CI 1.02-1.13), p=0.007], Pr [OR 1.17 (95%CI 1.06-1.28), p=0.001] 
and PWVcf [OR 1.62 (95%CI 1.03-2.55), p=0.04]. On multivariate regression analyses, adjusting for 
other variables (age, stroke, systolic BP, treatment with warfarin), PP, Pr, PWVcf remained as 
independent predictors of AHRE. [Table 13.5] 
 
13.5. Discussion 
In this one-year longitudinal follow-up study of patients with dual chamber pacemakers, patients who 
developed AHRE were noted to have higher degree of arterial stiffness, as evidenced by increased PP, 
PWVcf and Pr compared to those without AHRE. Also all the measures of arterial stiffness appear to 
independently predict the presence of AHRE, irrespective of the modality and the degree of pacing. 
These findings were consistent with the results from my baseline study of dual chamber pacemaker 
patients as discussed in chapter 11.  
 
Patients who developed AHRE also had significantly larger LAV compared to their baseline measures 
(p<0.001). This is consistent with the study by Tsang et al, which suggested that a 30% larger LA 
volume was associated with a 43% greater risk of AF, even after adjusting to age, sex, valvular heart 
disease and hypertension.(Tsang et al., 2001) 
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Table 13.5: Univariate and multivariate analysis of variables as the predictors for atrial high rate 
events (AHRE) 
Variables 
Variable 
Unadjusted odds ratios Adjusted odds ratios* 
(95% CI) p (95% CI) p 
PP (mm of Hg) 1.07 (1.02-1.13) 0.007 1.19 (1.06-1.33) 0.004 
Pr (mm of Hg) 1.17 (1.06-1.28) 0.001 1.57 (1.00-2.46) 0.05 
PWVcf (m/s) 1.62 (1.03-2.55) 0.04 1.80 (1.01-3.23) 0.05 
LA diameter (cms) 1.09 (0.69-1.71) 0.73   
LA volume (mls) 1.02 (0.99-1.05) 0.09   
EF (%) 1.01 (0.98-1.05) 0.49   
E-vel (cm/s) 1.00 (0.97-1.02) 0.60   
A-vel (cm/s) 0.98 (0.95-1.01) 0.21   
E/A ratio 1.08 (0.37-3.14) 0.88   
IVRT (ms) 1.00 (0.97-1.02) 0.73   
DT (ms) 0.99 (0.98-1.00) 0.06   
CMM Pv (cm/s) 0.99 (0.95-1.03) 0.46   
MAPSE (cm) 0.86 (0.12-6.18) 0.88   
PVs/d ratio 0.26 (0.04-1.71) 0.16   
TAPSE (cm) 1.06 (0.33-3.35) 0.92   
Sep EM vel (cm/s) 0.94 (0.63-1.39) 0.75   
Sep AM vel (cm/s) 0.97 (0.74-1.28) 0.84   
Sep SM vel (cm/s) 0.76 (0.51-1.13) 0.18   
E/EM ratio  1.01 (0.93-1.09) 0.85   
%Ap 1.00 (0.99-1.02) 0.61   
%Vp 1.00 (0.99-1.01) 0.57   
*adjusted for age, stroke, systolic BP and treatment with warfarin 
 
In my present study there was no significant correlation observed between arterial stiffness and 
echocardiographic variables of cardiac remodelling (including LAD, LAV and EF as well as indices 
of LV diastolic function). I believe this may be due to the fact that this is very small cohort of 
pacemaker patients (n=11), who developed AHRE during one-year follow-up. However Abhayaratna 
et al, demonstrated in a study of patients over 65 years or older, the indices of arterial stiffness 
(brachial PP, aortic PP, AP, PWVcf) correlated positively with left atrial volume and diastolic function 
grade. After adjusting for age, gender, and clinical and echocardiographic covariates, 1-SD increases 
in aortic PP, brachial PP, PWV, and AP were associated with 6%, 6%, 4%, and 4% increases in 
indexed left atrial volume, respectively. Similarly 1-SD increase in aortic PP was associated with 84% 
increased risk of diastolic dysfunction. (Abhayaratna et al., 2006) In a small study of pacemaker 
  149 
patients’ post AV-nodal ablation,  there was deterioration in ejection fraction preceded by the 
development of intra-ventricular mechanical dyssynchrony observed with RV apical pacing over a 
mean follow-up 4 months. (Ahmed et al., 2014)  
 
Study limitations 
I acknowledge that the sample size is small, in particular the proportion of pacemaker patients who 
developed new AHRE during one-year follow-up were only 11. This invariably limits interpretation 
of results and its significance. Nonetheless, the primary reason for this follow-up study is to assess 
and explore the other possible pathophysiological mechanism(s) associated in the development of AF 
in these pacemaker patients. Also most of these patients are heterogeneous with multiple co-existent 
cardiovascular conditions which may affect characteristics of the arterial tree and its stiffening 
properties and these measurements might not truly reflect whether they are related to the arrhythmia 
or the degree of pacing. 
 
Conclusion 
In dual chamber pacemaker patients during one-year follow-up, higher arterial stiffness independently 
predicts AHRE, irrespective of the degree or mode of pacing. Adverse cardiac remodelling and the 
subsequent higher risk of AF in these pacemaker patients in long-term may be due to the additive 
effects of progressive increase in arterial stiffening properties, endothelial dysfunction as well as the 
effects of pacing. Larger studies with long-term follow-up to identify the individual effects of arterial 
stiffness on cardiac remodelling and subsequent therapies to modify and modulate the ill effects in 
preventing atrial arrhythmia as well as its thrombo-embolic complications are required.  
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CHAPTER FOURTEEN 
 
14. Summary 
14.1. Summary of Chapters and studies 
Literature review 
Atrial fibrillation (AF) is the most common sustained arrhythmia, which is associated with a higher 
risk of stroke and thromboembolism. The natural history and the clinical expression of the AF have 
several distinct pathobiological underpinnings. The thromboembolic risk associated with AF appears 
largely heterogeneous and the pathogenesis associated with the thrombus formation is often 
multifactorial. In Chapter 2, I have outlined the basic concepts of Virchow’s triad for thrombogenesis 
and focussed on ‘blood vessel abnormalities’ recognised as ‘endothelial damage and or dysfunction’ 
as an integral component mediating thrombogenesis in AF. A continuum of endothelial activation, 
dysfunction and ultimately damage has been proposed in the initiation and perpetuation of AF as well 
as its complications.  
 
In Chapter 3, I have briefly illustrated the clinical perspectives of several biomarkers for endothelial 
cell injury/dysfunction (von Willebrand factor, asymmetrical di-methyl arginine, soluble E-Selectin, 
circulatory endothelial cells, endothelial progenitor cells, circulatory micro-particles, soluble 
thrombomodulin). Similarly the pros and cons of other non-invasive techniques like FMD and 
Augmentation Index as well as invasive techniques like measurement of coronary flow reserve have 
been discussed. The inherent beat-to-beat variability in AF may limit or even preclude the use of some 
routine methods of assessing endothelial function. Nevertheless, there is strong evidence that higher 
von Willebrand factor levels independently predict future cardiovascular events in AF patients, 
thereby suggested its possible role in thromboembolic risk stratification in identifying patients at 
greater risk. 
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In Chapter 4, I have briefly outlined the basic model of ‘arterial stiffness’ and its measurement using 
various techniques like pulse pressure, pulse wave velocity, augmentation index and wave form 
analysis. Despite limited evidence, there appears a close relationship between arterial stiffness and 
development of AF, possibly mediated adverse cardiac remodelling. However the precise 
pathophysiological mechanisms involved in this process haven’t been well elucidated.   
 
In Chapter 5, I have discussed the detrimental effects of right ventricular pacing on the cardiac 
structure and its function in the form of both ‘abnormal electrical activation’ and ‘mechanical 
dyssynchrony’ in the ventricles. Despite maintaining atrio-ventricular synchrony or even using 
minimal ventricular pacing algorithms, long-term pacing is associated with higher risk of developing 
AF. No previous studies looked into the contribution of the arterial tree and its stiffening properties 
towards perpetuation of AF. New generation pacemakers incorporate in-built sophisticated algorithms 
and device detection technologies to accurately monitor and measure atrial high rate events as well as 
true arrhythmic burden. Also device detected atrial high rate events are associated with adverse 
clinical outcomes.  Chapter 6 outlined my research proposal. 
 
Research Studies 
In Chapter 7, I examined the relationship between arterial stiffness and both micro-vascular/macro-
vascular endothelial function in patients with paroxysmal AF. My data confirmed the presence of 
significantly higher arterial stiffness (pulse pressure, carotid-femoral pulse wave velocity and 
reservoir pressure) and greater micro-vascular (Δ laser Doppler flowmetry with acetyl choline, Δ% 
laser Doppler flowmetry with acetyl choline) and macro-vascular endothelial dysfunction (Δ 
augmentation index with salbutamol, Δ% augmentation index with salbutamol) in patients with 
paroxysmal AF compared to healthy controls. Furthermore, I have demonstrated for the first time that 
there was a significant negative correlation observed between arterial stiffness and macro-vascular 
endothelial function in paroxysmal AF patients. On extrapolating the results from my study, it was 
rather apparent that greater endothelial dysfunction and higher arterial stiffness in paroxysmal AF is 
related to co-existent risk factors rather than arrhythmia per se.  
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In Chapter 8, the relationship between arterial stiffness and cardiac remodelling was investigated in 
patients with paroxysmal AF. My data acknowledged the results from previous studies that patients 
with paroxysmal AF have significantly larger left atrial volume and left atrial diameter as well as 
significantly higher arterial stiffness (pulse pressure, carotid-femoral pulse wave velocity and 
reservoir pressure) compared to healthy controls. On analyses of the data, there was a significant 
positive relationship observed between arterial stiffness and left atrial remodelling in paroxysmal AF 
patients. My study results support that abnormal cardiac remodelling in patients with paroxysmal AF 
is related to higher arterial stiffness, but increased arterial stiffness is related to co-existent 
cardiovascular risk factors. Therefore these observations suggest that development and perpetuation 
of AF may be related to greater left atrial remodelling driven by higher arterial stiffness. 
 
In Chapter 9, I examined the relationship between von Willebrand factor, soluble E-Selectin and 
clinical adverse events (including ischaemic stroke, acute myocardial infarction and all-cause 
mortality) in a ‘real world’ community cohort of AF patients. In my study during the 19-months 
follow-up period, patients who have had clinical events were noted to have significantly higher levels 
of von Willebrand factor and soluble E-selectin levels compared to those were event free. Also my 
data demonstrated in AF patients, higher levels of von Willebrand factor and soluble E-selectin were 
independently associated with an increased risk of clinical adverse events (ischaemic stroke, acute 
myocardial infarction). Furthermore, my study results were consistent with available evidence(s) that 
higher baseline levels of von Willebrand factor and soluble E-selectin independently predicts the 
increased risk of future clinical adverse events in AF patients and may aid clinical stroke risk 
stratification. 
 
In Chapter 10, the relationship between arterial stiffness, endothelial function and atrial high rate 
events/episodes were investigated in patients with dual chamber pacemakers. In this study, I observed 
that patients with atrial high rate events have significantly higher arterial stiffness (pulse pressure, 
carotid-femoral pulse wave velocity and reservoir pressure) as well as significantly impaired 
endothelial dependent both micro-vascular (Δ%  laser Doppler flowmetry with acetyl choline) and 
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macro-vascular (Δ% augmentation index with salbutamol) function, compared to those without atrial 
high rate events. Importantly, there were significant negative correlations observed between 
percentage of ventricular pacing and micro-vascular endothelial dysfunction (Δ% laser Doppler 
flowmetry with acetyl choline) as well as between pulse pressure and Δ% laser Doppler flowmetry 
with acetyl choline, suggesting that micro-vascular endothelial dysfunction in dual chamber 
pacemaker patients appears to be related to both arterial stiffening properties and pacing. Furthermore, 
my study results revealed that pulse pressure, reservoir pressure, carotid-femoral pulse wave velocity 
and Δ% augmentation index with salbutamol were independently associated with the presence of 
atrial high rate episodes. These observations suggest that higher arterial stiffness and greater 
endothelial dysfunction may potentially contribute to the perpetuation of the atrial arrhythmia beyond 
the adverse effects of ventricular pacing alone. My data thereby confirms the contribution of the 
neglected interaction between arterial system, wave reflection and ventricular contraction towards the 
pathogenesis of AF in patients with dual chamber pacemakers.  
 
In Chapter 11, I studied the interaction between arterial stiffness, cardiac remodelling and atrial high 
rate events in patients with dual chamber pacemakers. In this present study with dual chamber 
pacemakers, despite no differences observed with left atrial volume or left atrial diameter, patients 
who had atrial high rate events have significantly higher arterial stiffness (pulse pressure, reservoir 
pressure, carotid-femoral pulse wave velocity) and abnormal diastolic parameters (E-velocity, E/A 
ratio, septal EM velocity) compared to no atrial high rate events. Furthermore, there was a significant 
positive correlation observed between percentage of ventricular pacing and left atrial diameter, as well 
as between carotid-femoral pulse wave velocity and left atrial volume. My study data revealed that 
pulse pressure, reservoir pressure, carotid-femoral pulse wave velocity, ejection fraction, E/A ratio, 
septal EM and septal AM velocities were independent predictors of atrial high rate events, even after 
adjusting for confounders. These observations suggest that in dual chamber pacemaker patients, there 
is noticeable contribution of arterial tree and wave reflection to abnormal cardiac remodelling and 
may potentially aid the progression and perpetuation of AF, on top of the adverse effects of pacing. 
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Results from a previous study (chapter 10) revealed the complex interaction between arterial stiffness 
and endothelial dysfunction in dual chamber pacemaker patients. However to evaluate whether this 
interaction persists during long-term in Chapter 12, I examined the relationship between the changes 
in endothelial function, arterial stiffness and atrial high rate events in patients with a dual chamber 
pacemaker over a follow-up period of one year. In this study, I have observed there were significant 
changes in both arterial stiffness (pulse pressure, carotid-femoral pulse wave velocity and reservoir 
pressure) and endothelial dysfunction (Δ% augmentation index with salbutamol, Δ% laser Doppler 
flowmetry with acetyl choline) in patients who developed new onset atrial high rate events at one-year 
follow-up, compared to their baseline levels. Also my data confirms that patients with atrial high rate 
events during the one-year follow-up have significantly higher arterial stiffness (pulse pressure, 
carotid-femoral pulse wave velocity and reservoir pressure) and lower micro-vascular (Δ% laser 
Doppler flowmetry with acetyl choline) as well as macro-vascular (Δ% augmentation index with 
salbutamol) endothelial function compared to those without atrial high rate events. Furthermore, there 
were significant negative correlations observed between reservoir pressure and Δ% augmentation 
index with salbutamol; as well as between pulse pressure and Δ% augmentation index with 
salbutamol. Results from this study demonstrate pulse pressure, carotid-femoral pulse wave velocity 
and reservoir pressure, Δ% augmentation index with salbutamol and Δ% laser Doppler flowmetry 
with acetyl choline were independently associated with the presence of atrial high rate events, even 
after adjusting for confounders. Nevertheless, taken together these observations suggest that both 
progressive worsening of arterial stiffness and greater endothelial dysfunction over time may 
potentially contribute to the progression of AF, on top of the proven detrimental effects of pacing. 
 
In Chapter 13, I studied the relationship between the changes in arterial stiffness and cardiac 
remodelling in those dual chamber pacemaker patients with atrial high rate events, during a one-year 
follow-up period. My study data revealed a significant change in left atrial volume and arterial 
stiffness (pulse pressure, reservoir pressure, carotid-femoral pulse wave velocity) in patients who 
developed new-onset atrial high rate events during the one-year follow period compared to their 
baseline levels. Furthermore, there was a significant positive correlation observed between carotid-
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femoral pulse wave velocity and left atrial diameter; a negative correlation between pulse pressure and 
and septal SM velocity as well as between reservoir pressure and septal EM velocity. My study results 
demonstrate that arterial stiffness (pulse pressure, reservoir pressure, carotid-femoral pulse wave 
velocity) independently associated with atrial high rate events and percentage of pacing (%Ap, %Vp) 
associated with abnormal left atrial remodelling (both left atrial diameter and left atrial volume) at 
one-year in dual chamber pacemaker patients. The study results suggest that on top of pacing, higher 
arterial stiffness does have a negative effect on left ventricular diastolic function and thereby 
potentiates adverse left atrial remodelling and subsequently the increased risk of AF. Nevertheless, it 
is plausible that cumulative ill effects of pacing and arterial stiffness over time appears to worsen 
adverse cardiac remodelling thereby precipitating and perpetuating AF in long-term in dual chamber 
pacemaker patients. 
 
14.2: Clinical implications of the findings 
Results from my cross-sectional study revealed an association between arterial stiffness, endothelial 
function and cardiac remodelling in patients with paroxysmal AF. Initially, these were thought to be 
related to the co-existent medical conditions like hypertension, diabetes or coronary artery disease. 
However, emerging evidence suggests the presence of abnormal endothelial function and cardiac 
remodelling in patients with ‘true lone AF’. (Polovina et al., 2015) Nevertheless if present, developing 
novel therapies targeting these precise mechanism(s) at both micro- and macro-vascular levels by 
intervention or treatment might help in modulating the disease process, thereby preventing the 
development and progression of arrhythmia as well as its’ thrombo-embolic complications. Similarly, 
further large scale studies are required to assess the interaction between arterial stiffness, endothelial 
function and cardiac remodelling in ‘lone AF’ patients. Few novel pharmacotherapies specifically 
targeting ‘arterial stiffness’ by inhibiting advanced glycation end products (pyridoxamine, 
aminoguanidine) were studied in animal models with good effect; however their clinical use in 
humans were limited by their side effects. (Chang et al., 2006; Chang, Liang, Tsai, Wu, & Hsu, 2009). 
Thus, there is the potential to explore novel therapies targeting arterial stiffness at the molecular level 
which may translate in to better clinical outcomes in the future. 
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Development of AF in pacemaker patients’ might not be solely due to ventricular pacing as was once 
thought; a close interaction between arterial stiffness, endothelial function and cardiac remodelling 
was revealed in my follow-up study. These precise mechanisms in combination appear to precipitate 
the development of AF as well as its’ thrombo-embolic complications, on top of the adverse effects of 
pacing per se. This is also evident in the analysis of ASSERT and TRENDS studies which revealed a 
temporal relationship between atrial high rate events and the development of clinical events such as 
stroke or systemic embolism. (Glotzer et al., 2009; Healey et al., 2012) As discussed earlier, targeting 
these mechanisms, including arterial stiffness and endothelial dysfunction, at both the micro- and 
macro-vascular levels individually, may be the ultimate treatment in these patients towards reduction 
in the development of AF and its complications. Also, the intended benefits of anticoagulation 
treatment towards minimising thrombo-embolic complications is quite well established in patients 
with overt clinical AF; however these effects might not be comparable in subclinical AF or patients 
with atrial high rate events. Therefore, on-going randomized control trials like ARTESIA (Apixaban 
for the reduction of thromboembolism in patients with device detected subclinical AF) might improve 
our knowledge and understanding of this condition in the near future. 
 
14.3: Strengths and limitations of the study  
The strengths of the study include a well conducted study with precise aims utilising clear 
methodologies. This is the first study to assess the association between arterial stiffness, micro-
/macro-vascular endothelial function and cardiac remodelling in patients with paroxysmal AF. I have 
used well validated tools and techniques in assessing arterial stiffness (pulse pressure, carotid-femoral 
pulse wave velocity, reservoir pressure), micro-vascular endothelial function (laser Doppler 
flowmetry), macro-vascular endothelial function (augmentation index) and cardiac remodelling (using 
echocardiography).  
 
Nevertheless, obvious limitations include a small sample size and multiple testing; therefore caution 
must be used whilst interpreting results of statistical significance. In the cross-sectional study to 
elucidate the true association between arterial stiffness and endothelial function (by eliminating 
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confounders like hypertension, diabetes, ischaemic heart disease and treatment strategies), it would 
have been preferable to include patients with ‘true lone paroxysmal AF’ ideally in this setting. Also, 
in the pacemaker follow-up study, participants had pacemakers for various durations of time and 
information on their baseline clinical characteristics as well as cardiac function when initially paced 
was not always available. Further, it would have been ideal to analyse arterial stiffness, endothelial 
function and cardiac structure in all these patients before their initial pacemaker implantation.  
 
Despite these limitations, I believe this study revealed new concepts as well as better understanding of 
the various unexplored pathophysiological mechanisms associated with the development of AF.  It 
also helps in identifying novel therapies targeting these specific mechanisms towards reduction in the 
arrhythmic burden and its complications in the future. 
 
14.4. Suggestions for future studies 
1. Arterial stiffness is prognostically important and indeed a predictor of future cardiovascular events. 
At present we have relatively simple non-invasive methods of measuring arterial stiffness, although 
the full clinical impact of these measurements are not yet clear. We clearly need larger studies to 
facilitate and to understand the effect of drugs and treatment on these parameters, which may well be 
truly relevant to important clinical outcomes. I also believe that measurement of arterial stiffness 
should be an important part of routine assessment of patients in both primary-care and hospital 
practice. 
 
2. Increased arterial stiffness and ED in patients with PAF appears to be related to co-existent 
cardiovascular risk factors rather than arrhythmia per se. Future studies could address the contribution 
of arterial stiffness or endothelial dysfunction towards disease progression in patients with ‘Lone’ 
atrial fibrillation. However, if present then targeting these high risk patients with early intervention 
and treatment may help in preventing the progression of arrhythmia as well as its complications. 
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3. Abnormal cardiac remodelling in patients with PAF is associated with higher arterial stiffness and 
the latter appears to be related to co-existent cardiovascular risk factors. On top of the conventional 
treatment of these cardiovascular risk factors, it is also worth exploring potential novel strategies 
towards modulating arterial stiffness; thereby determining whether these interventions would translate 
to favourable long-term CV outcome(s). 
 
4. Higher vWf and sE-Sel levels in AF patients are prognostically significant. However, further 
studies incorporating these plasma markers into the conventional thrombo-embolic risk stratification 
schemata may help us targeting those high risk AF patients towards minimising complications by 
choosing appropriate antithrombotic therapy. 
 
5. Clearly conventional pacemaker studies as well as the proposed pathophysiological mechanisms in 
the development of AF, neglected the salient intrinsic interaction between arterial system, wave 
reflection and ventricular contraction. Nevertheless, my data revealed that there is a close inter-
relationship between arterial stiffness, endothelial function and cardiac remodelling towards the 
progression of AF, beyond the deleterious effects of pacing alone. Indeed we need larger pacemaker 
studies with long-term follow-up to assess these interaction(s) as well as to explore its clinical 
implications. However, a deeper understanding of arterial stiffness in both molecular and cellular 
terms might encourage the development of novel effective therapies and interventions thereby 
translating to favourable cardiovascular outcomes.  
 
14.5. CONCLUSIONS 
A continuum of endothelial cell activation, dysfunction and ultimately damage has been proposed as a 
key component mediating thrombogenesis in atrial fibrillation. In the cross-sectional study, the 
observed higher arterial stiffness and greater endothelial dysfunction in PAF patients appears to be 
mediated by co-existent cardiovascular risk factors rather than arrhythmia per se. Furthermore, it is 
evident that abnormal cardiac remodelling in PAF patients is related to higher arterial stiffness. The 
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greater LA remodelling driven by higher arterial stiffness probably aids in the perpetuation and 
progression of the arrhythmia. 
 
Consistently as seen in trial settings, even in a ‘real world’ community cohort of AF patients, higher 
plasma levels of vWf and sE-sel levels independently predict the future risk of clinical adverse events 
(including ischaemic stroke, AMI and all cause death). Therefore incorporating these plasma markers 
in the clinical risk stratification schemata might help in identifying the high risk patients’ thereby 
tailoring appropriate therapy and interventions towards preventing complications as well as improving 
clinical outcomes. 
 
Finally, there appears a close noticeable intrinsic interaction between arterial system, wave reflection 
and ventricular contraction in patients with dual chamber pacemaker patients. The longitudinal 
pacemaker follow-up study revealed a close relationship between arterial stiffness, endothelial 
function and cardiac remodelling in patients with AHRE. Therefore it is rather apparent that higher 
arterial stiffness, greater endothelial dysfunction and adverse cardiac remodelling observed in these 
patients with AHRE probably aid in the development of AF, on top of the proposed deleterious effects 
of pacing alone. Also the subsequent deterioration in arterial stiffness, worsening endothelial 
dysfunction and adverse cardiac remodelling over time are likely to contribute to the progression of 
AF, on top of the detrimental effects of pacing. 
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